472 evidence-backed Q&A aggregated from 61 ingredient + evidence pages across asxan.ai. Each answer carries a source link back to the
page it was authored on. PubMed-verified · GEO-native · no medical claims.
Yes. Oral NMN at 250 to 1000 mg per day raises blood NAD+ to approximately twice baseline in multiple randomised controlled trials, including Yoshino 2021 (Science), Yi 2022 (GeroScience), Okabe 2022 (Frontiers in Nutrition), Pencina 2023 (J Clin Endocrinol Metab), and the Zhang 2025 meta-analysis of 12 trials totalling 513 participants. This is one of the most reproducible biochemical findings in the supplement literature.
· source: NMN
Is NMN better than nicotinamide riboside (NR)?
No head-to-head randomised controlled trial in humans has compared NMN and NR on a clinical endpoint. Marketing claims of superiority in either direction are not supportable.
· source: NMN
What is the right dose of NMN?
Most RCTs showing functional benefit have used 250 mg per day, particularly in older adults. Athletic-endpoint trials used 600 to 1200 mg per day. Safety data extend to 1250 mg per day for four weeks (Fukamizu 2022). The Australian TGA permissible upper limit is 500 mg per day.
· source: NMN
Should NMN be taken in the morning or the afternoon?
Two independent randomised trials in older adults (Kim 2022 PMID 35215405, Morita 2024) found that afternoon dosing outperformed morning dosing on sit-to-stand, sleep quality, and self-reported fatigue. This is one of the more reproducible timing-of-administration findings in the supplement literature.
· source: NMN
Are there serious side effects of NMN?
Across all published randomised controlled trials reviewed here, no serious adverse events have been reported. The most common mild events are occasional gastrointestinal disturbances and headache, at rates statistically indistinguishable from placebo. Long-term safety beyond six months has not been studied.
· source: NMN
Is NMN safe during pregnancy or breastfeeding?
No. There are no adequate human safety data for NMN during pregnancy or lactation. NMN should be avoided in these contexts.
· source: NMN
Is NMN appropriate alongside diabetes medication?
Because NMN may modulate insulin signalling, consult your physician before initiating NMN if you are taking glucose-lowering medication. This is a precautionary recommendation, not evidence of harm.
· source: NMN
Is NMN legal in my country?
The legal status varies by jurisdiction. In the United States, NMN is a legal dietary supplement following the FDA September 2025 withdrawal of the 2022 IND exclusion. In Australia, NMN became a permitted therapeutic-good ingredient under TGA Determination No. 4 of 2025 on 10 December 2025, with a 500 mg/day ceiling. In the European Union, NMN is not currently permitted as a food or food supplement; six Novel Food applications are under EFSA evaluation. In Brazil, NMN is prohibited across the full supply chain under ANVISA RE 1139/2022 (7 April 2022), including cross-border e-commerce.
· source: NMN
Will NMN extend my lifespan?
No human trial has measured lifespan as an endpoint, and no human evidence supports a lifespan-extension claim. Mouse lifespan studies exist but do not transfer onto human use.
· source: NMN
What is the SLC12A8 transporter controversy?
Grozio and colleagues proposed in 2019 (Nature Metabolism) that SLC12A8 is a mammalian-specific NMN transporter allowing intact NMN to cross cell membranes. Schmidt and Brenner published a 2020 rebuttal in the same journal reporting they could not reproduce the finding. The dispute remains unresolved as of 2026, and SLC12A8 should be presented as a contested hypothesis rather than an established absorption route.
· source: NMN
NMNH is the reduced (dihydropyridine) form of NMN — chemically, NMN with two additional hydrogens at the nicotinamide ring. The relationship of NMNH to NMN is analogous to that of NADH to NAD+. NMNH was first cleanly chemically synthesised by the Liu group at Tsinghua University in 2021 (PMID 33793246).
· source: NMNH
Does NMNH raise NAD+ more efficiently than NMN?
In hepatocyte culture and mouse liver tissue, yes. Three preclinical studies (Liu 2021 PMID 33793246, Zapata-Pérez 2023 PMID 36869544, Vinten 2026 PMID 41701114) report higher NAD+ elevation with NMNH than with equimolar NMN in these systems. However: all of this evidence is preclinical, and NMNH simultaneously elevates the NADH pool, which NMN does not. The dual-pool elevation has unknown physiological consequences in humans.
· source: NMNH
Are there any human trials of NMNH?
No. As of 2026-05-26, PubMed contains zero human clinical trials of NMNH, ClinicalTrials.gov contains zero registered trials, and the EU Clinical Trials Register contains zero registered trials. There are zero human safety data, zero human pharmacokinetic data, and zero published dose-exploration studies. NMNH is a research-stage compound.
· source: NMNH
Can I buy NMNH as a dietary supplement?
As of 2026-05-26 the United States FDA has not received an NDI notification or GRAS notification for NMNH, the European Union EFSA has not received a Novel Food application for NMNH, and Brazil ANVISA has no specific approval pathway. Even where consumer products labelled NMNH may be available, they are not supported by human safety, pharmacokinetic, or efficacy data. ASXAN does not recommend NMNH for routine supplementation in 2026.
· source: NMNH
What is the Gst "pseudo-stress" signal in Vinten 2026?
Vinten 2026 (FASEB J PMID 41701114) compared NMN, NMNH, NR, and NRH in mouse hepatocyte primary cells using RNA-sequencing, proteomics, and metabolomics. The reduced precursors NMNH and NRH triggered upregulation of glutathione-S-transferase family genes (a transcriptional pattern that resembles a response to oxidative stress) without depleting glutathione itself — a "pseudo-stress" pattern that NMN and NR did not produce. Whether this signal is beneficial adaptation or hepatic warning is not yet known.
· source: NMNH
Is NMNH better than NMN for my longevity goals?
There is no human evidence supporting that. Preclinical efficiency (test tube and mouse liver) does not predict human clinical outcomes, and the Gst pseudo-stress and glycolysis-suppression signals in Liu 2021 and Vinten 2026 are additional unknowns. For consumer-relevant NAD+ support in 2026, the evidence-supported choices are NMN, NR, and NADH — all with human RCT data and known safety profiles. Read the NMN page for the deep evidence base.
· source: NMNH
Has the 2025 FDA reversal on NMN also applied to NMNH?
No. The September 2025 FDA withdrawal of the 2022 IND exclusion determination was specific to the NMN chemical entity. NMNH is a distinct chemical entity (the reduced form) and would require a separate NDI or GRAS process. The FDA has not received any NDI or GRAS notification for NMNH as of 2026-05-26.
· source: NMNH
Does NMNH have any regulatory authorisation in the European Union?
No. The EFSA OpenEFSA registration system contains zero Novel Food applications for NMNH as of 2026-05-26. Under EU Novel Food regulation, any food ingredient not significantly consumed in the European Union before 15 May 1997 requires EFSA evaluation and European Commission authorisation before it can be sold as a food or food ingredient. NMNH falls into this category and has not been authorised.
· source: NMNH
Is NMNH safe?
There are zero human safety data of any duration for NMNH. The preclinical findings include cell-cycle arrest in cultured cells and suppression of glycolysis and the TCA cycle (Liu 2021 PMID 33793246), and the Vinten 2026 Gst pseudo-stress signal. These are signals that need human Phase I safety evaluation before any claim about NMNH being well tolerated can be made.
· source: NMNH
When might NMNH have enough evidence to be a reasonable consumer choice?
It depends on the speed of clinical development. The first benchmark is a registered Phase I human safety trial — none is registered as of 2026-05-26. Even on an accelerated path, accumulating the level of evidence that NMN has today (over a dozen RCTs, multi-jurisdictional regulatory status, multi-year safety record) would typically take several years from the first registered human trial.
· source: NMNH
NADH is the reduced electron-carrier form of nicotinamide adenine dinucleotide. It is structurally identical to NAD+ except for one extra hydride at the 4-position of the nicotinamide ring. It is the molecule that directly donates two electrons to Complex I of the mitochondrial electron transport chain, starting the proton-pumping cascade that drives cellular ATP synthesis.
· source: NADH
Is NADH the same as NAD+?
They are interconvertible oxidation-reduction forms of the same nicotinamide-adenine dinucleotide framework. NAD+ is the oxidised cofactor; NADH is the reduced electron-carrying form. The cell uses both forms continuously. Supplementing one is not the same as supplementing the other.
· source: NADH
Is NADH a precursor like NMN or NR?
No. NMN and NR are precursors that the cell uses to synthesise NAD+ via the salvage pathway. NADH is not a precursor — it is the active reduced cofactor that directly donates electrons at mitochondrial Complex I. Supplementing NADH and supplementing the precursors are mechanistically different strategies that have never been compared head-to-head in a human trial.
· source: NADH
What is the strongest human evidence for oral NADH?
The strongest single trial is Forsyth 1999 (PMID 10071523) — a randomised double-blind placebo-controlled crossover trial in 26 adults with chronic fatigue syndrome, reporting that 31 percent of subjects experienced clinically meaningful improvement on NADH 10 mg/day for four weeks versus 8 percent on placebo. Birkmayer 2002 (PMID 12385067) reported preserved cognitive performance during transatlantic jet lag in 35 air travellers on 20 mg NADH versus placebo. Demarin 2004 (PMID 15134388) reported preserved cognitive scores in 26 Alzheimer disease patients on 10 mg/day for six months. All three are small single-centre trials; replication has been limited.
· source: NADH
What is the appropriate oral dose of NADH?
Most published trials used 10 mg/day for chronic fatigue and Alzheimer endpoints, 20 mg/day for jet-lag cognition, and 5 to 20 mg/day for general adult use. Oral NADH must be in a stabilised enteric-coated form (the original Enada formulation is the canonical reference); without enteric coating, oral NADH is degraded in stomach acid before absorption.
· source: NADH
Is NADH safe?
The cumulative safety record across roughly 25 years of US DSHEA availability and more than 25 ClinicalTrials.gov entries is excellent for a dietary-supplement category. No serious adverse events have been attributed to NADH at supplement doses (up to 20 mg/day for up to 6 to 8 months). Mild adverse events (loss of appetite, mild dyspepsia, occasional headache) are infrequent and not statistically different from placebo.
· source: NADH
Is NADH safe in pregnancy?
No dedicated safety randomised controlled trial exists for pregnancy or lactation. NADH should be avoided in these contexts unless under qualified clinical supervision.
· source: NADH
Does NADH interact with medication?
No clinically significant drug interactions are currently established. A theoretical interaction with L-dopa in Parkinson disease via the dopamine biosynthesis pathway should be discussed with the prescribing physician before adding NADH. As with all NAD+-family compounds, oncology patients on PARP inhibitors should not self-initiate NADH and should consult their oncology team.
· source: NADH
Is NADH approved as a dietary supplement in the United States, the European Union, and Brazil?
In the United States NADH is a legal dietary supplement ingredient under DSHEA (Enada and equivalent products have been on the market since the late 1990s). In the European Union NADH is sold as a dietary supplement in several member states under national rules with zero EFSA-authorised health claims. In Brazil NADH has no specific ANVISA approval pathway and is evaluated case by case.
· source: NADH
Should I take NADH or NMN or NR?
No head-to-head randomised controlled trial exists. The three compounds target different points: NADH is the active reduced cofactor at Complex I; NMN and NR are precursors that the cell uses to synthesise more NAD+. Each has its own evidence base and its own appropriate use cases. Discuss with a qualified healthcare provider before adding any of them.
· source: NADH
If I buy a product labelled NAD+, am I actually swallowing NAD+?
In most cases no. The intact NAD+ dinucleotide (molecular weight 663 daltons) is poorly orally bioavailable: it is partially hydrolysed in stomach acid, cleaved by intestinal NADase enzymes into smaller fragments such as NR, NMN, and niacinamide, and further degraded in hepatic first-pass metabolism. Most "NAD+" products on the market are in fact NR, NMN, or niacinamide once you read the supplement-facts panel.
· source: NAD+
Does intravenous NAD+ have strong human evidence?
No large double-blind randomised controlled trial of intravenous NAD+ is currently indexed in PubMed for any clinical indication. The frequently cited 1961 OHollaren report is a historical case series that does not meet modern randomised-trial standards. The FDA, EFSA, and ANVISA have not approved intravenous NAD+ for any clinical indication. Functional-medicine clinic protocols often combine NAD+ with B vitamins, minerals, and glutathione, which makes any single-component attribution difficult.
· source: NAD+
Is NAD+ decline with age a real phenomenon?
Yes. NAD+ concentrations decline measurably with age across multiple human tissues — for example skin NAD+ at 50 is approximately half the level at 20 (review PMID 39326681), and skeletal-muscle NAD+ in adults over 70 is reduced by 30 to 50 percent compared with younger controls. The factual question is biological. The harder question is which intervention reliably reverses the decline at the tissue level in humans.
· source: NAD+
If direct NAD+ is poorly absorbed, why does anyone sell it?
Commercial branding often uses the word "NAD+" because it is the consumer-recognised end-state molecule. Read the supplement-facts panel: the actual active ingredient is typically NR, NMN, or niacinamide, which are precursors that re-enter the salvage pathway inside cells. The branding shortcut and the bioavailable molecule are not the same thing.
· source: NAD+
What is the evidence-supported way to raise NAD+ via oral supplements?
Use a precursor — NR or NMN — both of which have multiple randomised controlled trials demonstrating that they raise blood NAD+ to approximately twice baseline at doses of 250 to 1000 mg per day. Niacinamide also raises NAD+ via the same salvage pool and has the strongest single trial (ONTRAC NEJM 2015) for non-melanoma skin cancer reduction. NADH has 25-plus years of human safety data and modest randomised evidence in chronic fatigue and jet-lag cognition.
· source: NAD+
How does NADH differ from NAD+ as a supplement strategy?
NADH is the reduced cofactor form — structurally NAD+ with an added hydride at the nicotinamide ring. NADH is not a precursor and not interconvertible by simple oral dosing into a higher NAD+ pool. It is the operative electron donor at mitochondrial Complex I. Stabilised oral NADH at 5 to 20 mg per day has randomised data in chronic fatigue (Forsyth 1999) and jet-lag cognition (Birkmayer 2002).
· source: NAD+
Should I do an intravenous NAD+ infusion at a functional-medicine clinic?
There is no large double-blind randomised controlled trial supporting routine clinical use of intravenous NAD+ infusion for any indication. If you are considering it, talk to a physician who is independent of the clinic selling the protocol. Do not treat user experience reports or testimonials as substitute for randomised evidence.
· source: NAD+
What is the regulatory status of NAD+ direct supplementation in the United States, the European Union, and Brazil?
In the United States, direct oral NAD+ as a discrete ingredient has no clear regulatory pathway, and what is sold is typically the precursors. Intravenous NAD+ is used in functional-medicine settings but is not FDA-approved for any indication. In the European Union, neither oral NAD+ nor intravenous NAD+ has authorised health claims, and direct NAD+ has no Novel Food authorisation. In Brazil, ANVISA has no specific approval pathway for direct NAD+ supplementation; NMN is specifically prohibited under ANVISA RE 1139/2022.
· source: NAD+
Will raising NAD+ make me live longer?
No human study has measured lifespan as an endpoint for any NAD+ precursor or for intact NAD+. Animal lifespan studies exist in mice; they do not transfer onto human use. The defensible framing is that raising NAD+ is one of several factors that may support cellular function, with documented effects on selected functional endpoints in older adults and amateur athletes for NMN specifically.
· source: NAD+
Why does this hub focus on the United States, European Union, and Brazil rather than on China?
This educational hub serves an international audience under the United States, European Union, and Brazil regulatory frameworks. The Chinese regulatory environment for NAD+ precursors is not the focus of this hub, and content here does not adjust for the Chinese regulatory framework.
· source: NAD+
What is the NAD+ precursor cluster, and which compounds does it cover?
The NAD+ precursor cluster covers five compounds that share one downstream goal — raising cellular NAD+ — but differ in absorption route, evidence base, dose, side-effect profile, and regulation: NMN (β-nicotinamide mononucleotide), NR (nicotinamide riboside), niacinamide (the amide form of vitamin B3, also called nicotinamide), niacin (the acid form of vitamin B3), and NADH (the reduced cofactor form).
· source: NAD+ Cluster
Which NAD+ precursor has the strongest single piece of human evidence?
Niacinamide carries the single most rigorous trial: the ONTRAC phase-three randomised controlled trial published in the New England Journal of Medicine in 2015 (Chen et al., n=386), which reported a 23% relative reduction in non-melanoma skin cancer with 500 mg twice daily for 12 months in a high-risk population. No other NAD+ precursor has reached this evidentiary tier.
· source: NAD+ Cluster
Is NMN better than NR?
No head-to-head randomised controlled trial in humans has compared NMN and NR on a clinical endpoint. The two precursors collapse to similar intracellular intermediates and both elevate blood NAD+ at typical doses. Claims of superiority either way are not supportable by the current human evidence.
· source: NAD+ Cluster
Why is direct oral NAD+ supplementation considered weakly supported?
The NAD+ dinucleotide is large (molecular weight 663 daltons), highly polar, and chemically unstable in stomach acid. It is largely degraded into smaller fragments (NR, NMN, niacinamide) before absorption, which then re-enter the salvage pathway. As of 2026 there is no large double-blind randomised controlled trial demonstrating that oral intact NAD+ raises blood NAD+ in humans more reliably than its precursors do.
· source: NAD+ Cluster
What is the role of NADH compared with the precursors?
NADH is the reduced electron-carrier form and is the molecule that directly donates electrons at mitochondrial Complex I. It is not a precursor — it is the operative cofactor that the precursors are ultimately trying to top up indirectly. Stabilised oral NADH has approximately 25 years of human safety data and modest randomised evidence in chronic fatigue syndrome (Forsyth 1999) and jet-lag cognition (Birkmayer 2002).
· source: NAD+ Cluster
Does any NAD+ precursor extend human lifespan?
No. No randomised controlled trial of any NAD+ precursor has used lifespan as an endpoint, and no human study has demonstrated lifespan extension. Mouse lifespan studies exist but do not transfer onto human use. The defensible framing is that NAD+ precursors raise blood NAD+ and produce selected functional improvements in some populations.
· source: NAD+ Cluster
Which precursor is most appropriate for healthy older adults?
For older adults the densest human evidence cluster is NMN at 250 mg/day, with three independent randomised trials (Igarashi 2022, Kim 2022, Morita 2024) showing functional improvements in walking speed, grip strength, and sleep. Two independent trials also report that afternoon dosing outperforms morning dosing for sleep and sit-to-stand outcomes in older adults — one of the more reproducible chronobiology findings in the supplement literature.
· source: NAD+ Cluster
Why is niacin treated differently from the other precursors in this cluster?
Niacin enters NAD+ via the distinct Preiss-Handler pathway and causes cutaneous flushing in over 80% of users at therapeutic lipid-modifying doses (1 to 3 grams per day). The modern post-statin trials AIM-HIGH (2011 NEJM) and HPS2-THRIVE (2014 NEJM) did not show added cardiovascular benefit on top of statin therapy. Ferrell 2024 in Nature Medicine identified the niacin metabolite 4PY as a promoter of vascular inflammation. Niacin therefore sits in a different risk-benefit category from the other precursors and is not recommended for self-supplementation outside medical supervision.
· source: NAD+ Cluster
Is the SLC12A8 NMN transporter mechanism settled science?
No. Grozio et al. 2019 in Nature Metabolism proposed SLC12A8 as a mammalian NMN transporter. Schmidt and Brenner 2020 in the same journal reported they could not reproduce the finding. The mechanism remains contested as of 2026. NMN absorption is more reasonably described as involving multiple proposed routes, including intestinal dephosphorylation to NR, and SLC12A8 should be referenced as a contested hypothesis rather than an established route.
· source: NAD+ Cluster
What regulatory status do NAD+ precursors have in the United States, the European Union, and Brazil?
In the United States, niacinamide, niacin, NR (Niagen GRAS), and NADH are legal dietary supplements; NMN status was restored on 29 September 2025 when the FDA withdrew its 2022 IND exclusion determination. In the European Union, niacinamide and niacin are authorised vitamin forms (with EFSA Article 13 claims at recommended daily intake levels), NMN is under Novel Food evaluation (six applications pending), NR has Novel Food status with national variation, and NADH is permitted as a supplement in some member states with no central EFSA authorisation. In Brazil, niacinamide and niacin are listed on ANVISA IN 28/2018; NMN, NR, and NADH require case-by-case evaluation, and NMN specifically is under a full-chain prohibition under ANVISA RE 1139/2022 of 7 April 2022.
· source: NAD+ Cluster
Where should I start reading if I want one precursor that has the most consumer-relevant evidence per dollar?
Niacinamide. It carries the ONTRAC NEJM phase-three trial for non-melanoma skin cancer reduction at high-risk populations, has EFSA-authorised general nutrition claims at recommended daily intake levels, has a clean and well-characterised long-term safety record across decades of vitamin B3 research, and is by an order of magnitude the lowest-cost member of the family. The honest caveat is that niacinamide does not carry NMN-style human data for muscle, walking speed, sleep, or aerobic capacity.
· source: NAD+ Cluster
There is no defensible "should" because no head-to-head randomized trial has compared NMN and NR on any clinical endpoint in humans. The honest framing is to match each precursor to its evidence base. NR has the longer trial history, an established RCT in mild cognitive impairment (Orr 2024 PMID 37994989), and the NICE peripheral artery disease trial (McDermott 2024 PMID 38871717). NMN has more positive functional endpoint RCTs in older adults (Igarashi 2022, Kim 2022, Morita 2024) and the strongest single athletic-endpoint trial (Liao 2021 PMID 34238308). If your priority is geriatric functional performance, NMN has a denser evidence base; if your priority is the cognitive or peripheral vascular indication, NR has the only positive randomized trials.
· source: Blog · NMN vs NR Decision Tree
Are NMN and NR interchangeable at equivalent doses?
Mechanistically they converge — the prevailing absorption model has oral NMN dephosphorylated in the gut to NR before enterocyte uptake, then rephosphorylated to NMN inside the cell — but their clinical evidence bases are not interchangeable. Doses studied also differ: most NMN RCTs use 250 to 1000 mg/day, while NR trials cluster around 1000 mg/day. Cross-equating "1 g NMN equals 1 g NR" is a marketing simplification not supported by pharmacokinetic head-to-head data in humans.
· source: Blog · NMN vs NR Decision Tree
Does NMN really raise blood NAD+?
Yes — this is the single most replicated biochemical finding in the supplement literature. The 12-RCT meta-analysis (Zhang 2025 PMID 39116016) pooling n=513 participants confirmed statistically significant elevation of blood NAD+ in NMN versus placebo. Individual RCTs (Yoshino 2021, Yi 2022, Okabe 2022, Pencina 2023) consistently report approximately two-fold elevation at 250 to 1000 mg/day.
· source: Blog · NMN vs NR Decision Tree
Does NR raise blood NAD+ as much as NMN?
Both raise blood NAD+ substantially. The Martens 2018 NR RCT (PMID 29599478) reported approximately 60 percent elevation at 1000 mg/day in healthy middle-aged adults. The Trammell 2016 NR pharmacokinetic study (PMID 27721479) established dose-dependent elevation at 100/300/1000 mg single-dose. NMN at 250 mg/day reaches roughly two-fold elevation by week 4 (Okabe 2022 PMID 35479740). Direct head-to-head NAD+ elevation comparison has not been published.
· source: Blog · NMN vs NR Decision Tree
Why was the FDA position on NMN reversed in 2025?
In late 2022 the FDA sent letters to NDI notifiers stating that NMN was no longer eligible for inclusion in dietary supplements because Metro International Biotech had previously made NMN the subject of an Investigational New Drug application. The Natural Products Association filed a citizen petition in March 2023 and a federal lawsuit in September 2024. On 29 September 2025 the FDA withdrew the 2022 IND exclusion determination, restoring NMN as a permitted dietary supplement ingredient subject to standard NDI notification under 21 CFR 190.6. NR was not affected by the 2022 determination and has held supplement-ingredient status throughout.
· source: Blog · NMN vs NR Decision Tree
Is the SLC12A8 transporter why NMN is "better" than NR?
No — that framing is not supportable. Grozio et al. 2019 (PMID 31131364) proposed SLC12A8 as a mammalian NMN transporter allowing intact NMN to cross plasma membranes. Schmidt and Brenner 2020 (PMID 32694648) reported they could not reproduce the SLC12A8-mediated transport. The hypothesis remains under debate; consensus has not formed. Claims that NMN absorption advantages over NR depend on SLC12A8 are based on a contested mechanism rather than an established route. The prevailing 2026 absorption model has both NMN and NR converging on intracellular NMN as an intermediate.
· source: Blog · NMN vs NR Decision Tree
What is the right dose of NMN or NR?
For NMN: 250 mg/day is the most-studied chronic dose with positive functional endpoints in older adults; 600 to 1200 mg/day is the range tested in athletic-endpoint RCTs (Liao 2021); the highest dose-duration combination validated in a published RCT is 1250 mg/day for four weeks (Fukamizu 2022 PMID 36002548). The Australian TGA Determination No. 4 of 2025 set the permissible upper limit at 500 mg/day. For NR: 1000 mg/day is the most-studied chronic dose (Martens 2018, Vreones 2023, Orr 2024). The NR-SAFE Parkinson trial (PMID 38016950) reported acceptable safety at 3000 mg/day over four weeks.
· source: Blog · NMN vs NR Decision Tree
Are there any serious side effects of NMN or NR?
Across all published RCTs reviewed here, no serious adverse events have been reported in either precursor. The most common mild events are occasional gastrointestinal disturbances (nausea, loose stools) and headaches at rates statistically indistinguishable from placebo in placebo-controlled trials. NMN safety data extend to 1250 mg/day for four weeks; NR safety data extend to 3000 mg/day for four weeks in the NR-SAFE trial. Long-term safety beyond six months has not been established for either compound.
· source: Blog · NMN vs NR Decision Tree
Should I take NMN or NR in the morning or the afternoon?
For NMN in older adults, two independent RCTs (Kim 2022 PMID 35215405, Morita 2024) found afternoon dosing outperformed morning dosing on five-times sit-to-stand, sleep quality, and self-reported fatigue. This is one of the more reproducible chronobiology findings in the supplement literature. The biologic plausibility rests on alignment of NAD+ availability with the body's natural NAD+ rhythm. For NR no equivalent chronobiology comparison has been published.
· source: Blog · NMN vs NR Decision Tree
Is NMN legal where I live?
United States: permitted as a dietary supplement following the 29 September 2025 FDA withdrawal of the 2022 IND exclusion. Australia: permitted under the TGA Permissible Ingredients Determination No. 4 of 2025 at 500 mg/day maximum. European Union: not currently permitted; six Novel Food applications are in EFSA evaluation, the most advanced being Uthever in public consultation. Brazil: prohibited across the full supply chain under ANVISA Resolução-RE No. 1,139 of 2022. NR has broader market acceptance: permitted in the United States (GRAS notifications cleared by FDA), under EFSA review in the EU, no equivalent ANVISA full-chain prohibition.
· source: Blog · NMN vs NR Decision Tree
Will NMN or NR extend my lifespan?
No human study has measured lifespan as an endpoint for either compound, and no human evidence supports a lifespan-extension claim for either. Mouse lifespan data exist for both precursors but do not transfer onto human use. Honest consumer framing positions both NMN and NR as evidence-anchored for NAD+ elevation and selected functional endpoints in middle-aged and older adults — not for lifespan.
· source: Blog · NMN vs NR Decision Tree
What is the most-studied NAD+ form in humans across the full 25-year history?
Counting randomized trials across all NAD+ family compounds, nicotinamide has the longest published randomized history (extending into the ONTRAC 2015 NEJM skin cancer chemoprevention trial), oral NADH has roughly 25 years of continuous availability and at least four placebo-controlled randomized trials, NR has eight to ten randomized trials clustered around 1000 mg/day, and NMN now has the densest 2020-2025 cluster with approximately 13 randomized trials including a meta-analysis. No single compound dominates; the family taken together represents one of the most studied supplement domains.
· source: Blog · NAD+ 25-year RCT History
When did NAD+ randomized human research actually start?
The first randomized placebo-controlled human trial in the NAD+ family was Forsyth, Preuss, MacDowell and colleagues in 1999, evaluating stabilized oral NADH in chronic fatigue syndrome in 26 adults (PMID 10071523). This pre-dated the first NR human pharmacokinetic study (Trammell 2016 PMID 27721479) by 17 years and the first high-impact placebo-controlled human NMN trial (Yoshino 2021 PMID 33888596) by 22 years.
· source: Blog · NAD+ 25-year RCT History
Is the NAD+ randomized literature dominated by positive findings?
Mostly yes on the biochemical primary endpoint (blood NAD+ elevation) — this is the single most replicated finding in the literature. On clinical functional endpoints the picture is more mixed: positive geriatric functional outcomes for NMN in three independent older-adult cohorts (Igarashi 2022, Kim 2022, Morita 2024); positive cognitive outcomes for NR in mild cognitive impairment (Orr 2024); positive skin cancer chemoprevention for nicotinamide (ONTRAC 2015); positive athletic outcomes for NMN in amateur runners (Liao 2021). Honest nulls and trends-not-significant exist too: the Katayoshi 2023 NMN baPWV arterial stiffness trend did not reach statistical significance, and STRENGTH-style hard cardiovascular outcome trials do not exist in the NAD+ precursor class.
· source: Blog · NAD+ 25-year RCT History
Has any NAD+ form been shown to extend human lifespan?
No. No randomized trial of any NAD+ form has measured human lifespan as an endpoint. Mouse lifespan data exist for NMN and NR but do not transfer onto human use. The honest reading of 25 years of evidence: precursor and reduced-cofactor supplementation reliably modifies blood NAD+ and selected functional surrogates in older adults; lifespan-extension claims go beyond the data.
· source: Blog · NAD+ 25-year RCT History
Why was the 2022 FDA position on NMN reversed in 2025?
In late 2022 FDA sent letters to NDI notifiers stating that NMN was no longer eligible for inclusion in dietary supplements because Metro International Biotech had previously made NMN the subject of an Investigational New Drug application. The Natural Products Association filed a citizen petition in March 2023 and a federal lawsuit in September 2024. On 29 September 2025 FDA withdrew the 2022 IND exclusion determination, restoring NMN as a permitted dietary supplement ingredient. The 2025 FDA reversal is the most significant regulatory event in the NAD+ precursor history since the EFSA NR Novel Food authorization in 2017.
· source: Blog · NAD+ 25-year RCT History
Which trial in this 25-year history is most often misquoted?
In our citation-audit experience the most commonly misquoted is the Pencina 2023 MIB-626 trial. The correct PMID is 36740954 in Journal of Clinical Endocrinology and Metabolism; a related Yi 2023 dose-finding trial in GeroScience carries PMID 36482258. The two are sometimes collapsed in third-party indexing. Other recurring drift cases: Castro-Marrero 2015 (often miscited as 2016), Nadlinger 2002 PMID 12399028 (sometimes attributed to "Mero 2008"), and the Zhang 2025 NMN meta-analysis PMID 39116016 (sometimes attributed to "Zhong O 2024"). All are flagged in the Transparent Disclosure section below.
· source: Blog · NAD+ 25-year RCT History
What does the chronological order of trials actually tell us?
Three patterns. First, the field began with reduced NADH (1999-2004) before the modern oxidised precursor era. Second, randomized trial volume accelerated sharply after 2020 with the Yoshino Science publication; roughly two-thirds of all NAD+ family RCTs were published in the last five years. Third, indication breadth has widened from chronic fatigue and Parkinson (early era) through cardiovascular surrogates and cognitive impairment (modern era) — but disease-endpoint hard outcomes still do not exist.
· source: Blog · NAD+ 25-year RCT History
Is the Birkmayer Parkinson programme considered an RCT?
No. The Birkmayer 1990 PMID 2239495 paper and subsequent Birkmayer/Vrecko mechanistic work in the 1990s were open-label observational reports from a single research group. They are mechanistically rich (NADH stimulates endogenous dopamine biosynthesis via tetrahydrobiopterin recycling) but do not constitute randomized evidence. No randomized placebo-controlled trial of NADH in Parkinson disease has been published. NADH should not be marketed as a Parkinson treatment regardless of historical use.
· source: Blog · NAD+ 25-year RCT History
What is the largest single NAD+ randomized trial in this history?
By participant count, the NICE peripheral artery disease trial of NR (McDermott 2024 PMID 38871717) at n=90 over six months is the largest randomized cardiovascular trial in the precursor class. The ONTRAC nicotinamide skin cancer chemoprevention trial (Chen 2015 PMID 26488693) at n=386 over 12 months is the largest randomized trial in the broader NAD+ family if nicotinamide is included. The Zhang 2025 NMN meta-analysis (PMID 39116016) pools n=513 across 12 trials and is the largest synthesis.
· source: Blog · NAD+ 25-year RCT History
When will NAD+ precursors get a hard cardiovascular outcome trial?
No registered trial as of mid-2026 has MACE (major adverse cardiovascular events), all-cause mortality or stroke as a primary endpoint in the precursor class. The NICE 2024 trial used the six-minute walk test as a secondary endpoint, which is functional rather than hard outcome. A genuinely large outcome trial in the REDUCE-IT or VITAL mould has not been launched.
· source: Blog · NAD+ 25-year RCT History
Does the SLC12A8 transporter controversy from 2019-2020 affect any of these clinical results?
No clinical RCT outcome depends on whether SLC12A8 is or is not the mammalian NMN transporter. The clinical evidence stands on its own outcome measurements. The mechanism debate matters for marketing claims of NMN absorption-route superiority over NR, which are not supportable regardless of how the transporter question ultimately resolves, because no head-to-head human RCT has compared the two precursors.
· source: Blog · NAD+ 25-year RCT History
In hepatocyte cell culture and short-duration mouse liver exposures, NMNH raises NAD+ more potently than NMN. In humans, no randomized trial has compared the two compounds on any endpoint. The honest 2026 reading is that NMNH preclinical data show "different from" rather than "better than" NMN — including a glutathione-S-transferase pseudo-stress transcriptional signal that NMN does not produce, and glycolysis and TCA cycle suppression that need human dose-finding before they can be evaluated as advantage or risk. NMNH is not yet a consumer option.
· source: Blog · NADH vs NMNH Evidence
Do I need NADH for chronic fatigue?
NADH has the original randomized placebo-controlled trial in chronic fatigue syndrome (Forsyth 1999 PMID 10071523, n=26, 31 percent active versus 8 percent placebo improvement). The Castro-Marrero CoQ10 + NADH combination trials (PMID 25386668 in 2015 with n=80, PMID 34444817 in 2021 with n=207) showed improvements in fatigue perception and health-related quality of life. The evidence supports NADH as a low-risk option in fatigue conditions under DSHEA structure/function framing. It does not support treating NADH as a treatment for chronic fatigue syndrome, which is a clinical diagnosis requiring medical management.
· source: Blog · NADH vs NMNH Evidence
How long has NADH been available commercially?
Stabilized oral NADH (enteric-coated, pioneered by the Birkmayer group in Vienna and commercialized as the ENADA / Enada brand) has been continuously available in the United States under DSHEA since the late 1990s. Approximately 25 years of safety-record availability across the supplement market, with no serious adverse events attributable to NADH reported in published randomized trials at doses up to 20 mg/day for up to 6 to 8 months.
· source: Blog · NADH vs NMNH Evidence
Why is NMNH considered Tier C while NADH gets Tier B?
NADH has approximately four placebo-controlled randomized trials in humans (Forsyth 1999, Birkmayer 2002 jet-lag, Demarin 2004 Alzheimer, Castro-Marrero combination work), 25 years of commercial safety record, and known dose ranges (10 to 20 mg/day enteric-coated). NMNH has zero human randomized trials, zero human safety data, zero human pharmacokinetic studies, and unknown dose ranges — all evidence sits in cell culture or short-duration mouse exposures. Tier B (limited but consistent randomized evidence in humans) is appropriate for NADH; Tier C (preclinical-only, emerging research compound) is the only honest designation for NMNH in 2026.
· source: Blog · NADH vs NMNH Evidence
Can I buy NMNH as a supplement in 2026?
NMNH is not authorized as a food, food supplement or therapeutic-goods ingredient in any of the four jurisdictions in scope for this hub (FDA, EFSA, ANVISA, TGA). FDA has no GRAS, NDIN or IND record for NMNH. EFSA Novel Food register has zero applications for NMNH. ANVISA has no listed pathway. TGA Determination No. 4 of 2025 covered NMN, not NMNH. Products marketed as "NMNH" without disclosure of human-evidence status should be treated with substantial skepticism; the 2025 FDA withdrawal of the NMN IND exclusion is a regulatory event specific to NMN as a chemical entity and does not extend to NMNH.
· source: Blog · NADH vs NMNH Evidence
What is the Gst pseudo-stress signal in NMNH research?
Vinten et al. 2026 in FASEB J ran a four-precursor multi-omics comparison (NMN vs NMNH vs NR vs NRH) in mouse primary hepatocytes using RNA-seq, proteomics and metabolomics. Reduced precursors (NMNH and NRH) produced a transcriptional response resembling oxidative stress — upregulation of the glutathione-S-transferase family — without depleting cellular glutathione. The authors describe this as a pseudo-stress signal: the cell behaves as if mounting a defense response that is not actually accompanied by the metabolic damage that response would normally protect against. The signal is uniquely produced by reduced precursors; NMN and NR do not produce it. The clinical meaning is unknown and would require human dose-finding to evaluate as biological advantage, neutral adaptation or signal of subtle stress.
· source: Blog · NADH vs NMNH Evidence
Does NADH have any documented mechanism advantage over NAD+ precursors?
Mechanism is straightforward: NADH is the terminal reduced cofactor that directly donates electrons to Complex I of the mitochondrial electron transport chain. Precursors (NMN, NR) must be enzymatically converted up several steps before reaching the dinucleotide pool. Whether that direct-donor mechanism translates to clinical superiority over precursor strategies on any endpoint has not been tested in a head-to-head human randomized trial — no such trial exists. The mechanistic difference is real; the clinical translation of that difference is not established.
· source: Blog · NADH vs NMNH Evidence
Are NADH and NAD+ the same thing?
No. NADH and NAD+ are interconvertible redox forms of nicotinamide adenine dinucleotide. NAD+ is the oxidized form (accepts electrons); NADH is the reduced form (carries two electrons and one proton as a hydride on the nicotinamide ring). Inside cells they exist in a ratio of approximately 700:1 (cytoplasm) or 7:1 (mitochondria), and they shuttle electrons through central metabolism. Supplementing NADH is a different strategy from supplementing NAD+ directly (which has poor oral bioavailability) or from supplementing NAD+ precursors (NMN, NR).
· source: Blog · NADH vs NMNH Evidence
Is there a head-to-head randomized trial of NADH versus NMN, NR or NMNH?
No. None of the four reduced and oxidized members of the cluster have been compared head-to-head in a human randomized controlled trial. Marketing claims of one member being superior to another are not supportable by trial evidence. The honest 2026 approach is precursor-by-use-case matching rather than crowning a winner.
· source: Blog · NADH vs NMNH Evidence
What dose of NADH is supported by evidence?
Across the published randomized literature, 10 mg/day (Forsyth 1999 chronic fatigue, Demarin 2004 Alzheimer) and 20 mg/day (Birkmayer 2002 jet lag, Castro-Marrero combination work) are the doses studied. The 25-year safety record supports cautious use within this range under DSHEA structure/function framing. Long-term safety beyond eight months has not been established in randomized trials.
· source: Blog · NADH vs NMNH Evidence
Carotenoids are a family of 700+ fat-soluble plant and algal pigments — the same compounds that give carrots, tomatoes, marigolds, salmon flesh, and brown seaweed their characteristic colours — of which about 8 are nutritionally and clinically important in human health.
· source: Carotenoids
Is "carotenoid" a single substance?
No. It is a family label. The 8 most studied compounds are α-carotene, β-carotene, β-cryptoxanthin, lycopene (the carotenes) and lutein, zeaxanthin, astaxanthin, and fucoxanthin (the xanthophylls). Each has distinct chemistry and distinct human evidence.
· source: Carotenoids
Which carotenoids provide vitamin A?
Only three: α-carotene, β-carotene, and β-cryptoxanthin. They contain the β-ionone ring required by the BCO1 enzyme. Lycopene, lutein, zeaxanthin, astaxanthin, and fucoxanthin do not convert to vitamin A.
· source: Carotenoids
Is taking β-carotene safe?
Whole-food β-carotene from fruits and vegetables is safe and recommended. Isolated high-dose β-carotene supplementation (≥20 mg/day) is not safe for people who currently smoke, recently smoked, or have a history of asbestos exposure — two large randomized trials (CARET, ATBC) found it increased lung cancer in those populations. Non-smokers without these exposures generally tolerate β-carotene supplements well; sustained very high intake produces benign, reversible carotenodermia.
· source: Carotenoids
Should I take lutein and zeaxanthin together?
The clinical evidence base (AREDS2 and follow-on studies) is built on lutein 10 mg + zeaxanthin 2 mg per day in combination. Separate or reduced doses do not directly inherit the AREDS2 evidence.
· source: Carotenoids
Does lycopene prevent prostate cancer?
No claim of disease prevention can be made. In 2005, the US FDA reviewed the evidence and permitted only Qualified Health Claims with the wording: "Very limited credible evidence suggests that consuming lycopene may reduce the risk of prostate cancer; however, the FDA concludes that this evidence is very limited." The EFSA reviewed the same area and declined all functional health claims. Lycopene from tomato products has clearer evidence for improvements in cardiovascular surrogate markers (blood pressure, LDL oxidation) than for prostate-specific outcomes.
· source: Carotenoids
How does astaxanthin differ from other antioxidants?
Astaxanthin uniquely spans the entire lipid bilayer of cell membranes because its molecule carries polar hydroxyl and keto groups at both ends. This bipolar geometry, combined with its non-pro-oxidant chemistry, underlies its meta-analysis-supported effects on oxidative stress, inflammation markers, and skin moisture and elasticity. It does not provide vitamin A.
· source: Carotenoids
Is fucoxanthin a "fat-burning" carotenoid?
Fucoxanthin is the only carotenoid with a randomized-trial mechanism (UCP1 upregulation) that translates to measurable weight and body-fat changes in humans. The best-known weight-loss data come from a combination formulation (Xanthigen, with pomegranate seed oil), and most other supportive studies are small. Fucoxanthin is a credible metabolic-syndrome adjunct, not a stand-alone weight-loss treatment.
· source: Carotenoids
Can I get all the carotenoids I need from food?
For most people, yes. A varied diet that includes leafy greens (lutein, zeaxanthin), orange and red vegetables (β-carotene, α-carotene, lycopene), cooked tomato products with olive oil (lycopene), egg yolk (lutein, zeaxanthin), and salmon or seafood (astaxanthin) supplies the full pattern. Supplementation is most justified for specific tissue-targeted goals with strong evidence, such as lutein + zeaxanthin for established AMD risk.
· source: Carotenoids
Are carotenoids antioxidants or just colourants?
Both, and the two roles are linked. The conjugated double-bond chain that absorbs visible light (giving the colour) is also what quenches singlet oxygen and lipid peroxyl radicals (giving the antioxidant activity). However, "antioxidant" is a much narrower description than the actual range of effects, which include vitamin A precursor activity, macular pigment formation, transmembrane membrane stabilization, and UCP1 metabolic signaling.
· source: Carotenoids
Are carotenoid supplements regulated the same way worldwide?
No. Acceptable doses, permitted source materials, and allowable health claims vary substantially across China, the US, Brazil, and the EU. The EU is the strictest market for functional claims; the US uses Qualified Health Claims with required disclaimer wording for several carotenoid-cancer combinations; China and Brazil permit broader registered supplement claims within defined dose ceilings.
· source: Carotenoids
What about safety in pregnancy and childhood?
Food-level intake of all carotenoids is safe across pregnancy and childhood. Supplemental β-carotene up to ~6 mg/day is the conventional preference in pregnancy because it self-limits conversion to vitamin A, unlike preformed retinyl palmitate (teratogenic at high doses). Higher-dose carotenoid supplements in pregnancy and routine carotenoid supplementation in young children are not adequately studied and are not generally recommended.
· source: Carotenoids
Will eating one carrot a day put a smoker at the documented risk?
No. The smoker warnings on this page apply exclusively to high-dose supplement forms (≥20 mg/day). A typical medium carrot contains roughly 3-6 mg of β-carotene with only 1-3% absorbed from raw whole-form chewing — an order of magnitude below the 30 mg/day synthetic dose used in CARET. Dietary β-carotene from vegetables and fruit has been associated in observational studies with lower lung cancer risk, not higher (see §4.1).
· source: Beta-Carotene
β-carotene is called "plant vitamin A" — can a strict vegan rely on it alone?
Theoretically yes, with two important caveats: (1) the official 12:1 dietary RAE conversion means total intake must be much higher than for omnivores eating preformed retinol; (2) common BCO1 gene polymorphisms (§3.3) reduce the conversion efficiency in roughly 30-45% of the population by 30-59%. Strict long-term vegans showing symptoms of vitamin A deficiency (night blindness, dry skin, weakened immunity) should obtain a serum retinol test and consider a 3-6 mg/day supplement under clinician guidance.
· source: Beta-Carotene
I have been eating carrots regularly and my palms have turned yellow — is this toxicity?
No. This is carotenodermia — a completely benign, fully reversible deposition of β-carotene in the stratum corneum and subcutaneous fat. It resolves within 2-6 weeks of stopping the high intake (§8.2). The single most important differentiation point is the sclera (the white of the eye): carotenodermia does NOT discolor the sclera because the elastin there does not bind carotenoids. Jaundice, by contrast, presents first in the sclera because bilirubin does bind elastin. If your eye-whites are yellow, see a physician promptly to rule out hepatobiliary disease.
· source: Beta-Carotene
Why did AREDS2 remove β-carotene from the formula?
For two converging reasons: (1) former smokers in the AREDS arms continued to show the lung cancer risk signal seen in ATBC and CARET; (2) lutein 10 mg + zeaxanthin 2 mg was shown to substitute for β-carotene with equivalent or modestly better AMD progression protection. This is a textbook example of evidence-based medicine updating a recommendation when a long-term safety signal converges with the availability of an equivalent or superior alternative — see §7 for the full paradigm-shift chapter.
· source: Beta-Carotene
Is a natural Dunaliella source safer than synthetic all-trans β-carotene?
Mechanistically there is a difference (Dunaliella contains approximately 40% 9-cis isomer vs <5% in synthetic all-trans), and the hypothesis exists that 9-cis may behave differently in hepatic and subcutaneous tissue retention. However, this hypothesis has NOT been validated by any large randomized controlled trial. EFSA, NIH-ODS, and USPSTF do not distinguish between natural and synthetic sources in the smoker warning. The current regulatory position is that dose (≥20 mg/day), not source, defines the risk threshold (see §6.4 for the Tier C strict caveat).
· source: Beta-Carotene
ATBC and CARET are 1990s trials — could they be outdated?
No. Both occupy the highest tier of evidence (large randomized controlled trials). The 2004 Goodman post-discontinuation follow-up of CARET and the 2014 Virtamo 18-year follow-up of ATBC both confirmed the risk signal persists for years after stopping supplementation. The 2010 Druesne-Pecollo meta-analysis (9 RCTs) and the 2012 Bjelakovic Cochrane review on antioxidants and all-cause mortality independently replicated the conclusion. The 2022 USPSTF still issues a Grade D recommendation against β-carotene supplementation for cancer or cardiovascular disease prevention. This is one of the most robust negative findings in the entire evidence-based nutrition literature.
· source: Beta-Carotene
My multivitamin contains 1-3 mg β-carotene — is that a problem?
The low doses (<6 mg/day) typical of multivitamin formulations are well below the high-dose thresholds used in ATBC (20 mg/d) and CARET (30 mg/d), and are regarded by EFSA as posing no adverse effect signal. That said, current and former smokers (within 15 years of quitting) are widely advised to prefer multivitamin formulations that do not contain β-carotene at all — most major manufacturers now offer "smoker-safe" formulations specifically for this reason.
· source: Beta-Carotene
Yes, for most adults. Daily intake at the 10–20 mg level used in mainstream supplements and AREDS2 has a strong safety record across more than fifty randomized trials, and EFSA sets an acceptable daily intake of 1 mg/kg body weight (about 70 mg/day for a 70 kg adult). Sustained intake above ~30 mg/day can produce a harmless, reversible yellowing of the skin (carotenodermia). Pregnant or breastfeeding women and children under 18 should obtain lutein from food unless a healthcare provider specifically recommends a supplement.
· source: Lutein
What is the difference between lutein and zeaxanthin?
Both are xanthophyll carotenoids with the same molecular formula and two hydroxyls, but lutein has one β-ring and one ε-ring while zeaxanthin has two symmetric β-rings. Lutein predominates in the peripheral macula and Henle fibre layer; zeaxanthin in the central fovea. AREDS2 used a 10:2 ratio (lutein : zeaxanthin), reflecting natural dietary patterns. The two are partners, not interchangeable. See the dedicated zeaxanthin sub-page.
· source: Lutein
Does lutein prevent age-related macular degeneration?
The AREDS2 trial tested lutein and zeaxanthin in adults who already had intermediate AMD or advanced AMD in one eye. In that population the combination reduced relative progression risk by approximately 26% in the subgroup with the lowest baseline dietary intake; the primary endpoint across the full study did not reach pre-specified statistical significance. No randomized evidence shows that lutein supplementation prevents AMD from developing in healthy adults without risk factors. NIH ODS and NEI recommend the AREDS2 formula for the at-risk population studied in the trial, not as general prevention.
· source: Lutein
Does lutein help with digital eye strain?
Small randomized trials suggest that 6–12 months of lutein and zeaxanthin supplementation can raise macular pigment optical density, improve contrast sensitivity and photostress recovery, and in some studies reduce self-reported visual fatigue in high-screen-time adults. These are supportive findings, not a treatment claim for digital eye strain or computer vision syndrome, which are clinical conditions with multiple causes that require comprehensive ergonomic and ocular-surface management (20-20-20 rule, proper lighting, corrected refraction, dry-eye care).
· source: Lutein
Is lutein safer than β-carotene for smokers?
Lutein does not carry the lung-cancer signal seen with high-dose β-carotene in heavy smokers (ATBC 1994 and CARET 1996), and lutein was specifically substituted for β-carotene in the AREDS2 formula to remove that concern. Lutein neither causes nor prevents lung cancer; it is simply a safer carotenoid choice for current and former smokers.
· source: Lutein
Should I take lutein with food?
Yes. Lutein is fat-soluble and absorbs several-fold better with a meal containing at least about 5 grams of fat (olive oil, avocado, nuts, eggs, fatty fish). Oil-based softgels generally outperform tablets, powders or gummies.
· source: Lutein
Free-form lutein versus lutein esters — which is better?
Free-form has slightly higher per-milligram bioavailability and is the form used in AREDS2; esters can deliver comparable plasma exposure when taken with a fat-containing meal. Check the label for which is provided and whether the milligram figure refers to free lutein equivalent or to ester weight.
· source: Lutein
What foods are highest in lutein?
Raw kale (18–39 mg per 100 g), raw spinach (~12 mg per 100 g), watercress (~6 mg per 100 g) lead; egg yolks deliver 0.25–0.36 mg per yolk with unusually high bioavailability. Corn, red peppers and goji berries are notable sources of zeaxanthin specifically. The average American adult eats only 1–2 mg of lutein + zeaxanthin per day from food, well below the 12 mg combined dose used in AREDS2.
· source: Lutein
Can lutein replace sunscreen?
No. Oral antioxidants including lutein do not replace broad-spectrum topical sunscreen. Trials reporting improved "photo-protective activity" measure skin redness, hydration and similar parameters, not skin cancer prevention. SPF 30+ sunscreen, shade and protective clothing remain the dominant evidence-based measures against UV damage.
· source: Lutein
Is lutein safe in pregnancy?
Dietary lutein from leafy greens, eggs and corn is regarded as safe across the lifespan. Supplement-level doses have not been specifically evaluated in randomized trials in pregnant or breastfeeding women; food is the conservative, widely endorsed default during these life stages.
· source: Lutein
Can I take lutein with a β-carotene supplement?
When high doses are taken together, they compete for intestinal absorption — lutein bioavailability can be reduced by approximately 39–46% (Kostic et al., 1995, PMID 7661123). Space them across different meals, or choose a single lutein-zeaxanthin product.
· source: Lutein
What is meso-zeaxanthin and do I need to supplement it?
Meso-zeaxanthin is a stereoisomer of zeaxanthin (3R,3′S) that the body generates in the retina from dietary lutein via enzymatic isomerization. It is not an independently essential nutrient and is essentially absent from the ordinary diet. Some advanced macular formulas add it; the clinical evidence base for the supplemental form is more limited than for the lutein-zeaxanthin pair, and adequate dietary lutein is the most reliable way for the body to produce meso-zeaxanthin where needed.
· source: Lutein
No. Lycopene is a carotenoid like β-carotene, but it lacks the β-ionone ring required for conversion to retinol. There is therefore no provitamin A activity, and no risk of vitamin A toxicity from lycopene intake — a meaningful safety difference from β-carotene at supplement-level doses.
· source: Lycopene
Is raw tomato better than tomato sauce for lycopene?
The intuitive answer is wrong here. Cooked, processed tomato products (sauce, paste, ketchup, juice) generally deliver more bioavailable lycopene per gram than raw tomato. Heat converts a portion of the all-trans isomer to cis isomers, which are preferentially absorbed; mechanical disruption breaks the chromoplast structure that traps lycopene in raw tissue; and the typical cooking medium (oil) supplies the fat required for micelle formation. The Mediterranean preparation of tomato simmered in olive oil is, in lycopene terms, biologically optimal.
· source: Lycopene
Does lycopene treat prostate cancer?
No. The honest answer is that observational studies link higher dietary lycopene intake to a modest reduction in prostate cancer risk (Tier B evidence) and two small intervention RCTs report biomarker-level signals (Tier C evidence). FDA's 2005 regulatory verdict on the totality of the evidence was "very limited credible evidence", the lowest tier of the Qualified Health Claim framework. There is no evidence that lycopene treats, prevents or cures prostate cancer at the level required for a treatment claim.
· source: Lycopene
I read that the SELECT trial showed lycopene increases prostate cancer risk — is that right?
This is one of the most common factual errors in popular prostate content. SELECT did not study lycopene. SELECT randomised men to selenium, vitamin E, both or placebo, and the headline finding was that high-dose vitamin E (400 IU/day) significantly increased prostate cancer risk. Lycopene was not in the trial. Any source that uses SELECT in a lycopene argument is mis-citing the data.
· source: Lycopene
Does lycopene lower blood pressure?
Pooled RCT data (Cheng 2017 CV, PMID 28129549) show lycopene supplementation reduces systolic blood pressure by approximately 5.66 mmHg on average (p = 0.002) — a reproducible biomarker effect. No RCT has shown this translates into reduced stroke, heart attack or cardiovascular mortality, so the causal link to hard outcomes has not been established.
· source: Lycopene
Can lycopene replace sunscreen?
No. Oral lycopene supplementation has been shown to increase the minimal erythemal dose (MED) — the UV dose required to produce visible reddening — by roughly the equivalent of an SPF 1.3–1.5 sunscreen. This is biologically meaningful as supportive antioxidant defence, but it is far below the SPF 30+ broad-spectrum protection recommended for sun-exposed skin. Position lycopene as supplementary to topical sunscreen, never as a replacement.
· source: Lycopene
I noticed my skin turning slightly orange after taking lycopene — should I be worried?
This is lycopenodermia, a benign, fully reversible orange-yellow skin discolouration described in the case-report literature at chronically high intakes (typically above 75 mg/day for many weeks). It is distinct from jaundice — no eye-white (scleral) colour change, no elevation of bilirubin. Reducing intake reverses the colouration. There is no known toxicity associated with the phenomenon. Practically, it is a signal to revisit dose rather than a signal of harm.
· source: Lycopene
Should I take lycopene with food or on an empty stomach?
With food, and specifically with food that contains fat. Lycopene is fat-soluble; without dietary fat there is insufficient micelle formation in the small intestinal lumen and absorption falls dramatically. Any meal containing oil, dairy fat, nut or avocado will support absorption. Taking lycopene with water on an empty stomach is the single most common practical mistake in lycopene supplementation.
· source: Lycopene
How does lycopene compare to astaxanthin as an antioxidant?
Both are efficient carotenoid antioxidants with different structural and tissue-distribution profiles. Lycopene is open-chain and partitions into LDL and adipose reservoirs; astaxanthin is an oxygenated keto-carotenoid that integrates into cell and mitochondrial membranes. Citing one as "stronger" in a single number is misleading — different mechanisms operate in different compartments. See the astaxanthin sibling page for the breakdown.
· source: Lycopene
Is synthetic or tomato-derived lycopene better?
Both are well-characterised and clinically studied. Synthetic lycopene has long been used in formal RCTs and food-fortification programmes. Tomato oleoresin and Blakeslea trispora fermentation lycopene naturally carry a higher cis-isomer fraction and trace tocopherols and phytosterols — contextual, not a free upgrade. Labels should disclose the source so consumers with tomato or fermentation sensitivities can choose informedly.
· source: Lycopene
How long until lycopene supplementation produces measurable biomarker changes?
Intervention-RCT data typically show measurable changes in oxidative-stress markers (MDA, oxidised-LDL) and cardiovascular biomarkers (SBP, LDL-C) over an 8- to 12-week window at 10–15 mg/day or above. Plasma half-life is 12–33 days, so tissue saturation lags first dose meaningfully — the biomarker meta-analyses capture steady-state biology.
· source: Lycopene
Is lycopene safe in pregnancy?
Dietary intake of lycopene-rich foods (tomato, watermelon, pink grapefruit) is considered safe in pregnancy. Supplemental high-dose lycopene has not been specifically studied in pregnancy, so the prudent position is to defer the supplementation decision to a clinician familiar with the individual case.
· source: Lycopene
No. They share the same molecular formula (C40H56O2) but differ in stereochemistry. Lutein is 3R,3′R,6′R (one terminal ring is an asymmetric ε-ionone ring). Zeaxanthin is 3R,3′R (both terminal rings are β-ionone). They deposit in different regions of the retina (lutein in the peripheral macula, zeaxanthin in the mid-peripheral macula), and clinical data on one cannot be extrapolated directly to the other. See §1.
· source: Zeaxanthin
What is the best food source of zeaxanthin?
Orange bell pepper (1.4-1.7 mg per 100 g) and saffron stigma (highest by mass, but impractical daily intake) lead the list. The realistic everyday sources are corn, orange peppers, and egg yolk. Egg yolk has a relatively modest absolute amount (0.2-0.3 mg per egg) but the highest bioavailability because the carotenoids are co-loaded with lecithin phospholipids. See §2.
· source: Zeaxanthin
What is meso-zeaxanthin? Do I need to supplement it separately?
meso-Zeaxanthin is the meso-stereoisomer of zeaxanthin (3R,3′S), the dominant macular pigment in the foveola — the highest-acuity retinal region. The honest answer on supplementation is that adequate dietary lutein intake itself maintains the foveal meso-Z pool, because lutein is the in-retinal precursor that gets isomerized to meso-Z. Standalone hard-endpoint RCTs of meso-Z are limited; the key trials (MOST AMD, CREST, LUNA, MacuPrime) all used triple-supplement (L + Z + meso-Z) formulations and the data cannot be attributed to meso-Z alone. See §5 and §9.2.
· source: Zeaxanthin
Did AREDS2 prove that zeaxanthin prevents age-related macular degeneration?
No. AREDS2 tested an L 10 + Z 2 mg/d combination (layered onto the AREDS1 antioxidant base of vitamin C, vitamin E, zinc, and copper) — it was not a zeaxanthin standalone trial. The primary endpoint was NOT statistically significant. Only in a secondary subgroup analysis of the lowest baseline L+Z intake quartile was an approximately 26% reduction in progression risk observed. Any reference to AREDS2 must specify "combination" and must not be split-attributed to zeaxanthin alone. See §4.
· source: Zeaxanthin
Where did the L:Z = 10:2 ratio come from?
Directly from the AREDS2 intervention arm design (10 mg lutein + 2 mg zeaxanthin per day). It is NOT a "natural optimal ratio" or a "maximum efficacy ratio" — it was a research dose chosen by AREDS2 investigators balancing safety, supply availability, and the dietary epidemiology of the time. The reason the industry treats it as a de facto gold standard is that AREDS2 remains the largest and longest (5-year intervention + 10-year follow-up) RCT in the field, so market language and regulatory framing anchor to it. See §9.1.
· source: Zeaxanthin
Does zeaxanthin actually protect against blue light?
At the mechanism level, yes — zeaxanthin’s absorption peak is at 470 nm, exactly in the high-energy blue band (400-500 nm), and a high macular pigment optical density (MPOD) acts as a built-in retinal blue-light filter. In a randomized trial of high-screen users (Stringham 2017, PMID 28661438), an L + Z combination over 6 months improved visual fatigue scores, headache frequency, eye discomfort, and sleep quality. As with AREDS2, the trial used the combination, not zeaxanthin alone. See §6.1-6.2.
· source: Zeaxanthin
Is there an upper limit for zeaxanthin? What happens if I take too much?
The EFSA Acceptable Daily Intake (ADI) is 0.75 mg/kg body weight/day, which works out to approximately 53 mg/day for a 70-kg adult. AREDS2 found no serious adverse events at the L 10 + Z 2 mg/d combination over 5 years and a 10-year follow-up. Very high long-term doses can produce mild reversible skin yellowing (carotenodermia, a class effect shared with β-carotene) that resolves on discontinuation. Most countries have not set a separate official UL for zeaxanthin. See §7.
· source: Zeaxanthin
Is zeaxanthin safe for everyone?
Ordinary dietary intake (eggs, corn, leafy greens) is safe across populations. Unlike β-carotene, AREDS2 confirmed that L + Z substitution for β-carotene is safer for smokers (no lung cancer signal). Pregnancy, breastfeeding, and pediatric populations lack dedicated high-dose supplementation safety data; consult a clinician. See §7.
· source: Zeaxanthin
Should I take zeaxanthin with food or on an empty stomach?
With a fat-containing meal. Zeaxanthin is a fat-soluble carotenoid and absorption rises sharply when taken with dietary fat (Kostic 1995, PMID 7661123 — the foundational lutein + β-carotene fat-absorption study whose mechanism extrapolates to zeaxanthin). Fasting administration substantially reduces uptake. Concurrent use of orlistat or other fat-blocking medications also reduces absorption (the standard fat-soluble-vitamin caution). See §3.1 and §7.
· source: Zeaxanthin
Are CREST and MOST AMD the same trial?
No — they are two separate trials from the same Irish research group (Akuffo / Beatty / Nolan). MOST AMD (PMID 25976647, Akuffo 2015, Eye (Lond)) was a 36-month trial in 67 early-AMD patients comparing three L/Z/meso-Z formulations. CREST (Central Retinal Enrichment Supplementation Trial) is a separate two-arm RCT: methodology paper PMID 24621122 (Akuffo 2014) and Report 1 PMID 27367585 (Nolan 2016, healthy population, 12-month L 10 + Z 2 + meso-Z 10 mg/d on contrast sensitivity). The PMIDs are not interchangeable and CREST must not be cited via PMID 25976647. See §5.2.
· source: Zeaxanthin
What is the difference between zeaxanthin and astaxanthin?
Both are xanthophylls (oxygenated carotenoids), but astaxanthin has additional keto + hydroxy groups (a distinctive bipolar terminal structure), can cross the blood-brain barrier, and acts as a broad-spectrum antioxidant in muscle / skin / brain / retina. Zeaxanthin specifically deposits in the macular pigment of the retina. Mechanism and tissue tropism differ substantially. See §10 and the carotenoids hub.
· source: Zeaxanthin
What is the regulatory status of zeaxanthin in China and the EU?
China NMPA: the registered functional health-food raw material is lutein ester (with the relieve-visual-fatigue function), where zeaxanthin can appear as a co-component; standalone zeaxanthin has not been independently listed. In 2024 China approved meso-zeaxanthin as a novel food raw material (marigold-derived process route). EU EFSA: synthetic / fermented zeaxanthin is on the Commission Regulation (EU) 2017/2470 Novel Food authorisation list with maximum-use-level limits, but L/Z specific macular-health function claims have NOT been authorised (EFSA rejected several Article 13 applications); only general antioxidant context is permitted. U.S. FDA: dietary supplement + GRAS; Structure / Function Claims permitted with the 30-day notification; disease claims prohibited. See §8.
· source: Zeaxanthin
What is the practical difference between natural Haematococcus and synthetic astaxanthin?
Three structural differences. Stereochemistry: Haematococcus is essentially all-(3S,3′S); synthetic is a 1:2:1 mixture of (3S,3′S), meso and (3R,3′R). Esterification: Haematococcus is predominantly mono- and di-esterified (~95%); synthetic is free astaxanthin without esters. Matrix: Haematococcus arrives co-extracted with algal lipids and minor co-carotenoids; synthetic is a neat purified compound. These map onto measurable differences in bioavailability, antioxidant capacity under standardised assays, and oxidative stability (see sections 1 and 2).
· source: Blog · Natural vs Synthetic Astaxanthin
Is natural astaxanthin really more bioavailable than synthetic?
It depends on conditions. Both forms are highly lipid-meal dependent. In the presence of an appropriate lipid carrier the natural ester form is frequently better absorbed because of its native co-occurring lipid matrix; Mercke Odeberg 2003 (PMID 12885395) quantified up to 3.7× Cmax improvement with phospholipid- and glyceride-enriched formulations. Synthetic free astaxanthin in fasted conditions can show ≤50% of fed-condition bioavailability (Coral-Hinostroza 2004 PMID 15556071).
· source: Blog · Natural vs Synthetic Astaxanthin
Why do most astaxanthin supplements use Haematococcus rather than synthetic material?
Four reasons. (i) The human RCT evidence base is almost entirely on Haematococcus. (ii) Regulatory positioning in several jurisdictions restricts synthetic astaxanthin to animal nutrition. (iii) The ester form has documented stability advantages under typical bulk-storage conditions (Aoi 2003 PMID 12626126). (iv) The 1:2:1 stereoisomer mixture in synthetic material does not match the all-(3S,3′S) form that the analytical literature shows to have higher antioxidant capacity (Capelli 2013).
· source: Blog · Natural vs Synthetic Astaxanthin
What dose of astaxanthin is supported by the clinical evidence?
Most documented benefits cluster at 4-12 mg/day of natural Haematococcus astaxanthin for 8-16 weeks, taken with a fat-containing meal. Higher doses (16-20 mg/day) have been studied in specific high-demand contexts (intensive training, assisted-reproduction preparation, certain reproductive indications). Doses far below 4 mg/day are unlikely to replicate the published RCT effects.
· source: Blog · Natural vs Synthetic Astaxanthin
Does astaxanthin actually improve skin?
The strongest current evidence is the Zhou 2021 meta-analysis (PMID 34578794) of 11 RCTs (n=481), which reported statistically significant standardised mean differences for skin moisture (~0.49) and elasticity (~0.46) with oral Haematococcus astaxanthin at 4-12 mg/day for 8-16 weeks. Wrinkle depth did not reach statistical significance — an honest reading of the meta-analysis. Earlier RCTs (Tominaga 2012, Yoon 2014 collagen co-administration, Ito 2018 photoprotection) support the moisture-and-elasticity signal.
· source: Blog · Natural vs Synthetic Astaxanthin
Does astaxanthin help with eye health?
There is a moderate but consistent signal for digital eye strain, accommodation fatigue and extended screen-time discomfort. Hecht 2025 (PMID 40014233) demonstrated benefit in children, and the Giannaccare 2020 review (PMID 32370045) of adult RCTs supports a similar direction in adults. Typical doses are 4-12 mg/day for 4-8 weeks. Astaxanthin is best understood as one carotenoid in a broader eye-support stack that includes lutein and zeaxanthin for macular pigment specifically.
· source: Blog · Natural vs Synthetic Astaxanthin
Does astaxanthin improve exercise performance?
The evidence is mixed but supportive of a recovery and adaptation effect rather than a direct ergogenic effect. The Liu 2024 meta-analysis (PMID 38243785) of 11 RCTs reported overall positive but heterogeneous effects on fatigue and motor function. Individual RCTs (Earnest 2011, Brown 2021, McAllister 2022, Waldman 2023, Gonzalez 2024) span a methodological range from null to clearly positive. Astaxanthin is unlikely to behave like creatine or caffeine as a direct performance booster, but is reasonable to consider for oxidative-stress modulation and training-adaptation contexts.
· source: Blog · Natural vs Synthetic Astaxanthin
Is astaxanthin safe?
The safety profile of natural Haematococcus astaxanthin in healthy adults at supplement doses is favourable. EFSA established an Acceptable Daily Intake of 0.2 mg/kg body weight per day in 2014 and reconfirmed it in 2020 — approximately 12 mg/day for a 60 kg adult and 16 mg/day for an 80 kg adult. FDA recognises natural Haematococcus astaxanthin as GRAS under multiple GRAS Notifications. As with any supplement, individuals on medication or with significant health conditions should consult a clinician. For pregnancy and lactation, defer to obstetric guidance because dedicated RCTs in those populations have not been performed.
· source: Blog · Natural vs Synthetic Astaxanthin
Should I take astaxanthin with food?
Yes — specifically with a fat-containing meal. Both natural and synthetic astaxanthin are highly lipid-meal dependent for absorption. The natural ester form requires intestinal hydrolysis followed by incorporation into mixed micelles, which depend on bile-acid-driven lipid emulsification. Fasted-state absorption of either form is markedly inferior. This is one of the most consistent and practically actionable findings in the astaxanthin pharmacokinetic literature (Mercke Odeberg 2003 PMID 12885395; Coral-Hinostroza 2004 PMID 15556071).
· source: Blog · Natural vs Synthetic Astaxanthin
What about astaxanthin during pregnancy or breastfeeding?
The reproductive-health RCT base is for preconception and PCOS contexts (Rodrigues 2025 PMID 39269488; Fereidouni 2024 PMID 38916710; Shafie 2024 PMID 39482765), not for pregnant or lactating women specifically. No astaxanthin RCT has been performed in pregnant women, and the standard regulatory framing is to refer to a clinician before supplementation during pregnancy and lactation. The absence of trials is not evidence of harm, but it is also not evidence of safety in those populations.
· source: Blog · Natural vs Synthetic Astaxanthin
How does astaxanthin compare to other carotenoid antioxidants?
Astaxanthin is unusual among dietary carotenoids in having two hydroxyl and two keto groups on its terminal rings, which gives it both lipid-soluble and (mild) amphipathic character. This is one reason its mechanistic literature emphasises mitochondrial-membrane traversal and antioxidant activity at the membrane interface (Kidd 2011 PMID 22214255; Yamashita 2021 PMID 33783748). It is not a direct substitute for lutein and zeaxanthin, which concentrate specifically in the macular pigment of the retina. In practice, astaxanthin and the lutein-zeaxanthin pair are often discussed together as complementary rather than competing carotenoids in an eye-support context.
· source: Blog · Natural vs Synthetic Astaxanthin
EPA (eicosapentaenoic acid, C20:5) and DHA (docosahexaenoic acid, C22:6) are both long-chain omega-3 fatty acids found in fish and marine algae, but they do different work in the body. EPA is the major precursor of anti-inflammatory and pro-resolution signaling molecules and has the stronger evidence for cardiovascular event reduction (in high-risk populations) and for adjunctive support in major depressive disorder. DHA is the major structural fatty acid of the brain and retina and is essential during fetal and infant neural development. For most general-maintenance use, a balanced EPA:DHA product is appropriate; for specific outcomes, match the ratio to the use case.
· source: Omega-3
Is ALA the same as omega-3? Is flaxseed enough?
ALA (α-linolenic acid) is the plant-based omega-3 and is essential — the body cannot make it. However, the body converts only a small fraction of ALA into EPA (roughly 8% in men, 21% in premenopausal women) and an even smaller fraction into DHA (below 5% whole-body in most adults). For most adults — and particularly for men, postmenopausal women, pregnant people, and infants — flaxseed alone does not deliver enough EPA and DHA for outcomes that depend on the long-chain forms. Plant-based eaters who want direct EPA and DHA should consider algal oil.
· source: Omega-3
Is fish oil or algal oil better?
Neither is universally better. Fish oil offers higher concentrations and lower cost per milligram of EPA+DHA, and most randomized-trial evidence used fish oil. Algal oil is the appropriate choice for vegetarians, vegans, pregnant and breastfeeding people, users avoiding marine contaminants, and users prioritizing sustainability. Many algal oils are DHA-dominant; choose an EPA-enriched algal product if EPA is your priority.
· source: Omega-3
Is krill oil really better than fish oil?
The strongest marketing claim for krill oil is that its phospholipid form improves per-milligram absorption. The data are mixed; in head-to-head trials, krill oil shows competitive plasma incorporation per milligram of EPA+DHA but typically delivers fewer total milligrams of EPA+DHA per softgel and costs more per milligram. Krill oil is reasonable for users with specific reasons to prefer the phospholipid form or the co-occurring astaxanthin; it is not generally superior to a third-party-certified rTG fish oil at higher EPA+DHA concentration.
· source: Omega-3
Can pregnant people take omega-3? How much?
Yes, omega-3 is recommended during pregnancy and lactation. The World Health Organization and the International Society for the Study of Fatty Acids and Lipids endorse at least 200 mg/day of DHA during pregnancy and lactation. The Cochrane systematic review (PMID 30480773) reported that omega-3 supplementation during pregnancy reduces the risk of early preterm birth (before 34 weeks gestation) by approximately 42%. Choose a low-contaminant source — third-party-certified fish oil or algal oil. Avoid stacking cod liver oil with other vitamin A supplementation during pregnancy.
· source: Omega-3
Does omega-3 prevent heart disease?
The answer is conditional, not yes-or-no. In statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes plus other risk factors, 4 g/day of pure prescription EPA (icosapent ethyl) reduced major cardiovascular events by 25% over five years (REDUCE-IT, PMID 30415628). In a general adult population without prior cardiovascular events, 1 g/day of an EPA+DHA combination did not reduce total major cardiovascular events over 5.3 years (VITAL, PMID 30415637). And 4 g/day of a mixed EPA+DHA carboxylic-acid combination did not reduce events and increased atrial-fibrillation risk in another high-risk population (STRENGTH, PMID 33190147). Dose, form, EPA-to-DHA ratio, and baseline risk all matter. Discuss high-dose omega-3 for cardiovascular prevention with a physician.
· source: Omega-3
Can omega-3 prevent or treat Alzheimer's disease?
DHA is a structural component of brain phospholipids, and meta-analytic evidence supports modest memory benefit in older adults with mild memory complaints (PMID 25786262). However, randomized trials in patients with already-diagnosed Alzheimer's disease do not show cognitive improvement or disease reversal from omega-3 supplementation (PMID 38924283; PMID 28986068). Omega-3 should not be presented as a treatment for established Alzheimer's disease; it is reasonable as part of cognitive maintenance across the lifespan.
· source: Omega-3
Does omega-3 help vision, dry eye, or AMD?
These are three distinct outcomes. Omega-3 has moderate evidence for symptomatic improvement in dry eye disease (improvements in tear film and symptom scores at 1–2 g/day EPA+DHA over 8–12 weeks). DHA is structurally essential for fetal and infant retinal development. However, omega-3 does not prevent or slow age-related macular degeneration (AMD) — the Cochrane systematic review (PMID 25856365) and the AREDS2 trial both concluded that omega-3 does not reduce AMD progression. Do not confuse the three.
· source: Omega-3
Does omega-3 help with depression?
Meta-analyses support an antidepressant effect for EPA-predominant formulations (EPA ≥60% of total long-chain omega-3) or pure EPA at roughly 1 g/day or below (PMID 31383846; PMID 26978738). DHA-predominant formulations do not show a clear antidepressant effect. Omega-3 is best considered an adjunct to standard care, not a substitute for evidence-based treatment of major depressive disorder. Choose an EPA-predominant product if mood support is the goal.
· source: Omega-3
Is high-dose omega-3 (4 g/day) risky?
At 4 g/day or higher, the risk of atrial fibrillation is increased — the STRENGTH trial reported about a 1% absolute increase, with a smaller signal in REDUCE-IT. Bleeding risk has been a theoretical concern but has not been demonstrated clinically in randomized trials at supplemental doses, including with concurrent anticoagulants. High-dose omega-3 should be used under physician supervision, particularly in people with a history of atrial fibrillation, atrial flutter, or other heart-rhythm disorders.
· source: Omega-3
How do I avoid fishy burps or aftertaste?
Three things help: (1) choose a higher-quality form (rTG over EE; concentrated softgels reduce the volume of oil per dose); (2) take omega-3 with the largest fat-containing meal of the day rather than on an empty stomach; (3) keep softgels refrigerated and inspect for signs of oxidation (off odor, broken softgels, fishy after-taste indicating that the oil has gone rancid). A product with a verified low TOTOX value (≤26, the GOED voluntary monograph upper limit) is less likely to cause reflux.
· source: Omega-3
Which form is best — rTG, EE, or TG?
On an empty stomach, rTG and natural TG forms achieve higher plasma incorporation than EE (rTG roughly 124%, TG 100% reference, EE roughly 73% in the Dyerberg 2010 head-to-head trial, PMID 20638827). With a fat-containing meal, the differences narrow substantially — EE absorption catches up to TG. For users who consistently take omega-3 with a meal, EE is acceptable; for users who often take it without food, rTG or TG is preferable. Krill phospholipid form is competitive per milligram but typically delivers less total EPA+DHA per softgel.
· source: Omega-3
For most healthy adults, yes — at 250–500 mg/day EPA+DHA from a third-party-certified product. Take with a meal. Doses ≥4 g/day have been associated with increased atrial fibrillation risk and should be used under medical supervision.
· source: Fish Oil
What is the best fish oil brand?
This page does not recommend brands. The evidence-based criteria are: third-party certification (IFOS 5-star, USP Verified, NSF), molecular distillation, anchovy or sardine sourcing, transparent per-softgel EPA + DHA mg disclosure, and TOTOX ≤26. Any product meeting all of these is a defensible choice.
· source: Fish Oil
What is the difference between fish oil and prescription omega-3?
Both prescription omega-3-acid ethyl esters and prescription icosapent ethyl are derived from fish oil that has been further concentrated and brought under medication regulation. Differences: concentration (≥96% pure EPA in icosapent ethyl), specified clinical indications (statin-treated patients with high triglycerides, in REDUCE-IT), and the requirement for a physician's prescription.
· source: Fish Oil
Why does my fish oil make me burp it back up?
Usually a sign of taking it on an empty stomach or using an oxidized product. Take with a fat-containing meal; choose a high-purity low-TOTOX product; refrigerate the bottle; consider enteric-coated softgels; consider a higher-concentration rTG; or switch to algal oil. See §7.3.
· source: Fish Oil
Is fish oil safe in pregnancy?
Standard EPA + DHA fish oil at 200–600 mg/day DHA is recommended in many pregnancy-nutrition guidelines, with Cochrane (PMID 30480773) supporting DHA's role in reducing early preterm birth. Choose a low-mercury source with third-party certification. Cod liver oil is a different story — its vitamin A content is teratogenic at high doses and it is not recommended in pregnancy. Algal oil is a fish-free alternative.
· source: Fish Oil
What is the difference between cod liver oil and regular fish oil?
Regular fish oil is extracted from body tissue; cod liver oil is extracted from cod liver, which naturally concentrates vitamins A and D. Cod liver oil carries a substantial vitamin A dose that can exceed the safe upper limit if stacked with multivitamins, and is teratogenic in pregnancy at high doses. See §6.3. They are not interchangeable.
· source: Fish Oil
Are mercury and PCBs a real concern with fish oil supplements?
The raw-material risk is real — high-trophic-level fish accumulate mercury and persistent organic pollutants. The finished-product risk is mitigated by modern refining: molecular distillation removes most contaminants, and IFOS / USP / NSF testing verifies. Choose anchovy or sardine sourcing, third-party certification, and molecular-distillation disclosure.
· source: Fish Oil
What is the difference between fish oil triglyceride and ethyl ester?
TG is the natural ester form fish oil arrives in from the fish. EE is a more concentrated form created during refining (50–90% EPA+DHA per gram). rTG re-attaches the concentrated EE to a glycerol backbone, recovering most of the bioavailability advantage of natural TG at the higher concentration. With a fat-containing meal, the bioavailability difference between TG, rTG, and EE is small (Schuchardt and Hahn 2013, PMID 23676322). See §3.
· source: Fish Oil
Can I take fish oil with my blood thinner?
At general-maintenance doses (≤1 g/day), most evidence does not show clinically meaningful bleeding interactions with anticoagulants or antiplatelets. At higher doses (≥2 g/day) and in combination with anticoagulants, inform your prescribing physician and be monitored. See the omega-3 hub page §6.
· source: Fish Oil
Does fish oil really prevent heart disease?
The honest answer distinguishes populations and doses. In statin-treated patients with elevated triglycerides, 4 g/day pure-EPA prescription reduced major events by 25% (REDUCE-IT, PMID 30415628). In post-MI patients in the pre-statin era, 1 g/day fish oil reduced mortality (GISSI-Prevenzione, PMID 10465168). In the broad 79-trial Cochrane synthesis in the statin era, low-dose long-chain omega-3 made little or no difference (PMID 30019766). In a general adult population, 1 g/day did not reduce events over 5.3 years (VITAL, PMID 30415637). The truthful summary: in specific high-risk, high-triglyceride, statin-treated populations the evidence supports targeted use; in the general adult population, fish oil does not appear to prevent cardiovascular disease at low-to-moderate doses.
· source: Fish Oil
What is algal oil, and how is it different from fish oil?
Algal oil is a long-chain omega-3 (mostly DHA) source produced by closed-system fermentation of microalgae — the organisms at the base of the marine food chain that fish indirectly accumulate DHA from. Algal oil is plant-derived and contains no marine contaminants, but it costs more than fish oil and is typically very low in EPA. Fish oil has a broader EPA-and-DHA profile and a deeper clinical evidence base in cardiovascular outcomes, but carries source-chain contaminant and sustainability considerations.
· source: Algal Oil
How much DHA and EPA does algal oil contain?
Most commercial algal oil (from Schizochytrium sp. or Crypthecodinium cohnii) is 35–55% DHA and less than 3% EPA. Algal oil from Nannochloropsis sp. is the opposite — 25–35% EPA and very little DHA — but is uncommon in retail supplements.
· source: Algal Oil
Why is EPA so low in most algal oil?
The Thraustochytrid microalgae (Schizochytrium, Ulkenia) and the dinoflagellate Crypthecodinium cohnii synthesize DHA through enzymatic pathways that terminate at C22:6 n-3 (DHA) without significantly producing C20:5 n-3 (EPA). EPA-rich algal oil requires a different microalga — Nannochloropsis — which uses a different pathway.
· source: Algal Oil
Is algal oil better than fish oil?
Not in a single direction. Algal oil and fish-derived DHA are bioequivalent in head-to-head testing (Arterburn 2008, PMID 18589030). Algal oil is the appropriate choice for vegans, vegetarians, kosher and halal observers, people concerned about marine contaminants during pregnancy, and infant-formula applications. Fish oil is the appropriate choice for cost-sensitive supplementation, for EPA-specific applications (mood support, anti-inflammation), and for cardiovascular event prevention (where prescription pure EPA has the strongest evidence). Many users benefit most from understanding which oil fits which question.
· source: Algal Oil
Is algal oil safe and appropriate during pregnancy?
WHO, ISSFAL, EFSA, ACOG, and the China dietary guidelines all recommend ≥200 mg DHA per day during pregnancy. Algal oil is a regulator-aligned source with the additional advantage of zero placental exposure to marine contaminants. The DOMInO trial tested a much higher dose (800 mg DHA + 100 mg EPA per day) and found no benefit on its primary endpoints (maternal depression, infant cognition) but did report, as a secondary finding, fewer early preterm births. The same trial also reported a small increase in post-term inductions and caesareans. Discuss higher-dose use with your obstetric care provider.
· source: Algal Oil
Can babies and children take algal oil?
Infant formula sold globally typically contains algal-derived DHA and is the standard channel for delivering DHA to infants. This is different from buying an algal oil food supplement for a child. In Brazil specifically, ANVISA IN 28/2018 restricts food-supplement algal oil to consumers aged ≥19 years; pediatric-positioned algal DHA supplements were suspended by VISA/SC in 2023. In other markets, parents considering algal oil for children should consult a pediatrician and verify local regulations.
· source: Algal Oil
Is algal oil suitable for vegans, kosher, halal, or Hindu vegetarian diets?
Yes. Algal oil contains no animal tissue, fish protein, or shellfish allergen and is the only scalable direct source of long-chain omega-3 for plant-based diets. Plant-derived alpha-linolenic acid (ALA, from flaxseed or chia) does not efficiently convert to EPA or DHA in the body — typically below 5% whole-body conversion to DHA in adults — so direct algal-oil supplementation is the most reliable route. Look for the relevant certification mark for your dietary tradition.
· source: Algal Oil
Does algal oil lower triglycerides?
Yes — a 2012 meta-analysis of 11 RCTs (Bernstein et al., PMID 22113870) found that algal-derived DHA significantly reduces serum triglycerides in adults without coronary heart disease. The same meta-analysis also reports that algal DHA modestly raises both HDL-cholesterol and LDL-cholesterol; both directions of the lipid effect should be communicated together. For cardiovascular event prevention in high-risk patients with hypertriglyceridemia, the strongest evidence comes from prescription pure EPA (icosapent ethyl, 4 g/d, REDUCE-IT trial); algal DHA has no comparable large outcome trial.
· source: Algal Oil
Does algal oil really contain no mercury or PCBs?
Independent contaminant testing on refined algal oil routinely reports heavy metals (mercury, lead, cadmium, arsenic) and PCB sums at below detection limit — below the lower bound of standard laboratory quantification, not merely below regulatory permissible maxima. This is a structural difference: closed-system fermentation does not expose the oil to the marine source chain that biomagnifies these contaminants in fish. No detection method has a true zero floor, so "below detection limit" is the most precise honest statement, not "absolute zero."
· source: Algal Oil
What are algal oil's most important limitations?
Higher cost than fish oil (typically 2–4×); very low EPA in the dominant Schizochytrium / C. cohnii forms (a poor match for EPA-driven uses such as MDD adjunct or prescription-strength cardiovascular event prevention); the LDL-cholesterol-raising effect alongside triglyceride lowering; the Brazilian ≥19-year age restriction on food-supplement use; and the relatively thin clinical-outcome evidence base specific to algal EPA. These are real and have been integrated into the discussion above; algal oil's case rests on its genuine differentiators, not on hiding its constraints.
· source: Algal Oil
Krill oil is an oil extracted from Antarctic krill (Euphausia superba), a small crustacean that lives in the Southern Ocean around Antarctica. Antarctic krill is one of the most abundant animal species on Earth by biomass. The fishery is managed by CCAMLR and was first MSC-certified in 2010.
· source: Krill Oil
Is krill oil better than fish oil?
The honest answer is "it depends what you mean by better." Per milligram of EPA+DHA, krill's phospholipid form may be modestly more bioavailable than fish oil's ethyl-ester form in short-term trials — though a 2015 head-to-head trial found no significant difference at matched doses, and a 2014 reexamination concluded the per-milligram advantage is smaller and less consistent than early marketing claimed. Per softgel, fish oil delivers substantially more EPA+DHA than krill oil (often 2–4 times more). For clinical doses ≥2 g/day, krill oil is impractical. For long-term clinical outcomes (cardiovascular events, depression, dry eye), the evidence base is overwhelmingly fish-oil and there is no demonstrated krill superiority.
· source: Krill Oil
Does krill oil have astaxanthin? Is the amount meaningful?
Yes, krill oil naturally contains astaxanthin — typically 0.1–0.4 mg per 500 mg softgel. The astaxanthin protects the oil from oxidation and contributes a small dietary dose, but the daily astaxanthin intake from standard krill dosing (~0.2–0.8 mg/day) is 5–60 times below the 4–12 mg/day used in dedicated astaxanthin clinical trials. If astaxanthin is your goal, a dedicated astaxanthin supplement is the practical choice. See the astaxanthin sub-page for details.
· source: Krill Oil
Is krill oil sustainable? Is the fishery harming penguins and whales?
The Antarctic krill fishery is one of the most precautionarily managed major fisheries in the world. CCAMLR's trigger limit (620,000 tonnes/year) represents approximately 0.4% of estimated krill biomass — far below typical wild-fishery exploitation rates. The fishery was first MSC-certified in 2010, with successive re-certifications since. However, environmental NGOs including the Pew Charitable Trusts and the Antarctic and Southern Ocean Coalition (ASOC) continue to raise concerns about geographic concentration of catch (Subarea 48.1, also a critical penguin and whale foraging area), climate-driven habitat stress, and the precautionary principle in a keystone-species fishery. Consumers who want to avoid the debate entirely have a structurally lower-impact alternative: algal oil, produced via closed-system fermentation.
· source: Krill Oil
Can I take krill oil if I am allergic to shellfish?
No. Krill is a crustacean and people with a documented shellfish (crustacean) allergy should not take krill oil. Cross-reactivity with other crustacean allergens is documented. Use fish oil (if fish allergy is absent) or algal oil (no marine-allergen cross-reactivity) instead.
· source: Krill Oil
Is krill oil safe during pregnancy or breastfeeding?
Krill oil is approved as a food supplement ingredient by EFSA and ANVISA without a pregnancy contra-indication, but the clinical-trial evidence base for omega-3 in pregnancy is built almost entirely on fish oil and algal oil, not krill oil. For pregnant or breastfeeding people, fish oil or algal oil is the better-evidenced choice. Algal oil is preferred for vegetarian, vegan, or shellfish-allergic mothers.
· source: Krill Oil
Why is krill oil more expensive than fish oil?
Three reasons: (1) krill oil softgels contain only 80–150 mg EPA+DHA — about half the EPA+DHA per softgel of standard fish oil and one-sixth of concentrated EE fish oil; (2) Antarctic krill harvest is technically demanding (long distances, harsh conditions, on-board immediate processing to prevent enzymatic degradation); and (3) the phospholipid extraction process is more complex than standard fish-oil refining. Per gram of EPA+DHA, krill oil typically costs 5–15 times more than standard fish oil.
· source: Krill Oil
Can krill oil prevent heart disease, depression, or Alzheimer's?
No randomized trial of krill oil has been conducted at the scale needed to test cardiovascular-event prevention, depression treatment, or dementia prevention. These outcomes have been studied with fish oil — with mixed results that depend heavily on dose, form, EPA:DHA ratio, and baseline risk (see the Omega-3 cluster hub). Statements that krill oil "prevents" any disease exceed the krill-specific evidence base.
· source: Krill Oil
Does krill oil burp less than fish oil?
In practice, many users report fewer fishy burps with krill oil at matched doses, attributable to the phospholipid form being more readily emulsified and to the antioxidant protection from astaxanthin. This is consistently reported across user populations though not rigorously quantified in head-to-head trials. People who tolerate fish oil well generally do not need to switch; people who experience reflux or aftertaste with fish oil may find krill oil more tolerable.
· source: Krill Oil
Is krill oil the right choice for me?
Krill oil is a reasonable fit if you want a marine omega-3 in the phospholipid form, are satisfied with a moderate (≤500 mg/day) EPA+DHA intake, do not have a shellfish allergy, are not pregnant or breastfeeding, and are not highly cost-sensitive. Fish oil is a better fit if you need higher EPA+DHA doses, are cost-sensitive, or are pregnant. Algal oil is the better fit if you are vegetarian, vegan, shellfish-allergic, or pregnant, or if sustainability is your highest priority.
· source: Krill Oil
No, not for indications that depend on EPA or DHA — including cardiovascular event prevention, mood support, anti-inflammatory effects in rheumatoid arthritis, dry eye, and pregnancy/infant neurodevelopment. Flaxseed provides ALA, and whole-body conversion to DHA is typically under 5%. Use fish oil or algal oil when EPA/DHA is the requirement.
· source: Flaxseed ALA
How do vegans get enough omega-3?
Combine plant-source ALA (1–2 tablespoons milled flaxseed daily, plus chia, hemp, walnut for variety) with algal oil for direct EPA and DHA — typically 200–500 mg/day combined EPA+DHA. Flaxseed alone is not enough for adult men, post-menopausal women, pregnant and lactating women, or infants.
· source: Flaxseed ALA
Flaxseed vs. chia — which is better?
Both deliver ALA. Flaxseed has higher ALA density (~22% vs. ~17%) and the richest lignan load of any common food. Chia has higher calcium and magnesium and forms a gel that improves whole-seed absorption without grinding. They are complementary rather than competitive — dietary variety wins.
· source: Flaxseed ALA
Does flaxseed cause cancer?
The honest summary: an early 2004 meta-analysis raised a question about high ALA intake and prostate cancer, but later large prospective cohorts have not consistently replicated the signal. Current institutional consensus does not restrict dietary ALA, including flaxseed, in the general population. Men with personal or family history of prostate cancer considering high-dose ALA supplementation should discuss with their clinician. For breast cancer, preclinical and observational lignan data lean protective, but human RCT outcome data are limited; survivors on endocrine therapy should consult their oncology team before high-dose use.
· source: Flaxseed ALA
Is flaxseed oil safe to cook with?
No. Flaxseed oil is rich in polyunsaturated ALA, which degrades rapidly with heat. Use it cold — drizzled on salads, blended into yogurt or smoothies — and store refrigerated in dark glass. Discard at the first hint of rancid or bitter flavor.
· source: Flaxseed ALA
Whole seed or ground — does it matter?
Yes — substantially. Whole seeds are physically resistant to digestion and many pass through intact, delivering little ALA. Grind at home and use within 24 hours, or buy pre-milled meal and refrigerate immediately.
· source: Flaxseed ALA
How much flaxseed per day?
One tablespoon of milled flaxseed (~10 g, ~2.4 g ALA) is enough to exceed adult Adequate Intake. Cardiovascular RCTs typically used 30 g/day (~3 tablespoons) over 12+ weeks. Start low to allow your gut to adapt to the fiber.
· source: Flaxseed ALA
Do I need to take a lignan supplement?
No. Milled flaxseed already supplies SDG lignans in their natural matrix. Concentrated lignan extracts are an extra step with weaker safety data, particularly during endocrine therapy or pregnancy.
· source: Flaxseed ALA
Will flaxseed lower my blood pressure?
Randomized trials suggest yes, modestly. A meta-analysis of 11 RCTs found average reductions of roughly –2.85 mmHg systolic and –2.39 mmHg diastolic; a single dedicated trial in patients with peripheral arterial disease reported larger effects (–10/–7 mmHg) over 6 months. Effects are stronger with whole or milled seed than with flax oil alone. Flaxseed is an adjunct to, not a replacement for, prescribed antihypertensive therapy.
· source: Flaxseed ALA
Is fish oil supplementation proven to prevent heart attacks?
For unselected healthy adults in primary prevention, the answer based on VITAL (2019, n=25,871) and the 2020 Cochrane review (86 RCTs, 162,796 participants) is that routine 1 g/d EPA+DHA supplementation has not been proven to prevent major cardiovascular events. For statin-treated patients with established cardiovascular disease, elevated triglycerides (135-499 mg/dL), and other REDUCE-IT entry criteria, prescription icosapent ethyl 4 g/d reduced major adverse cardiovascular events by 25% — but this is a prescription medicine at a specific dose in a specific population, not the over-the-counter fish oil at the supplement-aisle dose.
· source: Blog · Omega-3 Evidence History
What is the difference between prescription icosapent ethyl and over-the-counter fish oil?
Icosapent ethyl (brand name Vascepa, generic in many markets) is a prescription medicine containing at least 96% pure EPA ethyl ester with no DHA. Over-the-counter fish oil supplements typically contain a mixture of EPA and DHA at varying ratios and purities. Icosapent ethyl at 4 g/d has FDA approval for cardiovascular risk reduction in specific high-risk statin-treated patients based on REDUCE-IT. Over-the-counter mixed EPA+DHA supplements do not have equivalent cardiovascular outcome evidence — and STRENGTH (2020) specifically tested 4 g/d of a mixed EPA+DHA preparation in a similar population and found no benefit.
· source: Blog · Omega-3 Evidence History
Why did REDUCE-IT and STRENGTH reach opposite conclusions?
Five plausible reasons that the field is still working through: EPA-only versus mixed EPA+DHA composition; mineral-oil placebo bias in REDUCE-IT (which raised LDL-C and hsCRP in the placebo arm); formulation pharmacology differences (ethyl ester versus free fatty acid carboxylic acid); minor patient-enrichment differences; and the honest possibility that these two trials simply represent equipoise — two well-designed studies that happen to disagree. The field’s current consensus: prescription EPA-only 4 g/d in eligible patients has the strongest evidence; mixed EPA+DHA at 4 g/d does not.
· source: Blog · Omega-3 Evidence History
Does omega-3 help with inflammation?
Yes, biologically — increasing EPA and DHA intake raises plasma and tissue levels of specialized pro-resolving mediators (SPMs: resolvins, protectins, maresins) and reduces hsCRP, IL-6, and TNF-α in meta-analytic evidence (Li 2014, 68 RCTs, 4,601 subjects). Clinically — whether biomarker reduction translates to disease outcomes — depends heavily on the condition. RA shows modest adjunctive benefit. IBD does not. Psoriasis evidence is thin. General "anti-aging inflammation" claims go beyond what trial data support.
· source: Blog · Omega-3 Evidence History
Should I take fish oil if I have rheumatoid arthritis?
Discuss with your rheumatologist. Meta-analytic evidence (Lee 2012, 17 RCTs) supports a modest adjunctive role — primarily in reducing NSAID consumption — at doses of 2.7-4 g/d EPA+DHA over 12-24 weeks. Omega-3 is not a substitute for DMARDs (methotrexate), biologics (anti-TNF, IL-6R blockers), or JAK inhibitors. It is one tool among many for symptom management.
· source: Blog · Omega-3 Evidence History
What dose of omega-3 is supported by evidence?
For triglyceride lowering, 1 g/d reduces TG by 5-10%; 4 g/d reduces TG by 25-30% (Cochrane 2020). For cardiovascular event reduction in eligible high-risk patients, REDUCE-IT supports prescription icosapent ethyl 4 g/d. For inflammation biomarker reduction, 1-3 g/d EPA+DHA over 12 or more weeks. For RA adjunctive therapy, 2.7-4 g/d. For primary cardiovascular prevention in healthy adults, no specific dose has been shown to reduce events — supplementation in this context is a nutrition-status correction rather than a pharmacologic intervention.
· source: Blog · Omega-3 Evidence History
Is plant-based omega-3 (ALA) equivalent to fish oil?
No. Alpha-linolenic acid (ALA) from flax, chia, and walnuts is converted to EPA at very low efficiency in humans (typically less than 5%) and to DHA at near-zero efficiency. The Cochrane 2020 review concluded that ALA "probably makes little or no difference" on cardiovascular outcomes. ALA has independent nutritional value as an essential fatty acid, but it is not a substitute for marine EPA+DHA if EPA+DHA is the target.
· source: Blog · Omega-3 Evidence History
Protein (Whey / Casein / Soy / Pea / Plant / Yeast) (78 Q)
Neither is universally better. Whey has the highest leucine per gram of any common source (~11%), the fastest digestion, the strongest endogenous GLP-1 / GIP release, and the deepest randomized-trial evidence base — it is the default for resistance-training adults, for pre-meal glycemic support, and for older adults targeting sarcopenia prevention. Plant proteins are essential for vegetarians and vegans, are typically more sustainable, and reach dairy-comparable DIAAS (0.90–1.00) when used as complementary blends (pea + rice ± hemp). For most general-maintenance users with no dietary restriction, a third-party-tested whey isolate is the highest-evidence default; for plant-based users, a third-party-tested pea-and-rice blend is the comparable choice.
· source: Protein
Will soy protein lower my testosterone or feminize me as a man?
No, not at dietary and supplement-realistic intakes. The Hamilton-Reeves et al. 2010 meta-analysis (PMID 19524224) covering 20–900 mg/day isoflavone and 0–71 g/day soy protein found no effect on male testosterone, sex-hormone-binding globulin, free testosterone, or free-androgen index. The Reed et al. 2021 expanded meta-analysis (PMID 33383165) reproduced the conclusion. At realistic intakes of approximately 25–50 g/day of soy protein (which corresponds to roughly 50–150 mg/day of isoflavones), there is no clinically meaningful effect on male reproductive hormones in the published evidence.
· source: Protein
Does high-protein eating damage your kidneys?
No, not in healthy adults. The Devries et al. 2018 meta-analysis (PMID 30383278) concluded that changes in kidney function do not differ between healthy adults consuming higher- compared with lower- or normal-protein diets. Up to 2.0 g/kg/day produces no measurable kidney harm in randomized trials; up to 3.0 g/kg/day for ≤1 year in trained adults also produced no harm in randomized data (Antonio et al. 2016, PMID 27807480). Adults with already-diagnosed chronic kidney disease are a separate case and should follow the KDIGO 2024 stage-specific recommendations (typically 0.6–0.8 g/kg/day) with medical and renal-dietitian supervision.
· source: Protein
Does high-protein eating cause calcium loss and weak bones?
No, not under the "acid-ash hypothesis" framing. The Fenton et al. 2009 meta-analysis (PMID 19419322) concluded that increasing dietary acid load did not promote skeletal bone mineral loss or osteoporosis. With adequate calcium and vitamin D, higher protein intake is neutral to favorable for bone health — particularly in older adults, where ESPEN consensus explicitly recommends against restricting protein "to protect bones."
· source: Protein
How much protein should I eat per meal?
Roughly 0.4 g/kg per meal — typically 25–30 g for younger adults and 35–40 g for older adults (who experience anabolic resistance). Aim to reach the per-meal target ≥2.5–3.0 g of leucine, which reliably triggers the muscle protein synthesis pathway. Distributing total daily protein across 4–5 meals at the per-meal target generally produces better cumulative muscle protein synthesis than 1–2 large meals at the same total.
· source: Protein
I'm on Ozempic / Wegovy / Mounjaro / Zepbound — how much protein should I be eating?
Current expert consensus suggests 1.5–2.0 g/kg/day of ideal body weight, with per-meal doses of 25–30 g from leucine-rich sources (whey, casein, soy isolate, or amino-acid-complete plant blends), combined with resistance exercise at least 2–3 times per week. The rationale is that GLP-1-receptor-agonist medications substantially reduce appetite and total caloric intake; without adequate protein and resistance training, 25–40% of the weight lost can come from lean muscle mass rather than fat alone. Most of this guidance is currently extrapolated from the sarcopenia-prevention and weight-loss-preservation literatures rather than from direct large randomized controlled trials in GLP-1-user populations (those direct trials are in progress). Discuss your individual targets with your prescribing physician and a registered dietitian.
· source: Protein
How much protein do older adults need?
1.0–1.2 g/kg/day for healthy older adults and 1.2–1.5 g/kg/day during acute illness or active resistance training, per ESPEN PROT-AGE 2014 and the ESPEN Geriatric Nutrition Guideline 2019. Per-meal doses should be in the 30–40 g range with ≥3 g of leucine to overcome the anabolic resistance that develops with aging. Whey is the best-supported single source because of its high leucine content; amino-acid-complete plant blends can deliver comparable benefit in vegetarian or vegan older adults.
· source: Protein
What is DIAAS, and how is it different from PDCAAS?
DIAAS (Digestible Indispensable Amino Acid Score) replaced PDCAAS (Protein Digestibility-Corrected Amino Acid Score) as the FAO-recommended protein-quality measure in 2013. The key differences: DIAAS uses ileal digestibility (measured at the terminal small intestine, capturing what actually enters circulation) rather than fecal digestibility; DIAAS has no score ceiling at 1.00 (so high-quality proteins can score above 1.00, reflecting capacity to complement lower-quality proteins in mixed meals); and DIAAS uses age-group-specific amino-acid reference patterns. Most product labels still display PDCAAS because regulatory adoption lags the FAO recommendation. The Mathai et al. 2017 study (PMID 28382889) is the most-cited empirical demonstration of the value of the DIAAS approach.
· source: Protein
Whey concentrate vs. isolate vs. hydrolysate — which should I buy?
Concentrate (WPC) is the lowest-cost, highest-mouthfeel option that retains naturally occurring immunoglobulins; it contains 4–8% lactose, which is a problem for lactose-intolerant users. Isolate (WPI) is ≥90% protein with <1% lactose, resolving lactose intolerance, at moderately higher cost. Hydrolysate (WPH) is pre-digested for fastest absorption, used clinically for glycemic support (the Jakubowicz 2014 trial used WPH) and post-surgical recovery; it has a bitter taste and the highest cost. For most general users with no lactose intolerance, isolate is a reasonable default; concentrate is a budget-friendly alternative; hydrolysate is reserved for specific clinical and pre-meal-glycemic uses.
· source: Protein
Is yeast protein safe and effective?
Yeast protein (Saccharomyces cerevisiae) is approved as a novel food ingredient in China under NMPA 2023 regulations and has FDA GRAS status in the United States, supporting safety in healthy adults at intended supplement doses. The direct human randomized-controlled-trial evidence base is newer and thinner than for whey, casein, soy, or pea (fewer than three published direct human RCTs as of late 2025); most current supporting evidence is by analogy to mycoprotein, a different organism (Fusarium venenatum) with a more developed RCT base. NMPA precautionarily excludes use in infants, pregnant women, and breastfeeding women on insufficient-data grounds (this is a precautionary, not a hazard-identified, exclusion). Yeast protein is a reasonable plant-alternative option for adults prioritizing sustainability and microbial-fermentation-derived nutrition; it is not yet established at the evidence-tier level of whey, casein, soy, or pea.
· source: Protein
Can a plant-protein blend really replace whey?
For amino-acid completeness, yes — a well-designed pea + rice (± hemp / sacha inchi) blend can reach DIAAS ≥0.90–1.00, comparable to dairy proteins. The relevant trade-offs to be honest about: blends generally have slightly lower leucine per gram than whey (~7–9% vs. ~11%), digest more slowly, and produce a somewhat smaller acute muscle-protein-synthesis spike per meal in head-to-head comparisons. For most general users, total daily protein and per-meal leucine across 4–5 meals matter more than the exact peak per-meal MPS rate, and well-designed plant blends deliver comparable practical results in vegetarian and vegan users. For older adults targeting sarcopenia prevention, a slightly higher per-meal dose (35–40 g) and possibly supplemental leucine may help close any remaining gap.
· source: Protein
Is collagen a complete protein?
No. Collagen is the most abundant structural protein in the body, but as a dietary source it is incomplete — it lacks adequate tryptophan and is unbalanced across several essential amino acids. Collagen supplementation can be a reasonable addition for users specifically targeting joint, skin, or connective-tissue support (acknowledging that the clinical evidence for those effects is moderate, not strong), but collagen should not be counted toward the per-meal complete-protein target and should not substitute for whey, casein, soy isolate, or a complete plant blend in the muscle-protein-synthesis context.
· source: Protein
For most healthy adults with no cow's milk allergy, yes — at 20–30 g/serving and total daily protein within the 1.0–2.2 g/kg/day range. Choose a third-party-certified product (Informed Sport, NSF Certified for Sport, or USP Verified) from a transparent dairy source. Lactose-intolerant adults should choose CFM WPI over WPC.
· source: Whey Protein
WPC vs. WPI vs. WPH — which should I buy?
WPC 80 is the lowest-cost option with the best mouthfeel and the highest retention of immunoglobulins and lactoferrin; it contains 4–8% lactose and is not suitable for lactose-intolerant adults. CFM WPI is ≥90% protein with <1% lactose, the leucine-dense option that resolves lactose intolerance at moderately higher cost — a reasonable default for most users. WPH is pre-digested for the fastest absorption and is the form with direct evidence support for pre-meal glycemic management in type 2 diabetes (the Jakubowicz 2014 and Smith 2022 trials both used WPH); it is bitter, requires flavoring, and is the most expensive. See §3.
· source: Whey Protein
Is whey protein good for weight loss?
Within an intentional caloric deficit, adequate protein at 1.6–2.4 g/kg/day supports lean-mass preservation while supporting fat loss (Miller 2014 PMID 24724774). Whey specifically — through its combination of high leucine content, fast absorption, and strong endogenous GLP-1 / GIP / CCK / PYY response — has direct evidence support for modest spontaneous weight loss in free-living overweight adults (Baer 2011 PMID 21677076 — whey produced ~1.8 kg body-weight reduction and ~2.3 kg fat-mass reduction over 23 weeks vs. maltodextrin; soy did not differ from maltodextrin in the same trial).
· source: Whey Protein
Can lactose-intolerant adults take whey protein?
Yes — choose CFM WPI (<1% lactose) over WPC (4–8% lactose). A 30 g WPI scoop delivers <0.3 g of lactose, well below the 4–12 g threshold most lactose-intolerant adults tolerate without symptoms. WPH is similarly low-lactose. Plant or fermentation alternatives are completely lactose-free.
· source: Whey Protein
Whey vs. casein — which is better?
Different roles, not a head-to-head winner. Whey is the fastest-digesting protein with the highest acute muscle-protein-synthesis response; casein is the slowest-releasing (its micellar structure gels in stomach acid and releases amino acids over 6–8 hours). The classic sports-nutrition framework: whey post-training or in the morning, casein before sleep or before long intervals between meals. In chronic 12–24 week resistance-training studies at adequate total daily protein, the head-to-head difference in lean-mass and strength endpoints is generally small.
· source: Whey Protein
Whey vs. plant protein blend — which is better?
Whey has the acute advantage on per-meal muscle-protein-synthesis response (higher leucine per gram, faster absorption). In chronic 12+ week training studies that meet 1.6–2.2 g/kg/day total daily protein, the head-to-head gap between whey and a DIAAS-matched plant blend (pea + rice at DIAAS ≥0.90) is generally not statistically significant on lean-mass or strength endpoints in trained adults. For vegan or vegetarian users, a third-party-tested plant blend is a reasonable alternative; for users with no dietary restriction, whey is the higher-evidence default.
· source: Whey Protein
Can whey protein help with type 2 diabetes?
Yes, as an adjunct to standard medical care — not a replacement for it. Pre-meal whey hydrolysate (15–50 g taken 15–30 minutes before the main meal) reliably raises endogenous GLP-1 and GIP and lowers the post-meal glucose peak in adults with type 2 diabetes (Jakubowicz 2014 PMID 25005331). A 7-day free-living continuous-glucose-monitoring study extended the result to a more practical 15 g × 3 daily protocol with significant time-in-range improvement (Smith 2022 PMID 35618446). Discuss any glycemic-management strategy with your prescribing physician and diabetes care team.
· source: Whey Protein
Should I take whey protein if I'm on Ozempic / Wegovy / Mounjaro / Zepbound?
Current expert guidance — emerging European Society for Clinical Nutrition and Metabolism (ESPEN) consensus and Cleveland Clinic Endocrinology practice advisories — suggests targeting 1.5–2.0 g/kg/day of ideal body weight, with per-meal doses of 25–30 g from leucine-rich sources combined with resistance training 2–3 times per week. Whey's high leucine content (~11% of protein by mass) makes it mechanistically well-suited to this use; CFM WPI is generally easier to consume than WPC at the reduced appetite associated with GLP-1-class therapy. Most direct trial evidence in GLP-1-user populations is still accumulating; current recommendations are extrapolated from the sarcopenia-prevention and weight-loss-preservation literatures. Discuss your individual targets with your prescribing physician and a registered dietitian. See hub page §4.6.
· source: Whey Protein
Is whey protein vegan?
No. Whey is a dairy product. For vegan, halal-strict, kosher-pareve, or cow's milk-allergic users, see the sibling plant protein blend, soy protein, pea protein, or yeast protein sub-pages. Most whey products meet kosher-dairy and halal standards (rennet source needs halal certification — microbial or plant-derived rennet typically satisfies this).
· source: Whey Protein
How much whey protein per day is too much?
Healthy adults tolerate total daily protein up to 3.0 g/kg/day in short-to-medium-term randomized trials (Antonio 2016 PMID 27807480 — ≤1 year demonstrated, no liver or kidney harm). The practical upper bound is not a safety ceiling but a diminishing-returns ceiling: per-meal muscle-protein-synthesis response saturates around 25 g in younger adults and 35–40 g in older adults, so a single 50 g bolus does not produce 2× the MPS response — the surplus is oxidized for energy. Adults with diagnosed chronic kidney disease should follow KDIGO 2024 stage-specific restriction (typically 0.6–0.8 g/kg/day) under medical and renal-dietitian supervision.
· source: Whey Protein
Neither is "better" — they answer different questions. Whey is the right answer post-workout and on waking (fast amino-acid spike, peak ~1–2 h). Casein is the right answer pre-sleep and during long meal gaps (sustained release over 6–8 h). The strongest practical pattern is morning whey, bedtime casein, with complete protein from any source at other meals. See §4.3 and §8.
· source: Casein Protein
Should I take casein before bed?
For active or resistance-trained adults, yes — 30–40 g of micellar casein about 30 minutes before sleep. Three RCTs (Res 2012 PMID 22330017, Snijders 2015 PMID 25926415, Trommelen 2016 PMID 27643743) show roughly 22% higher overnight MPS, greater 12-week training gains, and synergy with same-day exercise. For sedentary adults focused on weight loss, calorie balance still applies — pre-sleep casein is a tool inside a calorie plan, not an exemption from it.
· source: Casein Protein
Will casein before bed make me fat?
Not in active populations. Kinsey-Ormsbee 2015 (PMID 25859885) systematically reviewed pre-sleep protein vs general nighttime eating and concluded that pre-sleep casein at 30–40 g in active or resistance-trained populations does not cause fat gain — it supports muscle and resting metabolism. The fat-gain signal in the broader nighttime-eating literature comes from late-night snacking on energy-dense, low-protein foods in sedentary populations, and is a different question from a 30 g protein dose. See §4.5.
· source: Casein Protein
What is the difference between micellar casein and caseinate?
Micellar casein retains the intact micelle structure that produces gastric curdling and the slow 6–8 hour release. Caseinates (calcium or sodium) have lost part of that structure during the acid-precipitation and neutralization steps in processing — they still release slowly compared with whey, but the slow-release advantage is partially blunted. For pre-sleep and long-interval use cases, prefer micellar casein. For general supplement use, caseinate is acceptable and usually cheaper.
· source: Casein Protein
Is casein hydrolysate the same as micellar casein?
No. Casein hydrolysate is pre-digested into small peptides and releases fast (similar to whey, 1–2 h). It has lost the slow-release advantage that defines micellar casein. Hydrolysate has legitimate roles — clinical nutrition, infant hypoallergenic formulas, and the small-dose α-casozepine sleep/anxiety segment — but is the wrong product if your reason for buying casein is pre-sleep overnight MPS. See §2.2 and §7.2.
· source: Casein Protein
What is A1 vs A2 milk / casein?
Cow β-casein comes in two main genetic variants. Digestion of A1 can release the peptide β-casomorphin-7 (BCM-7); digestion of A2 does not, because the cleavage site is disrupted by the A2 proline-67 substitution. Small pilot RCTs in self-reported milk-intolerance populations (Ho 2014 PMID 24986816; Jianqin 2016 PMID 27039383, n ≈ 40–45 each) report better digestive comfort on A2-only milk; larger independent RCTs are limited; some studies were partly funded by A2 milk producers. If you have persistent dairy discomfort despite confirmed lactose tolerance, trying A2-only products is reasonable; for the general population, the distinction is not clinically established as meaningful. See §6.2.
· source: Casein Protein
Is casein OK for people with lactose intolerance?
Often, depending on form and severity. Calcium or sodium caseinate and casein hydrolysate contain <1% lactose and are usually well tolerated. Micellar casein contains ~1–2% lactose and may produce symptoms at higher doses in moderately or severely lactose-intolerant consumers. Lactose-free-labeled caseinate or hydrolysate is an option; alternatively, choose a plant-protein sibling. See §6.1.
· source: Casein Protein
Can people with a milk allergy take casein?
No. Casein is one of the two main allergens in cow's-milk protein allergy (CMPA), and CMPA patients should not use standard casein products. Extensively hydrolyzed casein formulas exist for infant nutrition and are a clinical-nutrition category used under pediatric supervision, not a consumer supplement. Adults and children with confirmed CMPA should choose a plant-protein sibling: pea, soy, plant blend, or yeast.
· source: Casein Protein
What is α-casozepine, and does casein really help me sleep?
α-Casozepine is a 10-amino-acid peptide from αs1-casein with GABA-A receptor binding activity in vitro. Small clinical trials (n ≈ 20–60, 2–4 weeks) of α-casozepine-enriched casein hydrolysate at 150–300 mg/day have reported modest improvements in self-reported stress, anxiety, and sleep. The European Food Safety Authority did not approve a sleep / stress health claim for this peptide in 2012, citing insufficient methodological strength. Products remain legally sold as supplements. This is a milligram-level peptide application — entirely separate from the gram-level pre-sleep micellar casein use case described in §4.2–§4.4. The pre-sleep casein RCT evidence is about overnight muscle protein synthesis, not about falling asleep faster. See §4.7.
· source: Casein Protein
Does casein cause kidney problems?
No, not in healthy adults at typical intakes. The Devries 2018 meta-analysis (covered on the protein hub page §6) found that total protein intake up to 2.0 g/kg/day does not impair kidney function in healthy adults. CKD patients should follow restricted-protein guidance (KDIGO 2024, typically 0.6–0.8 g/kg/day) under medical supervision — and that restriction is source-neutral; casein is treated the same as any other protein.
· source: Casein Protein
Does soy protein lower men's testosterone or feminize men?
No. Three independent meta-analyses — Hamilton-Reeves et al. 2010 (PMID 19524224), Messina 2010 (PMID 20378106), and Reed et al. 2021 (PMID 33383165, expanded through April 2020) — examined this question directly. None found a clinically meaningful effect of soy or isoflavone intake on total testosterone, free testosterone, estradiol, estrone, or SHBG in adult men, across isoflavone doses from 20 to 900 mg/day and soy protein doses from 0 to 71 g/day. NIH-ODS, Cleveland Clinic, Mayo Clinic, and NAMS all characterize soy as safe for men at typical intakes.
· source: Soy Protein
Does soy cause breast cancer?
No, according to current expert consensus. The American Institute for Cancer Research / World Cancer Research Fund (2018), American Cancer Society (2024), and North American Menopause Society (2023) characterize moderate dietary soy intake as safe — and possibly modestly protective — both for breast cancer prevention in the general population and for survival after diagnosis. Several large cohort meta-analyses (including Nechuta et al. 2012, PMID 22648714) found women consuming soy foods after breast cancer diagnosis had similar or lower recurrence and mortality compared with women who avoided soy. A separate, narrower caveat applies to high-dose concentrated isoflavone supplements during tamoxifen treatment — discuss with your oncology team. Dietary soy is well-supported as safe.
· source: Soy Protein
How much better is whey than soy for muscle building?
Modestly but consistently better. In Volek et al. 2013 (PMID 24015719) — a 9-month resistance-training RCT comparing whey, soy, and carbohydrate — whey produced significantly greater lean-body-mass gains than soy, which in turn substantially outperformed carbohydrate. Whey carries higher leucine (~11% vs soy's ~8%) and faster absorption. Practical implication: if maximum muscle gain is your primary goal, whey is the evidence-supported first choice. If you prefer plant-based protein for other reasons, soy is still effective — consider slightly higher per-meal serving sizes (30–40 g) to compensate.
· source: Soy Protein
How much isoflavone is enough for menopausal symptoms?
Typical effective dose in clinical trials is 40–80 mg/day aglycone-equivalent isoflavones for at least 12 weeks (Taku 2012, PMID 22433977; NAMS 2023). Individual response varies based on baseline hot-flash frequency, dose, and gut-microbiome production of S-equol (a daidzein metabolite, produced by an estimated 20–50% of adults). Alcohol-washed soy protein isolate may have most of its isoflavones removed during processing and will not deliver this effect — check the label for isoflavone milligrams per serving, or use wholefood soy. NAMS characterizes soy isoflavones as a non-hormonal option of limited but real effect, not a replacement for hormone therapy when HT is clinically indicated.
· source: Soy Protein
Does GMO vs non-GMO soy matter?
The scientific consensus (NAS 2016; EFSA; WHO) is that currently-commercialized GMO soy varieties show no demonstrated food-safety difference from conventional soy. Glyphosate-residue monitoring by EFSA, EPA, and FDA finds the great majority of commercial soy well below regulatory safety thresholds. About half of US consumers nonetheless prefer Non-GMO Project Verified soy, and Organic certification provides additional reassurance. This is more of a values choice than a safety choice — both options are defensible.
· source: Soy Protein
What about deforestation — should I avoid soy for environmental reasons?
Soy production carries genuine ESG considerations: while approximately 77% of global soy goes to animal feed (not direct human consumption), some supply chains have been linked to deforestation in Brazilian and Argentine growing regions. Practical mitigations: choose USDA Organic / EU Organic, Non-GMO Project Verified, RTRS-certified, or ProTerra-certified soy; look for North American, European, or Chinese origin; or look for Brazilian Soy Moratorium-compliant sourcing. The mitigations work — they do not require avoiding soy entirely.
· source: Soy Protein
I'm a breast cancer survivor on tamoxifen — can I eat soy?
Moderate dietary soy (1–2 servings/day of tofu, tempeh, soy milk, edamame, or moderate soy protein) is characterized as safe by current consensus (AICR/WCRF 2018; ACS 2024; NAMS 2023). The narrower caveat applies to high-dose concentrated isoflavone supplements (≥100 mg/day aglycone-equivalent), particularly during tamoxifen — evidence for this specific scenario is more limited and warrants discussion with your oncology team before starting.
· source: Soy Protein
I have hypothyroidism — can I eat soy?
In iodine-sufficient individuals, multiple RCTs show no clinically meaningful effect of soy or isoflavones on thyroid function (Bruce 2003; Dillingham 2007; 2022 technical review). Two practical guides apply: (a) if you have subclinical hypothyroidism on a low-iodine diet, monitor thyroid function when substantially increasing soy intake; (b) if you take levothyroxine, separate soy intake from your medication by at least 3–4 hours to avoid absorption interference. Soy itself is not contraindicated for people with hypothyroidism — the timing of levothyroxine is what matters.
· source: Soy Protein
Does soy protein really work for cholesterol?
Modestly, yes. A 2019 meta-analysis (Blanco Mejia et al., PMID 31006811) re-analyzed the same 46 randomized trials FDA used in its review and found soy protein at a median 25 g/day for at least 6 weeks reduced LDL-cholesterol by approximately 4.76 mg/dL (~4–6%). The effect is smaller than 1990s-era estimates because of changes in background diet and concurrent statin therapy, but remains statistically significant. FDA authorized a soy heart-health claim in 1999, proposed to revoke it in 2017, and as of mid-2024 had not finalized that proposal — so the regulatory status is best described as "in limbo." EFSA still permits a related claim conditional on ≥25 g/day soy protein with sufficient isoflavone content. Soy is a sensible component of a heart-healthy dietary pattern, not a substitute for statin therapy in those who need it.
· source: Soy Protein
What's the difference between alcohol-washed and aqueous-extracted soy protein isolate?
Both processes produce ≥90% protein SPI, but they differ in what else gets removed. Alcohol-washing uses ethanol or methanol to extract residual sugars and other components, and in the process removes most of the isoflavones — alcohol-washed SPI may contain only 0–5 mg/g isoflavones. Aqueous extraction uses water-based processing and preserves more of the native isoflavone content (typically 1–2 mg/g). For muscle, satiety, or general protein-quota purposes the two are interchangeable. For cardiovascular or menopausal benefit the isoflavone content matters and you want either aqueous-extracted SPI, SPC, or wholefood soy. If a label discloses the extraction method, great; if not, assume alcohol-washed.
· source: Soy Protein
For muscle adaptation outcomes at adequate per-meal doses (25–30 g), three head-to-head human trials — Babault 2015, Banaszek 2019, and Pinckaers 2024 — show pea producing comparable muscle thickness gains, strength gains, and acute muscle protein synthesis rates to whey or milk protein. Honest caveats: Babault's whole-group primary endpoint was p = 0.09 (with subgroup significance), Banaszek was a small pilot (n = 15), and Pinckaers was an acute single-dose mechanism study. Older adults should use 35–40 g per meal rather than 25–30 g to compensate for pea's lower leucine density.
· source: Pea Protein
Does pea protein build muscle?
Yes, when consumed in adequate amounts (25–30 g per serving, ~1.6 g/kg/day total protein) alongside resistance training. The mechanism is the same as for any high-quality protein source: post-meal essential amino acid delivery triggers muscle protein synthesis via the mTORC1 pathway. The pea-specific evidence is the three head-to-head trials in §4.1, and the cluster-level evidence is on the protein hub page §4 (Morton 2018 meta-analysis of 49 RCTs across protein sources, total daily intake the dominant variable).
· source: Pea Protein
What is the DIAAS of pea protein?
0.82 in standalone form, which places it above the FAO 0.75 "good quality" threshold and above hemp, rice, and wheat — but below whey (1.09), casein (1.00), and soy (0.90). The limiting amino acid is methionine + cysteine. A pea + rice blend in roughly 70:30 to 80:20 ratio achieves DIAAS in the 0.90–1.0 range (dairy-comparable) through complementary amino-acid pairing.
· source: Pea Protein
Why pair pea with rice?
Because the two have complementary amino-acid profiles: pea is rich in lysine but limited in sulfur amino acids (methionine + cysteine), while rice is rich in sulfur amino acids but limited in lysine. Combining them produces a more complete amino-acid profile than either alone, lifting the combined DIAAS to approximately 0.90–1.0. The complementarity does not require same-meal consumption — a 24-hour window is sufficient, per modern FAO guidance.
· source: Pea Protein
Can people with peanut allergies use pea protein?
A minority (roughly 5–15% in published studies) of severely peanut-allergic individuals show IgE cross-reactivity to pea proteins through shared protein-family epitopes. People with documented severe peanut allergy or anaphylaxis history should consult an allergist before starting pea protein. For the general population without peanut allergy, pea is one of the lowest-allergenicity plant proteins available — new-onset pea allergy without prior peanut sensitivity is uncommon.
· source: Pea Protein
Do plant proteins have leucine adequacy problems?
Pea protein contains approximately 78–85 mg of leucine per gram of protein, compared with whey at approximately 110 mg/g. For most adults at typical 25–30 g per-meal doses, pea delivers 2.0–2.5 g of leucine per serving — close to but slightly below the ~3 g threshold for maximal muscle protein synthesis stimulation. The practical adjustments are: (1) consume 35–40 g per meal (older adults specifically need this), (2) use a pea + rice blend, or (3) choose products with added free leucine.
· source: Pea Protein
Is pea protein safe for older adults concerned about muscle loss?
Yes. For sarcopenia prevention, the per-meal dose should be 35–40 g (not 25–30 g) to reach the ~3 g leucine threshold needed to overcome age-related anabolic resistance, with daily intake at 1.0–1.5 g/kg/day total protein and ideally combined with resistance exercise. Pea + rice blends and leucine-fortified pea products are reasonable workarounds. The cluster framework on older-adult protein needs (ESPEN PROT-AGE consensus) is on the protein hub page §4.
· source: Pea Protein
Why does pea protein taste earthy or beany, and what can I do about it?
Pea protein has a characteristic earthy, slightly beany flavor and a more textured mouthfeel than whey in beverages — these are properties of the original pea matrix that survive processing. Modern high-quality isolates use low-bitter processing technologies and flavoring systems (natural flavors, stevia, monk fruit) that substantially improve palatability. Mixing with strong-flavored bases (chocolate, coffee, fruit smoothies) generally masks the residual note. Taste preference is highly individual — finding the right product formulation often matters more than the source ingredient.
· source: Pea Protein
Are heavy metals a concern with pea protein?
All plant proteins can accumulate trace heavy metals from soil. Independent third-party testing — including Clean Label Project surveys — generally finds pea protein at lower contamination levels than rice or hemp protein, and broadly comparable to soy. To minimize concerns: choose products with published third-party heavy metals testing, USDA Organic or EU Organic certifications, or third-party certification marks (Clean Label Project, USP Verified, NSF, Informed Sport).
· source: Pea Protein
I'm taking a GLP-1 medication (semaglutide, tirzepatide) — does pea protein make sense?
Yes, as one of several plant-based options that fit the higher-protein-intake recommendation (approximately 1.5–2.0 g/kg/day) increasingly applied alongside GLP-1 receptor agonist therapy to support muscle preservation during weight loss. Pea is particularly useful for vegan, dairy-intolerant, or multi-allergy users on these medications, where reduced appetite makes total intake harder to reach. Direct GLP-1-user-population RCTs are still emerging across all protein sources — recommendations currently extrapolate from the established protein literature. See protein hub §4 for the GLP-1-era muscle-preservation framework.
· source: Pea Protein
Is a plant protein blend really as good as whey for building muscle?
At equivalent total daily protein intake and per-meal leucine targets, the randomized-trial evidence (Babault 2015 pea PMID 25628520, Joy 2013 rice PMID 23782948, Reidy 2013 blend PMID 23343671, Banaszek 2019 pea HIFT, Pinckaers 2024 three-source plant blend) supports comparable gains in lean mass and strength. The blend is the operative word — multi-source amino-acid complementarity is what lifts plant protein quality into the dairy-equivalent range.
· source: Plant Protein
What is the best plant protein blend?
This page does not recommend brands. The evidence-based criteria are: source ratios disclosed (not "proprietary blend"), pea + rice as the base, ≥80% protein content per serving, ≥2,500 mg leucine per 30 g serving, third-party heavy-metals testing (Clean Label Project, USP, NSF, or Informed Sport), explicit allergen statement, and cGMP manufacturing. Any product meeting all of these is a defensible choice.
· source: Plant Protein
Pea protein alone or pea + rice blend — which is better?
A pea + rice blend has materially higher protein quality (DIAAS approximately 0.93–1.05) than pea alone (approximately 0.82). For users who can accept a multi-source product, the blend is the better choice. The "blend ≠ single plant" point is the central reason this category exists.
· source: Plant Protein
Is plant protein safe in pregnancy?
Standard plant blends at the dosing guidance for pregnancy (+25 g/day in mid-trimester) are appropriate, provided the product carries third-party heavy-metals testing. This is non-negotiable. Hemp-heavy formulations are best avoided due to regulatory ambiguity around trace cannabinoid residues. Discuss with your prenatal-care provider.
· source: Plant Protein
Why does pea protein give me gas?
Residual α-galactosides in the raw material. The fixes: split the dose across the day, choose an enzyme-treated pea protein isolate, add an α-galactosidase digestive enzyme, or move to a blend in which pea is one of three or four sources rather than the dominant component.
· source: Plant Protein
Are heavy metals really a concern in plant protein powders?
Yes, the raw-material risk is real — particularly cadmium, lead, and inorganic arsenic from rice, hemp, and cocoa-flavored products. The 2018 Clean Label Project survey documented meaningful variation across products. The operational answer is third-party certification (Clean Label Project, USP Verified, NSF, Informed Sport), formulations where rice is held to 30–40% of the blend rather than the dominant source, and brand-level supply-chain transparency. In pregnancy and for users with young children, third-party testing is not optional.
· source: Plant Protein
Can vegans build muscle with a plant blend?
The trial evidence supports lean mass and strength outcomes comparable to whey at equivalent total protein and per-meal leucine targets. The practical configuration: per-meal 30–40 g plant blend, ≥2.5 g leucine, total daily intake 1.6–2.2 g/kg/day for strength training. For older vegan adults, free leucine fortification of 1–2 g per meal is a defensible strategy.
· source: Plant Protein
Plant protein for GLP-1 (Ozempic, Wegovy) users — does it work?
Yes. The muscle-preservation case for GLP-1 users — total protein 1.5–2.0 g/kg/day, per-meal 25–30 g, leucine ≥2.5 g per meal — applies regardless of source. A vegan or lactose-intolerant GLP-1 user is a textbook fit for a high-quality plant blend with leucine fortification and a low-sugar formulation.
· source: Plant Protein
Is ESG a real reason to choose plant protein, or is it greenwashing?
Both, partially. The carbon, water, and land footprint advantages versus dairy are well-documented in lifecycle analysis (Poore & Nemecek 2018). The complications — pea long-distance shipping, rice water use, hemp regulatory status, soy deforestation, processing energy — are real and routinely under-disclosed in marketing copy. The honest read is that plant blends are environmentally lower-impact than dairy on most measures, but the magnitude of the advantage depends on formulation and accounting method.
· source: Plant Protein
Does plant protein cause kidney damage?
No, not in healthy adults at protein intakes up to 2.0 g/kg/day (Devries 2018 systematic review, PMID 30383278). The plant-vs-animal acid-load hypothesis is no longer the consensus view. In chronic kidney disease, all protein intake should be managed by the patient’s nephrologist and registered dietitian — plant protein is not a special exception.
· source: Plant Protein
What is yeast protein, and how is it different from nutritional yeast?
Yeast protein concentrate or isolate is a high-protein (70–85% dry basis) supplement ingredient produced from Saccharomyces cerevisiae by enzymatic processing and nucleic-acid reduction. Nutritional yeast is a flake-form vegan flavoring with ~45–55% protein and unreduced nucleic acids — a different product with a different use case and a higher purine load. See the six-yeast-form distinction table in the Overview section.
· source: Yeast Protein
Is yeast protein as good as whey for building muscle?
The honest answer: one 8-week RCT (n=79, journal not indexed by PubMed) showed yeast and whey both increased lean mass over placebo with no significant difference between the two protein arms. This single trial is a directionally encouraging signal but cannot support a confident "yeast equals whey for muscle" claim — broader independent replication is needed. Whey has hundreds of supporting RCTs; yeast has fewer than three direct trials. If maximum evidence depth for hypertrophy matters most to you, choose whey or blend whey with yeast rather than relying on yeast alone.
· source: Yeast Protein
Is yeast protein vegan, halal, and kosher?
All three, yes — verify the third-party certification mark (OU or Star-K for kosher, recognized halal certifications for halal, vegan-certification for vegan) on the product label when these are non-negotiable for you.
· source: Yeast Protein
Can pregnant or breastfeeding women take yeast protein?
No — China's NMPA explicitly excludes infants, pregnant women, and breastfeeding women from the 2023 novel-food approval. Important framing: this is a precautionary exclusion (data in these groups is not yet sufficient) — not a hazard-identified exclusion (no demonstrated harm). During pregnancy or breastfeeding, choose well-studied protein sources (dairy, eggs, fish, soy, pea) with established perinatal safety data, and discuss any new supplement with your prenatal-care provider.
· source: Yeast Protein
Will yeast protein cause gout?
A properly processed supplement-grade yeast protein concentrate (RNA reduced to ≤2%) at normal serving sizes (20–30 g/day) does not constitute a gout risk and is comparable in purine load to dairy or plant proteins. However, dairy whey and casein are the evidence-preferred protein choices for gout patients — cohort data show dairy lowers gout risk. Large, sustained nutritional yeast intake is a different question and is contraindicated for gout patients.
· source: Yeast Protein
What is the difference between mycoprotein (Quorn) and yeast protein?
Mycoprotein is Fusarium venenatum — a filamentous fungus with a hyphal whole-food matrix; the academic mycoprotein standard for muscle-protein-synthesis RCTs. Yeast protein is Saccharomyces cerevisiae — a single-celled fungus processed into an isolated concentrate. Both are fungi, but they differ in biology, matrix structure, and amino-acid spectrum. Mycoprotein RCT data does not directly extrapolate to yeast protein. Mycoprotein (Quorn) is widely available in Western markets but not commercially available in China; yeast protein is NMPA-approved in China and increasingly available globally as a supplement ingredient.
· source: Yeast Protein
Is nutritional yeast the same thing as yeast protein supplement?
No — and this is the most common reader confusion. Nutritional yeast is a vegan flavoring flake (~45–55% protein, unreduced nucleic acids, used to add cheesy flavor to vegan cooking). Yeast protein concentrate or isolate is a supplement ingredient (70–85% protein, nucleic acids reduced to ≤2%, used as a protein source). They are different products with different processing, different purine loads, and different use cases.
· source: Yeast Protein
Why is the evidence base for yeast protein so small? Why is it worth considering at all?
Honest answer: yeast protein only became commercially significant as a supplement ingredient in the 2020s, and China's NMPA novel-food approval came in 2023. The clinical evidence base is genuinely young. It is worth considering today not because it is proven superior to mainstream proteins (it is not) but because it occupies a unique combination of practical advantages — top-tier ESG profile, vegan + halal + kosher + dairy-free + soy-free + gluten-free + non-allergen simultaneously, and an amino-acid spectrum closer to animal protein than to most single-source plant proteins. For consumers facing multiple overlapping dietary or religious restrictions, those practical advantages are real even if the muscle-endpoint evidence base is still emerging.
· source: Yeast Protein
Will yeast protein boost my immunity?
Yeast-derived β-glucan supplements have a Tier A evidence base for immune support (Zhong 2021 13-RCT meta, PMID 33900466; Auinger 2013 multicentric RCT, PMID 23340963), but β-glucan is a cell-wall polysaccharide, not a protein — and high-purity yeast protein concentrates have typically had β-glucan separated out during processing. If immune support is your goal, choose a standalone yeast β-glucan supplement, not a yeast protein concentrate. Only if a yeast protein product explicitly discloses a β-glucan content on the label do the β-glucan immune-support trials apply.
· source: Yeast Protein
Because the GLP-1 receptor agonist class works by replicating and amplifying the natural incretin effect, and whey is the most powerful natural incretin stimulator among protein sources, increasing GLP-1 by 141 percent and reducing postprandial glucose by 28 percent in T2DM users (Jakubowicz 2014, PMID 25005331). Whey complements rather than competes with prescription GLP-1 RA therapy, and supports the muscle preservation that is the primary unintended consequence of rapid GLP-1-mediated weight loss.
· source: Blog · Protein Source Decision Tree
If yeast protein DIAAS can reach 0.97 to 0.99, why do you cite 0.86 to 0.93 as the mid-range?
The 0.97 to 0.99 figure (2025 IVDIAAS PMID 40934397) applies to the older-children-and-adults reference pattern under optimal in-vitro digestion conditions. For broader applicability across age groups and real-world processing variability, the conservative 0.86 to 0.93 mid-range better represents typical commercial yeast protein products. Always request strain-specific data from suppliers.
· source: Blog · Protein Source Decision Tree
Is the "soy lowers testosterone" claim true?
Not at typical dietary or supplemental doses. The Hevia-Larrain 2021 RCT (PMID 33599941) showed that soy-led vegan diets matched whey-led omnivore diets on muscle hypertrophy at equivalent protein intake plus resistance training. Companion analysis from Gorissen 2018 (PMID 30167963) confirms soy isolate ranks in the upper tier of plant proteins for both essential amino acid content and leucine percentage. If soy meaningfully suppressed anabolism, the Hevia 2021 null result would be impossible. The cherry-pick does not survive critical appraisal at relevant dietary doses.
· source: Blog · Protein Source Decision Tree
Can I combine whey and yeast protein in one stack?
Yes, and the evidence supports complementary mechanisms. Whey delivers rapid leucine spike and incretin stimulation; yeast delivers sustained satiety via beta-glucan and cell-wall matrix, plus cardiometabolic adjunct effects. A combined daily intake of 20 to 25 g whey (post-workout or pre-largest-meal) plus 25 to 30 g yeast (with another meal) is a reasonable evidence-supported pairing, with combined daily protein still within the 1.6 g/kg/d optimal range identified by Morton 2018 (PMID 28698222).
· source: Blog · Protein Source Decision Tree
Are mycoprotein and yeast protein the same thing?
Technically no. Mycoprotein (Fusarium venenatum, the source of Quorn) is a filamentous fungus, while true yeast (Saccharomyces cerevisiae and related) is a unicellular fungal genus. In DIAAS, MPS, and metabolic literature they are consistently grouped together because cell-wall biology and amino acid profile are analogous. Consumer products labeled "yeast protein" most often derive from S. cerevisiae or related yeast species; "mycoprotein" specifically denotes Fusarium-derived products.
· source: Blog · Protein Source Decision Tree
I am lactose intolerant. Should I avoid all whey?
Whey protein isolate (WPI) at 90 percent or higher protein content has residual lactose below 1 percent, typically tolerated by all but the most severe lactose-intolerant individuals. Whey protein concentrate (WPC) at 30 to 80 percent protein retains approximately 5 percent lactose and is more likely to cause symptoms. If you have any dairy intolerance, choose WPI rather than WPC, or transition to yeast / soy / pea-based plant proteins for full dairy avoidance.
· source: Blog · Protein Source Decision Tree
Does the choice of protein matter if my total daily intake is at 1.6 g/kg/d?
For total lean mass and strength outcomes in chronic supplementation, the Morton 2018 meta-analysis (PMID 28698222) and Hevia-Larrain 2021 RCT (PMID 33599941) together suggest that once total daily protein and leucine intake are equalized, the source matters less than people often assume. Source choice becomes meaningful when (1) you have a specific use case like incretin stimulation or pre-sleep slow release, (2) you cannot consume dairy, (3) sustainability or ESG considerations factor into your purchase decision, or (4) you want the cardiometabolic matrix bonus of yeast beta-glucan.
· source: Blog · Protein Source Decision Tree
Vitamin E Family (Tocopherols / Tocotrienols) (32 Q)
Vitamin E is a family of eight chemically related fat-soluble compounds — four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ). All eight occur in food and all eight can carry a "vitamin E" label, but they differ in chemistry, bioavailability, tissue retention, and clinical evidence. The body preferentially retains α-tocopherol through a liver protein called α-tocopherol transfer protein (α-TTP), so the Recommended Dietary Allowance (15 mg/day for adults) refers specifically to α-tocopherol.
· source: Vitamin E
What is the difference between natural (d-α) and synthetic (dl-α) vitamin E?
Natural d-α-tocopherol is a single stereoisomer (RRR) that α-TTP recognizes with high affinity. Synthetic dl-α-tocopherol contains eight stereoisomers in equal proportion, only four of which are well retained. The U.S. FDA's 2018 Final Rule established that 1 mg of natural d-α-tocopherol delivers approximately twice the biological activity of 1 mg of synthetic all-rac-α-tocopherol. Conversion: 1 mg natural = 1.49 IU; 1 mg synthetic = 2.22 IU.
· source: Vitamin E
How much vitamin E should I take per day?
The Recommended Dietary Allowance for adults is 15 mg α-tocopherol per day (about 22 IU natural or 33 IU synthetic), best met through food. If a supplement is used for general wellness, current evidence favors ≤ 200 mg α-tocopherol per day — above the RDA but well below the dose ranges where mortality, heart-failure, hemorrhagic-stroke, and prostate-cancer signals have appeared. The U.S. IOM upper limit is 1,000 mg/day; the European EFSA upper limit (revised in 2024) is now 300 mg/day. Therapeutic high-dose use (NASH at 800 IU, Alzheimer's at 2,000 IU, AVED at 800–2,000 mg) belongs under medical supervision.
· source: Vitamin E
Is vitamin E good for the heart?
Several large randomized controlled trials — HOPE (n=9,541), HOPE-TOO (n=3,994 long-term), and Physicians’ Health Study II (n=14,641) — found no reduction in major cardiovascular events from vitamin E supplementation. HOPE-TOO observed a modest increase in heart-failure hospitalizations, and PHS II observed an increase in hemorrhagic stroke. The European authorized health claim for vitamin E is narrow: vitamin E "contributes to the protection of cells from oxidative stress" — a biochemical claim, not a cardiovascular-disease claim. Current cardiology guidelines do not recommend vitamin E for heart-disease prevention.
· source: Vitamin E
Does vitamin E prevent cancer?
The SELECT trial (Klein 2011, n=35,533 healthy men) found that 400 IU/day of synthetic vitamin E was associated with a 17% relative increase in prostate cancer over a median 7 years. The ATBC trial (1994) showed no protection against lung cancer in smokers. Current evidence does not support vitamin E supplementation for cancer prevention. Healthy men should be specifically cautious about the prostate-cancer signal at 400 IU/day; smokers should avoid combined β-carotene + vitamin E products.
· source: Vitamin E
Does vitamin E help with Alzheimer's disease?
In already-diagnosed mild-to-moderate Alzheimer's disease, one randomized trial (TEAM-AD, Dysken 2014, n=613) showed that 2,000 IU/day α-tocopherol slowed decline in activities of daily living by about 19% per year and reduced caregiver burden — though it did not preserve cognition itself. The 2,000 IU dose exceeds upper intake limits and requires medical supervision. For prevention of dementia in healthy adults or in mild cognitive impairment, the Cochrane review (Farina 2017) concludes the evidence is insufficient.
· source: Vitamin E
Is vitamin E good for the liver / NASH?
In adults with biopsy-confirmed non-alcoholic steatohepatitis without diabetes, the PIVENS trial (Sanyal 2010, n=247) showed that 800 IU/day of natural vitamin E for 96 weeks improved liver histology compared with placebo (43% versus 19% achieved improvement). This is now part of major hepatology guideline recommendations for that specific population — under specialist supervision. It is not a general-wellness recommendation, does not apply to people with diabetes, and does not apply to people without biopsy-proven NASH.
· source: Vitamin E
Does topical vitamin E heal scars or improve skin?
The most-cited randomized trial of topical vitamin E for scars (Baumann 1999) found no improvement in scar appearance and contact dermatitis in 33% of users. Oral vitamin E for skin anti-aging has limited evidence and is not a substitute for proven dermatological interventions (broad-spectrum sunscreen, retinoids, established cosmeceutical actives). Some topical combination products containing vitamin E with vitamin C and ferulic acid show modest aesthetic benefit, but credit is shared across the formulation.
· source: Vitamin E
How do I convert International Units (IU) to milligrams?
For natural d-α-tocopherol: 1 IU = 0.67 mg; 1 mg = 1.49 IU. For synthetic dl-α-tocopherol: 1 IU = 0.45 mg; 1 mg = 2.22 IU. The U.S. FDA 2018 Final Rule mandated conversion to milligrams of α-tocopherol on Nutrition and Supplement Facts labels effective 2020; many international products and older publications still use IU.
· source: Vitamin E
What are the side effects of vitamin E?
At or below the upper intake limit, vitamin E is generally well tolerated. The principal concerns at higher doses (≥ 400 IU/day) are: increased bleeding risk (especially with anticoagulants, antiplatelet drugs, or fish oil; and the PHS II hemorrhagic stroke signal); a small but reproducible increase in all-cause mortality (Miller 2005 meta-analysis); a 17% increase in prostate cancer in healthy men (SELECT); and an increase in heart-failure hospitalizations (HOPE-TOO). Stop high-dose vitamin E approximately two weeks before elective surgery.
· source: Vitamin E
What are tocotrienols, and how are they different from tocopherols?
Tocotrienols are a distinct sub-class of vitamin E with an unsaturated farnesyl side chain (three double bonds), whereas tocopherols have a saturated phytyl side chain. Tocotrienols have distinctive mechanisms — including HMG-CoA reductase ubiquitination (lowering hepatic cholesterol synthesis by a route different from statins) and stronger NF-κB suppression — and a separate clinical evidence base (lipids, NAFLD, bone, neurological signaling). The α-TTP system retains tocotrienols poorly, so plasma half-lives are short. See the dedicated Tocotrienols sub-page.
· source: Vitamin E
What is mixed tocopherols?
Mixed tocopherols are products that contain α, β, γ, and δ-tocopherols together, usually in proportions reflecting the source vegetable oil (soybean, corn, sunflower distillates) where γ ≫ α > δ > β. They appeal to consumers who want a vitamin E profile closer to the dietary matrix than pure α-tocopherol provides; they also include γ-tocopherol's unique reactive-nitrogen-species scavenging chemistry. Direct randomized-trial evidence for mixed tocopherols at clinical endpoints is limited compared with α-tocopherol alone.
· source: Vitamin E
At food and RDA-level intakes (15 mg α-tocopherol per day) yes. At low-to-modest supplement doses (≤200 IU/day) generally yes for healthy adults. Doses ≥400 IU/day have been associated with a small all-cause mortality signal in the Miller 2005 meta-analysis and should not be used long-term without medical guidance.
· source: Tocopherols
What is the difference between natural and synthetic vitamin E?
Natural d-α-tocopherol (RRR) is a single stereoisomer made by plants. Synthetic dl-α-tocopherol (all-rac) is an equal mixture of eight stereoisomers from chemical synthesis. The synthetic form delivers roughly 50–55% of the biological activity per milligram — the basis of the FDA's 2:1 conversion factor. The label prefix tells you which one: "d-" / "RRR-" / "natural" indicates plant-derived; "dl-" / "all-rac-" / "synthetic" indicates the chemically synthesized mixture.
· source: Tocopherols
How do I convert IU to mg for vitamin E?
Use the §3 table — the conversion depends on both the form (free vs. acetate vs. succinate) and the stereoisomer (natural vs. synthetic). The shorthand: a "400 IU" natural-d-α-tocopheryl-acetate softgel ≈ 268 mg α-tocopherol; a "400 IU" synthetic-dl-α-tocopheryl-acetate softgel = 180 mg α-tocopherol.
· source: Tocopherols
Does vitamin E prevent heart disease?
No — not in the modern large-trial record for healthy adults. HOPE (n=9,541) and PHS II (n=14,641) both found no cardiovascular benefit from 400 IU/day. HOPE-TOO surfaced a heart-failure signal at the same dose over 7 years. The 2005 Miller meta-analysis suggested a small all-cause mortality increase at ≥400 IU/day. NIH ODS, Cochrane, and the Linus Pauling Institute all recommend obtaining vitamin E from food rather than from high-dose supplements for healthy adults.
· source: Tocopherols
Does vitamin E cause prostate cancer?
SELECT (Klein 2011, JAMA; n=35,533) found a 17% relative increase in prostate cancer in healthy men ≥50 taking 400 IU/day synthetic dl-α-tocopheryl acetate for 5.5+ years — about 11 additional cases per 1,000 men over 7 years. Long-term high-dose α-tocopherol supplementation is not recommended in healthy men.
· source: Tocopherols
What is the difference between α and γ tocopherol?
Both share the chromanol head, but γ has one less methyl group (the C5 position is unmethylated). That single chemistry change lets γ-tocopherol neutralize reactive nitrogen species like peroxynitrite, which α-tocopherol cannot. Western diets are naturally γ-rich (γ:α ≈ 4:1), but most supplements contain α only — and high-dose α supplementation can lower blood γ by 30–50%.
· source: Tocopherols
Are mixed tocopherols better than α-tocopherol alone?
For people who choose to supplement, yes — that is the position of NIH ODS, the Linus Pauling Institute, and Examine.com. Mixed tocopherols preserve γ-tocopherol's RNS-neutralizing activity, more closely match the dietary tocopherol distribution, and avoid the α-only effect of suppressing blood γ levels.
· source: Tocopherols
What foods are highest in vitamin E?
For α-tocopherol: wheat-germ oil, sunflower oil, sunflower seeds, almonds, hazelnuts, olive oil, avocado, spinach. For γ-tocopherol: corn oil, soybean oil, walnuts, pecans, sesame oil. A diverse diet across both groups delivers the full tocopherol spread without supplementation.
· source: Tocopherols
What is "tocopheryl acetate" in my skincare?
It is the acetate ester of α-tocopherol — the same chemistry class as oral supplements but applied topically. The strongest topical evidence is for the combination of vitamin C + vitamin E + ferulic acid (≈4-fold UVB photoprotection in human studies, Lin 2003 and follow-up RCTs), not vitamin E alone. Topical vitamin E alone for scar treatment is not effective and causes contact dermatitis in roughly 30% of users (Baumann 1999, PMID 10417589) — choose a combination antioxidant serum if you want photoprotection, and skip vitamin E as a stand-alone scar product.
· source: Tocopherols
Can I take vitamin E with my blood thinner?
At general-maintenance doses (at or near the RDA, well under 200 IU/day), most evidence does not show clinically meaningful interaction. At higher doses (≥400 IU/day) combined with warfarin, aspirin, clopidogrel, or other anticoagulants/antiplatelets, the bleeding risk is real — inform your prescribing physician, monitor INR if applicable, and plan to stop high-dose vitamin E 1–2 weeks before any planned surgery.
· source: Tocopherols
What are tocotrienols, and how are they different from "regular" vitamin E?
Vitamin E is a family of eight related molecules — four tocopherols and four tocotrienols. "Regular vitamin E" in most products means α-tocopherol. Tocotrienols carry an unsaturated tail, penetrate mitochondrial and nuclear membranes more readily, drive HMG-CoA reductase degradation, suppress NF-κB-mediated inflammation, and have a shorter plasma half-life. They are not interchangeable with α-tocopherol — different mechanism profile, different evidence base, different dosing window. See §2.
· source: Tocotrienols
Which source of tocotrienol is best — annatto, palm, or rice bran?
Annatto is the best choice for most readers because it contains ~100% tocotrienol and zero α-tocopherol (eliminating the self-interference problem described in §4), with 90% of its content as the most active δ-T3 isomer. Palm-derived tocotrienol-rich fraction is acceptable when replicating a specific historical trial protocol (Tomeo carotid, Gopalan brain) and carries ~25% native α-tocopherol. Rice-bran-derived concentrate is the lowest-cost option but also the lowest tocotrienol fraction with the highest α-tocopherol interference. See §3.
· source: Tocotrienols
Can I take tocotrienol together with my multivitamin?
Usually not in the same window — most multivitamins supply 15–30 mg of α-tocopherol, which is at or above the threshold that meaningfully reduces tocotrienol absorption and retention. Choose an annatto-derived tocotrienol (zero α-tocopherol, no interference), or separate the multivitamin and the tocotrienol by at least six hours every day, or — if your diet already meets the vitamin E RDA — discontinue the standalone α-tocopherol product. See §4.
· source: Tocotrienols
Do tocotrienols really lower cholesterol?
The honest answer is dose-specific. Qureshi 2002 (PMID 11882333) showed dose-dependent reductions of approximately 14–17% in total cholesterol and 15–22% in LDL at 100–200 mg/day in adults with elevated cholesterol. Above ~250 mg/day, the effect reverses (the U-shape described in §6.1). Tocotrienol works through a different pathway than statins (enzyme degradation, not active-site inhibition) and is not a replacement for statin therapy when statins are indicated.
· source: Tocotrienols
Can tocotrienols help with fatty liver / NAFLD?
Two reasonable-quality randomized trials suggest yes for intermediate biomarkers — Magosso 2013 (PMID 24373555) with mixed tocotrienol over 12 months and Pervez 2020 (PMID 32951743) with δ-tocotrienol 600 mg/day over 24 weeks. Both showed improvements in liver enzymes (ALT, AST), Fatty Liver Index, ultrasound-graded steatosis, and inflammatory markers. This evidence supports the use of tocotrienol as an adjunct in NAFLD management strategies; it does not establish tocotrienol as a cure for fatty liver disease, and a hepatologist should be involved in any clinical NAFLD plan.
· source: Tocotrienols
Are tocotrienols good for bone health in menopause?
Shen 2018 (PMID 29954374) randomized 87 postmenopausal osteopenic women to 430 or 860 mg/day annatto tocotrienol plus 400 IU vitamin D and 500 mg calcium over 12 weeks, and found dose-related reduction in bone-resorption markers and oxidative-stress markers. This is a bone-turnover biochemistry trial, not a bone-mineral-density or fracture trial. The evidence supports annatto tocotrienol — combined with adequate vitamin D and calcium — as a postmenopausal bone-turnover intervention. It does not yet support a fracture-prevention claim.
· source: Tocotrienols
Can tocotrienols help prevent stroke or dementia?
Gopalan 2014 (PMID 24699052) showed in a two-year RCT of 121 adults with cardiovascular risk and MRI-detected white-matter lesions that mixed tocotrienol 400 mg/day slowed white-matter lesion progression. White-matter lesions are a risk marker for stroke and vascular dementia, not a clinical endpoint. The honest statement is that tocotrienol slowed an imaging risk marker in this trial; no tocotrienol trial has shown a reduction in stroke or dementia incidence as a clinical endpoint.
· source: Tocotrienols
Should I take tocotrienol with food or on an empty stomach?
Always with a fat-containing meal (≥10 g of fat). Tocotrienols are fat-soluble and depend on chylomicron transport for intestinal absorption; fasting administration loses an estimated 30–50%+ of the dose. Breakfast or dinner that includes visible fat (eggs, nuts, avocado, oil, dairy) is the practical guideline.
· source: Tocotrienols
Can I take tocotrienol if I am on warfarin or another blood thinner?
Higher-dose tocotrienol (≥300 mg/day) combined with anticoagulation warrants medical supervision and INR / bleeding monitoring. This is the same general caution that applies to the rest of the vitamin E family. Inform your prescribing physician before adding tocotrienol if you are taking warfarin, a DOAC, or any antiplatelet agent.
· source: Tocotrienols
Is tocotrienol the same as the vitamin A in cod liver oil?
No. Tocotrienol is vitamin E (the unsaturated branch). Cod liver oil contains vitamin A and vitamin D (and EPA + DHA from the fish), with the vitamin A content carrying a pregnancy-teratogenicity concern at high doses. Tocotrienol products contain no vitamin A. The two are unrelated and should not be confused — see fish oil sub-page §6.3 for the cod liver oil discussion.
· source: Tocotrienols
What is the difference between oat / barley beta-glucan and yeast or mushroom beta-glucan — are they interchangeable?
No. They are structurally different molecules (β-1,3/1,4 linear in cereal vs β-1,3/1,6 branched in yeast / mushroom) with different mechanisms (viscous gel + bile-acid binding for cereal vs Dectin-1 receptor activation for yeast / mushroom), different evidence directions (cholesterol and glucose for cereal vs immune function for yeast / mushroom), and different regulatory authorizations. Doses and claims established for one form do not apply to the other.
· source: Beta-glucan
How much oat beta-glucan do I need per day for the cholesterol effect?
The FDA 21 CFR 101.81 and EFSA Article 14 authorized claims are conditioned on a daily intake of at least 3 g of oat or barley β-glucan, taken as part of a diet low in saturated fat and cholesterol. About 1 cup of rolled oats plus one barley-for-rice substitution reaches this threshold. Effects typically appear over 4-12 weeks of consistent intake.
· source: Beta-glucan
I have type 2 diabetes — can I take oat beta-glucan?
Cereal β-glucan can reduce the post-meal blood-glucose rise (EFSA Article 13(1) authorized for ≥4 g per 30 g of available carbohydrates per meal). However, type 2 diabetes is a clinical diagnosis and people on insulin, sulfonylureas, or other glucose-lowering medication should consult their healthcare provider before adding cereal β-glucan, because additive lowering of blood glucose could increase the risk of hypoglycemia. Do not stop or change prescribed therapy on the basis of dietary β-glucan intake.
· source: Beta-glucan
I have heart disease or high cholesterol — can beta-glucan replace my statin?
No. The FDA and EFSA wording is "may reduce the risk" of heart disease as part of a heart-healthy diet — not a treatment for diagnosed cardiovascular disease and not a substitute for prescribed lipid therapy. Decisions about prescription medication must be made with the prescribing clinician.
· source: Beta-glucan
Will beta-glucan prevent COVID-19, flu, or the common cold?
No. Yeast β-1,3/1,6-glucan has randomized evidence supporting immune system function in research populations, with effect sizes comparable to daily vitamin D in respiratory-immune research. The evidence does not support claims that β-glucan prevents, treats, or cures COVID-19, influenza, the common cold, or any other named respiratory illness. Vaccination and other evidence-based preventive measures should be discussed with your healthcare provider.
· source: Beta-glucan
Does AHCC clear HPV or treat cervical disease?
No. The current AHCC HPV evidence base consists of two small pilot studies (Smith 2019) with 10 participants per arm and Phase II trials in progress. AHCC is not characterized on this page as a treatment, cure, or preventive therapy for HPV infection, cervical disease, or any other named condition. Persistent HPV infection requires medical evaluation and management.
· source: Beta-glucan
Can beta-glucan be used to prevent or treat cancer?
No. The Steimbach 2021 systematic review summarized 16 trials of fungal β-glucan used as an adjunct to standard chemotherapy or radiotherapy under medical supervision and reported reductions in treatment-induced immune suppression. It does not support cancer prevention or standalone cancer treatment claims. Cancer prevention and treatment decisions must be made with an oncologist.
· source: Beta-glucan
I have an autoimmune disease (lupus, RA, MS, IBD, psoriasis, autoimmune thyroid disease) — can I take yeast or mushroom beta-glucan?
Use with caution and medical supervision. Yeast and mushroom β-glucans are innate-immune receptor ligands and could in principle amplify already-heightened immune responses. Do not start yeast or mushroom β-glucan supplementation without explicit consultation with your rheumatologist or treating specialist. Cereal (oat / barley) β-glucan, used as dietary fiber for cholesterol or glucose support, operates through a different mechanism and is not typically subject to the same caution — but any supplement decision in the context of autoimmune disease should be discussed with the treating clinician.
· source: Beta-glucan
Why does the EU allow oat beta-glucan cholesterol claims but not yeast beta-glucan immune claims?
The EFSA evaluation framework requires authorized health claims to meet defined evidence thresholds. Cereal β-glucan and cholesterol / post-meal glucose claims have cleared this threshold (Regulations 432/2012 and 1228/2014). Yeast and mushroom β-glucan immune claims have not received EFSA authorization to date, so they may not appear on labels or in advertising in the EU. Cross-border e-commerce intended for the EU must strip immune-related claim language from yeast / mushroom β-glucan product communications.
· source: Beta-glucan
Are there drug interactions or safety cautions I should be aware of?
Yes. Glucose-lowering medication plus cereal β-glucan can additively lower blood glucose (monitor for hypoglycemia); statins and cereal β-glucan additively lower cholesterol (do not modify prescribed therapy without your clinician); immunosuppressive therapy and yeast / mushroom β-glucan are mechanistically antagonistic (generally avoid); and individuals with autoimmune disease, recent transplant, glycogen storage disease, celiac disease (use certified gluten-free oats), or pregnancy / lactation should consult a healthcare provider before initiating supplemental β-glucan.
· source: Beta-glucan
Akkermansia muciniphila is a mucin-degrading gut bacterium that resides in the intestinal mucus layer. It has been studied in pasteurized form in a small Belgian feasibility RCT (Depommier C et al., Nature Medicine 2019, PMID 31263284) for metabolic markers in overweight/obese adults. A full evidence-first fact sheet — covering strain identity, pasteurization status, dose-response, and safety — is scheduled for the future ingredient expansion on this hub.
· source: Akkermansia
Does Akkermansia muciniphila help with weight loss?
The 2019 Depommier RCT (n=32, 3 months) reported small directional improvements in insulin sensitivity and modest changes in body composition markers in the pasteurized-Akkermansia arm versus placebo; it was a single small feasibility trial and is not yet supported by independent pooled meta-analytic evidence. Akkermansia is not characterized as a weight-loss treatment on this hub, and obesity is a clinical condition requiring lifestyle and where appropriate medical management.
· source: Akkermansia
Is Akkermansia muciniphila safe?
In the 2019 feasibility RCT, pasteurized Akkermansia muciniphila was reported as well tolerated over three months at the dose studied. Long-term human safety data beyond three months remain limited, and live-Akkermansia products carry different safety considerations than the pasteurized form. Individuals who are pregnant, lactating, immunocompromised, or managing a chronic gastrointestinal condition should consult a healthcare provider before use.
· source: Akkermansia
What dose of Akkermansia muciniphila is studied?
The published RCT evaluated 10^10 pasteurized Akkermansia muciniphila cells per day in overweight/obese adults. Commercial product dosing varies and may use different strain forms (pasteurized vs live) — consult the product label and a healthcare provider.
· source: Akkermansia
Where does the current evidence-first content for this page sit?
This is a Lite reference page. The full fact sheet — mechanism deep-dive, dose-response, safety profile, complete PMID citation set, and negative-findings transparency — is part of the future ingredient expansion on this hub and is not yet published. The page does not currently make any health claim beyond the single RCT signal referenced above.
· source: Akkermansia
Ashwagandha (Withania somnifera) is an adaptogenic plant whose root and leaf extracts have been studied in randomized controlled trials for stress, sleep, and androgen-related markers. A small-to-moderate body of RCTs supports stress and perceived-anxiety endpoints; the full evidence-first fact sheet covering standardization (e.g., KSM-66 vs Sensoril), withanolide content, and complete PMID citation set is scheduled for the future ingredient expansion on this hub.
· source: Ashwagandha
Does ashwagandha help with stress and anxiety?
Multiple small-to-moderate RCTs in adults with self-reported stress have reported reductions in Perceived Stress Scale (PSS) scores and serum cortisol markers over 8–12 weeks. Effect sizes vary across trials, sample sizes are typically modest, and the evidence is reported as rct-supported (not meta-analysis-supported at the strongest tier). Anxiety disorders (ICD-10 F41) are clinical diagnoses; ashwagandha is not characterized on this hub as a treatment for any anxiety or depressive disorder.
· source: Ashwagandha
Is ashwagandha safe to take long-term?
Most RCTs studied 8–12 weeks of supplementation; long-term human safety data beyond ~12 weeks remain limited. Case reports of liver injury (hepatotoxicity) have been published in the post-2020 literature and reported to international pharmacovigilance databases; the absolute frequency appears low but is non-zero. Individuals with pre-existing liver disease, autoimmune thyroid conditions, or on sedative/thyroid medications, and those who are pregnant or lactating, should consult a healthcare provider before use.
· source: Ashwagandha
What dose of ashwagandha is studied?
Most stress and sleep RCTs evaluated 300–600 mg/day of standardized root extract (often as two divided doses), typically for 8–12 weeks. Withanolide standardization (e.g., 1.5–5%) varies by product; the dose is not directly transferable across non-equivalent extracts.
· source: Ashwagandha
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full mechanism narrative, dose-response cluster, standardization landscape, hepatotoxicity case-report transparency, complete PMID citation set, and negative-findings disclosure are part of the future ingredient expansion and are not yet published on this hub.
· source: Ashwagandha
Vitamin B12 (cobalamin) is a water-soluble B-vitamin essential for DNA synthesis, red blood cell formation, and central and peripheral nervous system function. It is found naturally in animal-source foods and supplemented in fortified plant-based products. Deficiency is a clinical diagnosis (ICD-10 D51 / E53.8) requiring evaluation; this page does not characterize B12 as a treatment for any disease.
· source: Vitamin B12
Who is at risk of vitamin B12 deficiency?
Risk groups documented in clinical literature include: adults aged 60+ (reduced gastric acid and intrinsic factor), strict vegetarians and vegans, individuals on long-term metformin or proton-pump inhibitors, those with autoimmune pernicious anemia or atrophic gastritis, and post-gastric-bypass patients. Testing and clinical evaluation by a healthcare provider — not self-supplementation — is the appropriate first step when deficiency is suspected.
· source: Vitamin B12
What is the recommended daily intake?
The U.S. RDA is 2.4 µg/day for healthy adults (slightly higher in pregnancy and lactation). EU EFSA adequate intake is 4 µg/day. Higher therapeutic doses (e.g., 1000 µg/day oral or intramuscular injection) are used under medical supervision for documented deficiency — not as self-managed supplementation.
· source: Vitamin B12
Is vitamin B12 safe at high doses?
No tolerable upper intake level (UL) has been set for B12 by U.S. IOM or EU EFSA because of the absence of documented adverse effects at high oral doses in healthy adults. Excess B12 is excreted in urine. Individuals managing pernicious anemia or other documented B12-related conditions should follow their treating clinician’s dosing plan rather than self-supplementing.
· source: Vitamin B12
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering methylcobalamin / cyanocobalamin / hydroxocobalamin form chemistry, deficiency clinical-decision support, fortification policy landscape, complete PMID citation set, and dementia / cognitive-decline trial transparency (where pooled meta-analyses do not support supplementation in non-deficient adults) is part of the future ingredient expansion and not yet published.
· source: Vitamin B12
BCAAs are three essential amino acids — leucine, isoleucine, and valine — characterized by branched side chains. Leucine in particular activates the mTOR pathway involved in skeletal muscle protein synthesis. Dietary BCAAs are abundant in animal-source protein, whey, soy, and most complete protein supplements; isolated BCAA powders represent only one of several supplementation formats.
· source: BCAA
Do BCAAs help build muscle?
In adults already consuming adequate total protein (≥1.6 g/kg/day for trained individuals), isolated BCAA supplementation has not consistently outperformed equivalent doses of complete protein in head-to-head RCTs. Several reviews and trials (including Wolfe RR 2017, J Int Soc Sports Nutr) argue that the muscle-protein-synthesis signal from isolated BCAAs is transient without the full essential amino acid (EAA) complement. Complete protein or EAA blends are generally regarded as more efficient than isolated BCAAs for hypertrophy goals.
· source: BCAA
What about BCAAs for endurance exercise or fatigue?
Some trials have reported reductions in subjective ratings of perceived exertion and central-fatigue markers with BCAA supplementation during endurance exercise, but pooled effects on objective endurance performance endpoints are inconsistent. BCAAs are not characterized on this hub as a performance-enhancement requirement; total daily protein adequacy is the primary determinant of training adaptation.
· source: BCAA
What dose of BCAAs is studied?
Common RCT doses range from 5–20 g/day, often in a 2:1:1 leucine:isoleucine:valine ratio. The 2:1:1 ratio is convention rather than the outcome of a dose-response optimization study, and the marginal benefit over equivalent leucine alone or whey protein remains debated.
· source: BCAA
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the BCAA-vs-EAA-vs-whey trial transparency, leucine-only sub-cluster, and the "anabolic-resistance in older adults" sub-cluster is part of the future ingredient expansion and not yet published.
· source: BCAA
Berberine is an isoquinoline alkaloid extracted primarily from Coptis chinensis, Berberis vulgaris, and Hydrastis canadensis. It is a dietary supplement category ingredient in the United States and a recognized pharmacopeial drug ingredient in China. Multiple pooled meta-analyses have evaluated berberine for glycemic and lipid markers in adults with prediabetes, type 2 diabetes, and metabolic syndrome research populations.
· source: Berberine
Does berberine work like a "natural Ozempic"?
No. This is a social-media framing that misrepresents the mechanism and effect size. Berberine activates AMPK and modulates gut microbiota; GLP-1 agonists (semaglutide / tirzepatide) act on GLP-1 / GIP receptors with pharmacologically distinct mechanisms and substantially larger effect sizes on weight reduction in head-to-head pharmacology. Berberine is not a substitute for any prescribed pharmacologic therapy, and obesity (ICD-10 E66) and type 2 diabetes (ICD-10 E11) are clinical conditions requiring medical management.
· source: Berberine
Is berberine safe?
Most berberine RCTs report tolerability across 8–24 weeks at 500 mg three times daily. Common side effects include gastrointestinal symptoms (cramping, diarrhea, constipation). Berberine is a known CYP3A4 inhibitor and interacts with multiple prescription medications including statins, immunosuppressants, and oral hypoglycemics — individuals on prescription medications must consult a healthcare provider before use. Berberine is contraindicated in pregnancy and lactation (kernicterus risk in neonates from related compounds).
· source: Berberine
What dose of berberine is studied?
The most common RCT dose is 500 mg three times daily (1500 mg/day total) for 8–24 weeks, typically with meals to reduce gastrointestinal side effects. Higher single doses are not better tolerated. Berberine has low oral bioavailability (<5%); some products use dihydroberberine or phytosome formulations claiming higher bioavailability — head-to-head clinical comparisons of these forms remain limited.
· source: Berberine
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering pooled meta-analysis HbA1c / FPG / LDL effect sizes, the drug-interaction transparency table, dihydroberberine bioavailability literature, and pregnancy contraindication rationale is part of the future ingredient expansion and not yet published.
· source: Berberine
Biotin (vitamin B7 / vitamin H) is a water-soluble B-vitamin that serves as a cofactor for five carboxylase enzymes involved in carbohydrate, fat, and amino acid metabolism. The U.S. adequate intake for healthy adults is 30 µg/day. Biotin deficiency is rare in healthy adults consuming a varied diet.
· source: Biotin
Does biotin help with hair growth?
The evidence that biotin supplementation improves hair growth in adults without a diagnosed biotin deficiency is weak. A 2017 systematic review (Patel DP et al., Skin Appendage Disorders) concluded that biotin supplementation benefits hair and nails primarily in cases of documented deficiency (inherited biotinidase deficiency, certain malabsorption syndromes, or genuine clinical deficiency). For otherwise-healthy adults experiencing hair shedding, evaluation of common alternative causes (androgenetic alopecia, thyroid dysfunction, iron deficiency, telogen effluvium triggers) by a dermatologist is the appropriate first step.
· source: Biotin
Can biotin interfere with lab tests?
Yes. The FDA has issued a Safety Communication noting that high-dose biotin (typically ≥5 mg/day, but documented at lower doses) can cause clinically significant interference with multiple immunoassay-based laboratory tests, including troponin (risk of false-negative myocardial infarction diagnosis) and thyroid hormone panels. Individuals taking biotin supplements should disclose this to any clinician ordering laboratory tests, and biotin is commonly held for 48–72 hours before testing.
· source: Biotin
What dose of biotin is safe?
There is no established tolerable upper intake level (UL) for biotin, and excess is excreted in urine. The primary concern at high doses is laboratory-test interference (see prior FAQ), not direct toxicity. Marketed hair-and-nail supplements often contain 5000–10000 µg per serving — orders of magnitude above the 30 µg/day adequate intake without proportional evidence of benefit in non-deficient adults.
· source: Biotin
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the FDA biotin-interference Safety Communication primary literature, deficiency clinical-decision support, brittle-nail trial transparency, and pregnancy supplementation considerations is part of the future ingredient expansion and not yet published.
· source: Biotin
Choline is an essential nutrient required for cell membrane phospholipid synthesis (phosphatidylcholine, sphingomyelin), the neurotransmitter acetylcholine, methyl-group donation (via betaine), and lipid transport. It is found in eggs, liver, fish, soy, and cruciferous vegetables. The U.S. National Academy of Medicine established a daily adequate intake of 550 mg/day (men) and 425 mg/day (women), increased in pregnancy and lactation; most national dietary intake surveys (NHANES) report population intakes below the AI.
· source: Choline
Why is choline important in pregnancy?
Choline is required for fetal brain development and is recommended at 450 mg/day during pregnancy and 550 mg/day during lactation in U.S. dietary reference intakes. Pregnant individuals should consult their obstetrician on whether prenatal multivitamins provide adequate choline, as many prenatal formulations historically under-dose it.
· source: Choline
Does choline help cognition or Alzheimer's disease?
Choline is a precursor to acetylcholine, which is depleted in Alzheimer-type dementia. However, oral choline supplementation has not been demonstrated to treat or prevent Alzheimer's disease in pooled clinical trial evidence. Alzheimer's disease (ICD-10 G30) is a clinical diagnosis requiring neurological evaluation; choline is not characterized on this hub as a treatment for any cognitive disorder.
· source: Choline
Is choline safe at high doses?
The U.S. tolerable upper intake level (UL) for choline in adults is 3500 mg/day. Doses above the UL can cause fishy body odor (due to trimethylamine metabolism), hypotension, and gastrointestinal symptoms. Higher-dose choline supplementation has been associated in some observational analyses with elevated serum TMAO (trimethylamine N-oxide), a biomarker under research for cardiovascular risk; the clinical significance for healthy adults supplementing at moderate doses remains an open research question.
· source: Choline
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the choline forms landscape (phosphatidylcholine / CDP-choline / alpha-GPC), the TMAO transparency note, pregnancy and infant neurodevelopment trial cluster, and NAFLD trial cluster is part of the future ingredient expansion and not yet published.
· source: Choline
Collagen peptides (also called hydrolyzed collagen) are short-chain peptides produced by enzymatic hydrolysis of bovine, porcine, marine (fish), or chicken collagen. They are not "collagen" in the structural sense once ingested — they are digested to constituent amino acids and short di-/tri-peptides (notably hydroxyproline-containing dipeptides) that have been studied as potential signaling molecules for fibroblast collagen synthesis.
· source: Collagen Peptides
Do collagen peptides improve skin elasticity and hydration?
A 2023 systematic review and meta-analysis (de Miranda RB et al., Int J Dermatol) of 26 RCTs reported significant improvements in skin hydration and elasticity following 8–12 weeks of hydrolyzed collagen supplementation at 2.5–15 g/day. Effect sizes are modest, and pooled wrinkle endpoints are less consistent than the hydration and elasticity signals. Most trials are industry-sponsored; transparency on this is important when interpreting the magnitude of effect.
· source: Collagen Peptides
Do collagen peptides help joint pain or osteoarthritis?
Several small-to-moderate RCTs have evaluated collagen peptides (and the distinct "type 2 collagen" preparation, see the type-2-collagen page) for joint discomfort markers and WOMAC scores in adults with osteoarthritis research populations. Pooled meta-analytic evidence is less robust than the skin cluster, and effect sizes vary by collagen source and trial. Osteoarthritis (ICD-10 M15–M19) is a clinical diagnosis requiring rheumatologic evaluation; collagen peptides are not characterized on this hub as a treatment for any joint disease.
· source: Collagen Peptides
Does it matter whether collagen is from bovine, marine, porcine, or chicken sources?
All sources yield similar amino acid profiles after hydrolysis, with subtle differences in hydroxyproline-peptide species. Marine (fish) collagen is sometimes preferred for kosher / halal / cultural considerations. Allergy considerations apply (fish-allergic individuals should avoid marine collagen). The clinical-trial database is heavily weighted toward bovine and marine sources.
· source: Collagen Peptides
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the 2023 de Miranda MA effect-size table, the bovine-vs-marine sub-cluster, the vitamin-C cofactor co-supplementation question, type-2-collagen distinction, and industry-sponsorship transparency is part of the future ingredient expansion and not yet published.
· source: Collagen Peptides
Coenzyme Q10 (ubiquinone / ubiquinol) is a lipid-soluble electron carrier in the mitochondrial electron transport chain (complexes I-III) and a membrane-bound antioxidant. It is synthesized endogenously through the mevalonate pathway (the same pathway inhibited by statins) and is found in dietary sources including organ meats, fatty fish, and certain vegetable oils. Endogenous CoQ10 production declines with age.
· source: CoQ10
Does CoQ10 help statin-associated muscle symptoms?
The trial evidence is mixed. The 2018 Qu H et al. meta-analysis reported a modest reduction in statin-associated muscle symptom scores with CoQ10 supplementation, while several individual placebo-controlled crossover trials (e.g., Taylor BA 2015) reported non-significant results. Statin therapy should never be discontinued without consulting the prescribing clinician, and CoQ10 is not a substitute for statin pharmacotherapy in patients with elevated cardiovascular risk.
· source: CoQ10
Does CoQ10 help heart failure?
The Q-SYMBIO randomized controlled trial (Mortensen SA et al. 2014, JACC Heart Failure) reported a reduction in major adverse cardiovascular events in patients with chronic heart failure receiving 300 mg/day CoQ10 over two years. As a single industry-supported trial, Q-SYMBIO is the strongest cluster anchor but is not yet supported by independent confirmatory mega-trials. Heart failure (ICD-10 I50) is a clinical diagnosis requiring cardiology management; CoQ10 is not a substitute for guideline-directed medical therapy.
· source: CoQ10
Ubiquinol or ubiquinone — which is better?
Ubiquinol (the reduced form) has been reported to have higher bioavailability than ubiquinone (the oxidized form) in some pharmacokinetic studies, particularly in older adults. However, head-to-head clinical outcome trials comparing the two forms are limited, and ubiquinone is the form used in most positive clinical trials including Q-SYMBIO. Cost-benefit considerations vary.
· source: CoQ10
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering Q-SYMBIO methodology, statin myopathy meta-analytic transparency, ubiquinol-vs-ubiquinone pharmacokinetics, mitochondrial disease research populations (where CoQ10 has primary medical-grade use under specialist supervision), and migraine-prophylaxis trial cluster is part of the future ingredient expansion and not yet published.
· source: CoQ10
Creatine is a tripeptide synthesized endogenously from arginine, glycine, and methionine, and obtained in the diet from red meat and fish. In skeletal muscle, creatine is phosphorylated to phosphocreatine, which serves as a rapid-turnover energy buffer for ATP regeneration during short-duration high-intensity work. Creatine monohydrate is the most extensively studied supplemental form and the form used in essentially all positive clinical trials.
· source: Creatine
Does creatine actually work for muscle and strength?
Yes — creatine monohydrate has one of the strongest and most reproducible evidence bases in the sports-nutrition category. Multiple pooled meta-analyses (including Chilibeck PD 2017 and Lanhers C 2017) report consistent improvements in lean mass, maximal strength, and high-intensity exercise performance when combined with resistance training, in adults across age ranges. The International Society of Sports Nutrition (ISSN) position stand on creatine monohydrate supports both safety and effectiveness in healthy adults.
· source: Creatine
Does creatine cause kidney damage or hair loss?
In healthy adults with normal kidney function, creatine monohydrate has been studied extensively (including long-term follow-up to 5 years) without evidence of kidney injury. The transient rise in serum creatinine reflects increased substrate turnover, not kidney dysfunction. The "hair loss" association traces to a single small DHT-marker study (van der Merwe 2009) that has not been replicated in subsequent investigations and has not been demonstrated to translate into clinical hair loss. Individuals with pre-existing chronic kidney disease should consult a nephrologist before use.
· source: Creatine
What dose of creatine is studied?
The standard protocol is 3–5 g/day of creatine monohydrate, taken continuously. An optional "loading phase" of 20 g/day (split into four 5 g doses) for 5–7 days accelerates muscle creatine saturation; outcomes are equivalent without loading after ~4 weeks of continuous 5 g/day dosing. Timing relative to workouts is not clinically meaningful — consistency is the primary driver.
· source: Creatine
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the ISSN position stand citation, cognition and aging RCT cluster (creatine + cognitive function emerging literature), the "alternative forms" (HCl, ethyl ester, buffered) transparency note (none have outperformed monohydrate in head-to-head trials), and the safe long-term-use safety profile is part of the future ingredient expansion and not yet published.
· source: Creatine
Curcumin is the most abundant curcuminoid in the rhizome of turmeric (Curcuma longa). Turmeric powder contains roughly 2–8% curcuminoids; isolated curcumin extracts standardized to 95% curcuminoids are the form used in most clinical trials. Curcumin has very low oral bioavailability in its native form, motivating the development of multiple enhanced-bioavailability formulations.
· source: Curcumin
Does curcumin help osteoarthritis or joint pain?
Multiple pooled meta-analyses have reported modest reductions in WOMAC pain and stiffness scores with curcumin supplementation in adults with osteoarthritis research populations, with effect sizes broadly comparable to over-the-counter NSAIDs in some pooled comparisons (but with substantially different safety profiles and trial designs). Osteoarthritis (ICD-10 M15–M19) is a clinical diagnosis requiring rheumatologic evaluation; curcumin is not characterized on this hub as a treatment for any joint disease.
· source: Curcumin
Why are there so many different curcumin formulations?
Native curcumin has roughly 1% oral bioavailability. Enhanced formulations — including piperine-co-formulated, phospholipid complexes (Meriva), nano-emulsions, gamma-cyclodextrin complexes, and theracurmin — have reported 2–30-fold higher plasma curcuminoid AUC in pharmacokinetic studies. Clinical-outcome head-to-head trials between formulations remain limited.
· source: Curcumin
Is curcumin safe?
Curcumin is generally well tolerated in clinical trials at common doses (500–2000 mg/day curcuminoids), with mild gastrointestinal symptoms the most commonly reported side effect. Hepatotoxicity case reports have been published (including in some high-bioavailability formulations), and curcumin can interact with blood-thinners (warfarin, antiplatelets) and may interfere with iron absorption. Individuals on prescription medications, with gallbladder disease, or who are pregnant or lactating should consult a healthcare provider before use.
· source: Curcumin
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the OA meta-analytic effect-size table, the bioavailability-formulation landscape, the hepatotoxicity case-report transparency, depression and metabolic-syndrome trial clusters, and the curcuminoid-vs-curcumin-only distinction is part of the future ingredient expansion and not yet published.
· source: Curcumin
Folate is a water-soluble B-vitamin required for one-carbon metabolism, DNA synthesis, and methylation reactions. The naturally occurring form in food is folate; the synthetic form used in supplements and fortified foods is folic acid (pteroylmonoglutamic acid); the active circulating coenzyme form is 5-methyltetrahydrofolate (5-MTHF / methylfolate).
· source: Folate
Why is folate critical in pregnancy?
Adequate periconceptional folate intake substantially reduces the risk of neural tube defects in offspring. Public-health agencies in the U.S., EU, and Brazil recommend 400 µg/day of folic acid for individuals of reproductive age and 600 µg/day during pregnancy, typically through prenatal multivitamins. Folate supplementation should ideally begin at least one month before conception. This is one of the most evidence-supported supplementation recommendations in nutrition science.
· source: Folate
What is the difference between folic acid and methylfolate?
Folic acid is the synthetic form used in nearly all clinical trials demonstrating neural tube defect prevention and in U.S. mandatory grain fortification. Methylfolate (5-MTHF) is the active coenzyme form. Some individuals carry MTHFR gene polymorphisms (C677T) that may modestly reduce conversion efficiency; for healthy individuals without documented metabolic concerns, folic acid is supported by the strongest population-level evidence base for neural tube defect prevention.
· source: Folate
Can folate mask vitamin B12 deficiency?
Yes — this is a documented clinical concern. High-dose folate (≥1000 µg/day) can correct the hematologic markers of B12 deficiency (macrocytic anemia) while allowing the neurologic damage of B12 deficiency to progress unrecognized. This is one reason supplemental folate UL is set at 1000 µg/day for U.S. adults and why B12 status should be considered alongside folate supplementation, particularly in older adults.
· source: Folate
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the MRC Vitamin Study (1991), the U.S./Brazil/EU fortification policy landscape, MTHFR polymorphism transparency, depression and methylfolate trial cluster, and the cancer-screening transparency (folate biology in established tumors) is part of the future ingredient expansion and not yet published.
· source: Folate
Hyaluronic acid (HA) is a glycosaminoglycan composed of repeating D-glucuronic acid and N-acetylglucosamine units. It is a major component of skin extracellular matrix and synovial joint fluid. It can be administered topically (cosmetic), injected intra-articularly (medical-grade viscosupplementation under physician supervision), or taken orally as a dietary supplement; this page covers the oral supplement context only.
· source: Hyaluronic Acid
Does oral hyaluronic acid help skin hydration?
A small-to-moderate body of RCTs (largely industry-sponsored) has reported improvements in skin hydration markers (corneometer readings) and self-reported skin moisture with oral HA at 120–240 mg/day over 8–12 weeks. Effect sizes are modest, sample sizes are typically small, and replication in independent academic trials is limited. The mechanism by which orally consumed HA reaches skin remains an active research question (oligosaccharide digestion products and gut-skin signaling are proposed but not definitively established).
· source: Hyaluronic Acid
Does oral hyaluronic acid help joint pain?
Several small RCTs have reported reductions in WOMAC pain scores in adults with osteoarthritis research populations on oral HA at 80–200 mg/day. Effect sizes are modest, and oral HA evidence is substantially weaker than evidence for intra-articular HA injection (which is administered under physician supervision and is regulated as a medical device, not a dietary supplement, in most jurisdictions). Osteoarthritis is a clinical diagnosis requiring rheumatologic evaluation.
· source: Hyaluronic Acid
Does the molecular weight of hyaluronic acid matter?
Some research differentiates high-molecular-weight (HMW) HA, low-molecular-weight (LMW) HA, and oligohyaluronic acid for skin and joint endpoints. Clinical-trial head-to-head comparisons remain limited, and oral HA molecular-weight specifications are not consistently disclosed on consumer product labels.
· source: Hyaluronic Acid
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the oral-HA skin trial cluster (with industry-sponsorship transparency), the oral-vs-injectable HA distinction for joint applications, molecular-weight landscape, and topical-cosmetic HA distinction is part of the future ingredient expansion and not yet published.
· source: Hyaluronic Acid
Iron is an essential trace mineral required for hemoglobin (oxygen transport), myoglobin, multiple iron-sulfur cluster enzymes, and DNA synthesis. Iron deficiency is the world's most common micronutrient deficiency and the leading cause of anemia globally. Iron-deficiency anemia (ICD-10 D50) is a clinical diagnosis requiring laboratory evaluation (ferritin, transferrin saturation, hemoglobin) by a healthcare provider.
· source: Iron
Who should take iron supplements?
Iron supplementation in healthy adults without documented deficiency or risk factors is not generally recommended. Indications established in clinical guidelines include: documented iron-deficiency anemia, pregnancy (where iron requirements increase substantially), heavy menstrual bleeding leading to iron loss, vegetarian/vegan diets with low ferritin status, post-surgical iron repletion, and athletes with documented sport-related iron deficiency. Testing should precede supplementation.
· source: Iron
Why is iron supplementation in non-deficient adults discouraged?
Excess iron is pro-oxidant, accumulates in the liver and heart (the body has no regulated iron excretion pathway), and has been associated in observational research with elevated cardiovascular risk. Individuals with undiagnosed hereditary hemochromatosis (HFE C282Y homozygotes, ~1 in 200 individuals of Northern European ancestry) face accelerated harm from iron supplementation. This is why iron should not be self-supplemented without testing.
· source: Iron
What dose and form of iron is studied?
For iron-deficiency repletion, common protocols include 60–120 mg elemental iron daily (ferrous sulfate, ferrous fumarate, or ferrous gluconate, taken on an empty stomach or with vitamin C to improve absorption). Emerging evidence (e.g., Stoffel NU et al. 2017) supports alternate-day rather than daily dosing for improved fractional absorption and reduced gastrointestinal side effects. Iron supplementation should follow a clinician's plan with appropriate follow-up labs.
· source: Iron
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the alternate-day vs daily dosing literature, iron-deficiency anemia clinical-decision support, athlete sport-related iron sub-cluster, hemochromatosis transparency, oral-vs-IV iron distinction (IV iron is a medical-supervised intervention), and pregnancy iron supplementation guidelines is part of the future ingredient expansion and not yet published.
· source: Iron
L-theanine is a non-protein amino acid (γ-glutamylethylamide) found in tea (Camellia sinensis) leaves, particularly green tea. It is structurally related to glutamate and is proposed to modulate glutamatergic and GABAergic neurotransmission. L-theanine crosses the blood-brain barrier and has been studied for relaxation, attention, and sleep-quality markers.
· source: L-Theanine
Does L-theanine help with stress and relaxation?
Several small-to-moderate RCTs have reported reductions in perceived-stress markers and self-reported calmness with 100–400 mg of L-theanine, often within ~60 minutes of dosing. EEG studies have reported increases in alpha-band activity associated with the "alert relaxation" subjective state. Effect sizes are modest, sample sizes are typically small, and replication across independent academic groups remains limited.
· source: L-Theanine
Does L-theanine with caffeine improve focus?
A small body of acute-dosing RCTs has reported that the combination of L-theanine (~100 mg) with caffeine (~50 mg) — roughly the ratio found in a cup of green tea — may improve attention and reaction-time measures with a smoother subjective profile than caffeine alone. This is one of the more frequently replicated nutrition-cognition signals but is still considered emerging evidence; many trials are short-duration acute-dosing studies.
· source: L-Theanine
Is L-theanine safe?
L-theanine is recognized as GRAS by the U.S. FDA and is generally well tolerated at 100–400 mg/day in clinical trials. Long-term safety data beyond ~8 weeks are limited. As with any psychoactive nutrient, individuals on prescription antidepressants, anxiolytics, or stimulants, and those who are pregnant or lactating, should consult a healthcare provider before use.
· source: L-Theanine
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the L-theanine + caffeine RCT cluster, sleep-quality emerging-evidence transparency, the EEG alpha-band literature, dose-response cluster, and pregnancy/breastfeeding considerations is part of the future ingredient expansion and not yet published.
· source: L-Theanine
Magnesium is an essential mineral required as a cofactor for more than 300 enzymatic reactions, including ATP synthesis, DNA and protein synthesis, muscle and nerve function, and blood-glucose regulation. Roughly 50% of body magnesium is stored in bone. The U.S. RDA is 400–420 mg/day (men) and 310–320 mg/day (women); a substantial fraction of the U.S. population (NHANES) consumes below the RDA.
· source: Magnesium
Which form of magnesium is best?
Magnesium glycinate (bisglycinate), citrate, malate, and L-threonate are organic-acid-bound forms generally reported to have higher bioavailability and lower gastrointestinal-side-effect profiles than magnesium oxide. Magnesium oxide has lower bioavailability but higher elemental magnesium content per gram. Magnesium L-threonate has been promoted for neurologic/cognitive applications based on a small trial (Liu G et al. 2016, MMFS-01) reporting cognitive improvements in older adults; independent replication remains limited.
· source: Magnesium
Does magnesium help with sleep?
A 2022 systematic review (Mah J & Pitre T, BMC Complement Med Ther) of 3 RCTs in older adults with insomnia reported modest improvements in sleep-onset latency and total sleep time with magnesium supplementation, with overall low-quality evidence and a recommendation for larger trials. The "magnesium for sleep" social-media positioning substantially overstates the strength of the underlying evidence; effect sizes are modest and the evidence base is small.
· source: Magnesium
Is magnesium safe?
The U.S. UL for supplemental magnesium is 350 mg/day for adults (this UL applies to supplemental magnesium, not dietary magnesium). Above the UL, magnesium can cause diarrhea and gastrointestinal symptoms. Individuals with reduced kidney function are at risk of magnesium accumulation and hypermagnesemia; chronic kidney disease patients should consult a nephrologist before supplementation.
· source: Magnesium
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the magnesium form bioavailability landscape, sleep evidence transparency, migraine prophylaxis RCT cluster, blood pressure meta-analytic effect-size table, cardiovascular disease association literature, and pregnancy-leg-cramp trial transparency is part of the future ingredient expansion and not yet published.
· source: Magnesium
Medium-chain triglycerides (MCTs) are saturated fats with carbon chain lengths of 6–12 (caproic C6, caprylic C8, capric C10, lauric C12). They are extracted primarily from coconut and palm-kernel oils. Compared with long-chain triglycerides, MCTs are absorbed more rapidly into the portal circulation and reach the liver directly, where they are preferentially oxidized for energy or converted to ketone bodies.
· source: MCT
Do MCTs help with weight loss?
A 2015 systematic review and meta-analysis (Mumme K & Stonehouse W, J Acad Nutr Diet) of 13 RCTs reported modest reductions in body weight, waist circumference, and total body fat with MCT substitution for long-chain triglycerides — effect sizes were small (e.g., ~0.5 kg over 8–12 weeks) and not clinically transformative. MCTs are not characterized on this hub as a weight-loss treatment, and obesity is a clinical condition requiring lifestyle and where appropriate medical management.
· source: MCT
Do MCTs help with ketogenic diets or ketone production?
MCTs (particularly C8 caprylic acid) are converted to ketone bodies in the liver more rapidly than long-chain fats. Acute MCT ingestion can transiently elevate blood β-hydroxybutyrate. This pharmacokinetic effect is well established; whether it translates to clinical benefit (cognition, performance) depends on the endpoint and trial design, and high-quality long-term RCTs in non-clinical populations remain limited.
· source: MCT
Are MCTs safe?
MCTs are generally well tolerated at common doses (1–2 tablespoons per day). The most common side effects are gastrointestinal — cramping, nausea, and diarrhea — particularly with high single doses on an empty stomach. Individuals with liver disease (cirrhosis, severe hepatic impairment) should consult a hepatologist before use, as MCT metabolism is hepatic.
· source: MCT
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the C8/C10/C12 carbon-chain distinction, the medically supervised MCT use in pediatric epilepsy / certain inborn errors of metabolism (which is distinct from dietary supplement use), the weight-loss meta-analytic effect-size table, and the cognition emerging-evidence transparency is part of the future ingredient expansion and not yet published.
· source: MCT
A multivitamin is a dietary supplement containing a defined mixture of vitamins and (typically) minerals, intended to supplement dietary intake. Formulations vary widely — by age band (pediatric / adult / senior), gender (men / women / prenatal), and "specialty" positioning. There is no universal formulation, and the U.S. FDA does not pre-approve multivitamin formulations before market.
· source: Multivitamin
Does taking a daily multivitamin improve health or extend lifespan?
The Physicians' Health Study II (Gaziano JM et al., 2012, JAMA) — a large randomized trial in middle-aged and older U.S. male physicians — reported a modest reduction in total cancer incidence but no significant effect on cardiovascular events, cognitive decline, or all-cause mortality with daily Centrum Silver multivitamin use over ~11 years. The 2022 USPSTF review concluded that the evidence is "insufficient to assess the balance of benefits and harms" of multivitamin use for the prevention of cardiovascular disease or cancer in healthy adults. Effect sizes, where present, are modest.
· source: Multivitamin
Who is most likely to benefit from a multivitamin?
Likely net-benefit groups documented in clinical literature include pregnant individuals (prenatal multivitamin for folate and iron adequacy), older adults at risk of micronutrient inadequacy, individuals on restrictive diets (vegan / very-low-calorie), post-bariatric surgery patients (where specific formulations are clinically required), and individuals with documented malabsorption. For healthy adults with a balanced diet, the marginal benefit is modest and not well established.
· source: Multivitamin
Are multivitamins safe?
For most healthy adults, properly formulated daily multivitamins are well tolerated. Specific safety considerations include: iron-containing multivitamins should be avoided in adults without documented iron need (see iron page); vitamin A from preformed retinol exceeds safety limits in pregnancy when stacked with prenatal sources; high-dose antioxidant multivitamins have been associated in some pooled analyses with neutral or modestly elevated mortality signals (Bjelakovic G et al. Cochrane reviews). "More is not better" applies to multivitamin formulations.
· source: Multivitamin
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the Physicians' Health Study II, USPSTF 2022 review, the cancer-prevention transparency, the Cochrane antioxidant-multivitamin mortality signal (Bjelakovic 2012), prenatal multivitamin formulation specificity, and senior-formulation rationale is part of the future ingredient expansion and not yet published.
· source: Multivitamin
Nervonic acid is a long-chain monounsaturated omega-9 fatty acid (24:1n-9) that is a structural component of sphingomyelin in the central and peripheral nervous system myelin sheath. It is enriched in neural tissue. Commercial dietary sources include seed oils from certain Asian-origin plants (notably Acer truncatum / xanthoceras) and is also synthesized endogenously from oleic acid.
· source: Nervonic Acid
Is nervonic acid clinically proven to support brain or nerve health?
The current clinical evidence base in healthy adults is small and rated as preclinical-major on this hub. Most published research consists of preclinical animal studies on myelination and developmental neuroscience, with very limited human randomized trial data. Marketing claims of "nerve repair" or "memory enhancement" in healthy adults substantially overstate the strength of the current evidence base.
· source: Nervonic Acid
Is nervonic acid related to omega-3 EPA / DHA?
No — nervonic acid is an omega-9 fatty acid (24:1n-9), structurally distinct from the omega-3 fatty acids EPA (20:5n-3) and DHA (22:6n-3). DHA, not nervonic acid, has the larger clinical evidence base for cognitive and developmental endpoints. See the omega-3, fish-oil, and algal-oil pages for the omega-3 evidence cluster.
· source: Nervonic Acid
Is nervonic acid safe?
Human safety data on isolated nervonic acid supplementation are limited. Acer truncatum seed oil has a longer history of food use in certain Asian dietary contexts. Pregnant and lactating individuals, children, and adults with chronic conditions should consult a healthcare provider before using nervonic acid supplements, given the limited human clinical safety database.
· source: Nervonic Acid
Where does the current evidence-first content for this page sit?
This is a Lite reference page with a preclinical-major evidence tier. Full content covering myelination biology, the small published human pilot trials (where they exist), the Acer truncatum seed-oil supply landscape, and regulatory novel-food status across markets is part of the future ingredient expansion and not yet published. Consumers should treat current marketing claims with appropriate skepticism until larger independent RCTs are published.
· source: Nervonic Acid
Phosphatidylserine is a phospholipid abundant in cell membranes, particularly neuronal membranes, where it is enriched on the inner leaflet of the bilayer. PS supplements were historically derived from bovine cortex but were transitioned to soy- and sunflower-derived sources after BSE transmission concerns. The form used in essentially all modern clinical trials is plant-derived soy- or sunflower-PS.
· source: Phosphatidylserine
Does PS help with age-related cognitive decline?
A small body of older RCTs (1990s–2000s) reported modest improvements in memory and cognitive composite scores in adults with age-associated memory impairment. The 2015 Glade MJ & Smith K (Nutrition) review synthesized this literature. Newer high-quality RCTs in well-defined cognitive populations are limited, and PS should not be characterized as a treatment or prevention for dementia or Alzheimer's disease (which are clinical diagnoses requiring neurological evaluation).
· source: Phosphatidylserine
Does PS help with cortisol or exercise recovery?
Several small RCTs have reported reductions in exercise-induced cortisol response and self-reported recovery markers in resistance-trained adults at PS doses of 600–800 mg/day. Effect sizes are modest, trial replication across independent groups is limited, and the cortisol-suppression endpoint does not by itself translate to a documented performance benefit.
· source: Phosphatidylserine
Is PS safe?
Soy- and sunflower-derived PS are generally well tolerated at common clinical-trial doses (100–600 mg/day) over 8–24 weeks. Long-term safety data beyond ~24 weeks are limited. Individuals on prescription medications (particularly anticholinergic medications or blood-thinners) and those who are pregnant or lactating should consult a healthcare provider before use. The historical FDA qualified health claim for PS is qualified with significant evidence limitations.
· source: Phosphatidylserine
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the bovine-to-plant PS source transition history, the age-associated memory impairment RCT cluster (with publication-bias and methodology transparency), the cortisol/recovery emerging-evidence cluster, ADHD pediatric trial transparency, and the FDA qualified-health-claim regulatory landscape is part of the future ingredient expansion and not yet published.
· source: Phosphatidylserine
PQQ is a redox cofactor identified in bacterial methanol-dehydrogenase enzymes and present in trace amounts in many foods (notably fermented soy, kiwi, green tea). Whether mammals have an absolute dietary requirement for PQQ remains an open research question. PQQ has been studied for mitochondrial biogenesis, cognitive markers, and sleep-quality endpoints.
· source: PQQ
Does PQQ stimulate mitochondrial biogenesis in humans?
Preclinical studies in rodents and cell culture have reported PGC-1α and NRF1/NRF2-related signaling effects consistent with mitochondrial biogenesis stimulation. Human RCT data are smaller in scale, with several small trials reporting changes in mitochondrial-related biomarkers and self-reported fatigue/sleep endpoints. Effect sizes are modest, sample sizes are small, and replication across independent academic groups remains limited.
· source: PQQ
Does PQQ help with cognition or memory?
A small body of Japanese RCTs (e.g., Nakano M et al. 2012; Itoh Y et al. 2016) has reported improvements on cognitive composite measures in older Japanese adults at 20 mg/day over 12 weeks. Independent replication outside Japan and in larger samples with rigorous blinding remains limited. PQQ should not be characterized as a treatment or prevention for any cognitive disorder.
· source: PQQ
Is PQQ safe?
PQQ at common supplemental doses (10–40 mg/day) has been generally well tolerated in the small clinical trial database. Long-term human safety data beyond ~12 weeks are limited. The FDA issued a partial GRAS no-objection letter for BioPQQ as a dietary ingredient. Individuals who are pregnant or lactating and those on prescription medications should consult a healthcare provider before use.
· source: PQQ
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the mitochondrial biogenesis preclinical-to-clinical translation gap, the small Japanese cognition RCT cluster (with cross-cultural replication transparency), the BioPQQ regulatory history, and PQQ-vs-CoQ10 mechanism distinction is part of the future ingredient expansion and not yet published.
· source: PQQ
Probiotics are defined by the WHO/FAO/ISAPP as "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host." Critically, probiotic effects are strain-specific — generic "Lactobacillus" or "Bifidobacterium" labels without specific strain identifiers (e.g., Lactobacillus rhamnosus GG; Saccharomyces boulardii CNCM I-745; Bifidobacterium longum 35624) do not reflect the same clinical evidence base.
· source: Probiotics
Do probiotics work?
For specific strain-indication pairs, multiple well-conducted RCTs and pooled meta-analyses support clinical use — examples include Saccharomyces boulardii CNCM I-745 for antibiotic-associated diarrhea, Lactobacillus rhamnosus GG for acute pediatric diarrhea, and specific multi-strain formulations for irritable bowel syndrome symptom clusters. For most consumer "probiotic" supplements lacking strain identification and indication-specific evidence, claims of "gut health" or "immune support" are not well supported by the clinical literature for the specific product. Strain transparency on the label is the single most important quality signal.
· source: Probiotics
Do probiotics restore the gut microbiome after antibiotics?
A 2018 Israeli study (Suez J et al., Cell) reported that empirical probiotic supplementation post-antibiotics actually delayed the recovery of native microbiome composition in some participants compared with no intervention or autologous fecal microbiota transplant. This finding complicates the simple "take probiotics after antibiotics" recommendation and is an active area of research. Patient-specific clinical judgment is warranted.
· source: Probiotics
Are probiotics safe?
For healthy adults, well-characterized probiotic strains have an excellent safety profile and are widely classified as GRAS by the U.S. FDA. However, probiotics are NOT generally safe in immunocompromised individuals (chemotherapy, transplant recipients, severe immunodeficiency), critically ill ICU patients, infants with central venous catheters, or individuals with certain bowel-wall integrity compromises — case reports of probiotic-related bacteremia and fungemia in these populations are documented. Consult a healthcare provider for clinical contexts.
· source: Probiotics
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the strain-specific evidence index (clinical guideline-supported strain-indication pairs), the consumer-product strain-transparency landscape, post-antibiotic recovery literature (Suez 2018 and the post-2018 debate), prebiotics-and-postbiotics distinction, and immunocompromised contraindication transparency is part of the future ingredient expansion and not yet published.
· source: Probiotics
Resveratrol is a stilbene polyphenol found in grape skins, red wine, peanuts, and Polygonum cuspidatum (Japanese knotweed, the dominant commercial source). The trans-resveratrol isomer is the form studied in essentially all clinical trials. Resveratrol attracted scientific interest in the 1990s–2000s as a proposed SIRT1 activator and "calorie-restriction mimetic," but human clinical translation has been substantially more mixed than the early preclinical enthusiasm suggested.
· source: Resveratrol
Does resveratrol actually extend lifespan or work like calorie restriction in humans?
No human longevity data support this claim. The "calorie-restriction mimetic" framing arose from preclinical work in yeast, worms, flies, and mice; multiple subsequent independent replications and lifespan studies in mice have produced inconsistent results, including null findings in standard-laboratory chow contexts. Human RCTs have not demonstrated lifespan extension (this would be impossible to demonstrate in standard RCT timelines anyway). The "longevity supplement" positioning substantially overstates the current evidence.
· source: Resveratrol
Does resveratrol help with cardiovascular markers?
Pooled meta-analyses have reported modest effects on blood pressure, lipid markers, and some inflammatory markers in adults with metabolic syndrome or type 2 diabetes research populations. Effect sizes are modest, with substantial heterogeneity across trials. Resveratrol is not characterized on this hub as a treatment for any cardiovascular or metabolic disease, which are clinical conditions requiring physician management.
· source: Resveratrol
Is resveratrol safe?
Resveratrol is generally well tolerated at common doses (≤500 mg/day) in short-term clinical trials. High doses (≥2.5 g/day) have been associated with gastrointestinal side effects. Resveratrol inhibits multiple cytochrome P450 enzymes and can interact with prescription medications. Pregnant individuals should avoid resveratrol supplementation due to one notable preclinical placental study (Bourque SL 2012 / Roberts VHJ 2014). Individuals on prescription medications should consult a healthcare provider before use.
· source: Resveratrol
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the "French paradox" historical framing transparency, the SIRT1 mechanism controversy (Pacholec 2010 specificity challenge), preclinical-to-clinical translation gap, cardiometabolic RCT meta-analytic table, drug-interaction transparency, and pregnancy contraindication rationale is part of the future ingredient expansion and not yet published.
· source: Resveratrol
Saw palmetto (Serenoa repens) is a dwarf palm native to the southeastern United States. The fatty-acid-rich extract of its berry has been used traditionally for urinary symptoms in adult men. Standardized hexane-extracted preparations (e.g., Permixon) are the most-studied formulation; saw palmetto powder products vary widely in active-constituent content.
· source: Saw Palmetto
Does saw palmetto help benign prostatic hyperplasia (BPH) symptoms?
The evidence is mixed and depends heavily on extract preparation. The STEP trial (Bent S et al. 2006, NEJM) and the CAMUS trial (Barry MJ et al. 2011, JAMA) — using saw palmetto extracts at 320–960 mg/day — reported no significant benefit over placebo on lower urinary tract symptom scores. Some European trials using the standardized hexanic Permixon preparation have reported more favorable results in pooled analyses. BPH is a clinical diagnosis (ICD-10 N40) requiring urologic evaluation; saw palmetto is not characterized on this hub as a substitute for guideline-directed medical or surgical therapy.
· source: Saw Palmetto
Does saw palmetto help with hair loss (androgenetic alopecia)?
A small body of trials has explored saw palmetto for androgenetic alopecia based on the mechanistic premise of 5-alpha-reductase inhibition. The evidence is preliminary, sample sizes are small, and effect sizes are substantially smaller than for FDA-approved interventions (finasteride, minoxidil). Saw palmetto should not be characterized as a substitute for FDA-approved hair-loss treatments, and androgenetic alopecia evaluation by a dermatologist is the appropriate clinical pathway.
· source: Saw Palmetto
Is saw palmetto safe?
Saw palmetto is generally well tolerated in clinical trials, with mild gastrointestinal side effects the most common adverse events. It has antiplatelet/anticoagulant activity in some preclinical and case-report literature and may interact with anticoagulant medications. Individuals undergoing surgery should disclose saw palmetto use. Pregnant individuals should avoid use due to hormonal-modulation activity. The extract is not appropriate for use in women without medical supervision.
· source: Saw Palmetto
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the STEP and CAMUS trials, the Permixon evidence cluster, the AUA / EAU clinical guideline position, the androgenetic alopecia transparency, and the surgical-bleeding-risk disclosure is part of the future ingredient expansion and not yet published.
· source: Saw Palmetto
Soy isoflavones are a class of polyphenolic compounds (notably genistein, daidzein, glycitein) found in soybeans and soy-derived foods. They are phytoestrogens — plant-derived compounds that bind selectively to estrogen receptors (with preferential ER-β affinity) and can exert weak estrogen-agonist or -antagonist activity depending on tissue and endogenous estrogen context.
· source: Soy Isoflavones
Do soy isoflavones help menopausal hot flashes?
A 2012 Cochrane review and multiple subsequent meta-analyses have reported a modest reduction in hot-flash frequency and severity with soy isoflavone supplementation at 40–100 mg/day over 12+ weeks in menopausal women. Effect sizes are smaller than for prescription hormone therapy and vary by trial. The metabolic conversion of daidzein to the more bioactive metabolite equol depends on gut microbiota (equol producers vs non-producers), which may contribute to between-individual response variability. Menopause symptom management should be discussed with a gynecologist or primary care provider.
· source: Soy Isoflavones
Are soy isoflavones safe for women with a history of breast cancer?
This is a clinically important and nuanced question. Earlier preclinical and observational concerns about phytoestrogen activity in hormone-receptor-positive breast cancer populations have been substantially revised by subsequent prospective cohort data (notably the Shanghai Breast Cancer Survival Study, Shu XO et al. 2009, JAMA) reporting neutral or modestly favorable outcomes with dietary soy intake in survivors. However, isolated high-dose isoflavone supplements are a different exposure than dietary soy food, and individuals with a personal or family history of hormone-sensitive cancer should consult their oncology team before isoflavone supplementation. The decision is not one-size-fits-all.
· source: Soy Isoflavones
Do soy isoflavones feminize men or affect testosterone?
A 2010 meta-analysis (Hamilton-Reeves JM et al., Fertility and Sterility) of 15 placebo-controlled studies reported no significant effect of soy protein or isoflavone exposure on testosterone, free testosterone, or estradiol in men. Case reports of gynecomastia with extreme high-dose soy intake exist but represent outliers and do not characterize typical dietary or supplemental use.
· source: Soy Isoflavones
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the Cochrane and post-Cochrane menopause meta-analytic table, equol-producer pharmacogenomics, the breast cancer survivor cohort literature, the soy-testosterone meta-analysis, bone density and lipid sub-clusters, and pediatric exposure (where appropriate caution is warranted) is part of the future ingredient expansion and not yet published.
· source: Soy Isoflavones
Spermidine is a naturally occurring polyamine present in nearly all eukaryotic cells and required for cell growth and proliferation. Dietary sources include wheat germ, aged cheese, mushrooms, soybeans, and certain fermented foods. Commercial dietary supplements are typically derived from wheat-germ extract. Endogenous spermidine production declines with age.
· source: Spermidine
Does spermidine extend lifespan or slow aging?
Preclinical studies in yeast, worms, flies, and mice have reported lifespan extension with spermidine supplementation, with autophagy induction as the proposed mechanism. Human evidence consists primarily of prospective cohort associations (e.g., Bruno F Salvatore Project; Italian / Bavarian cohorts) linking higher dietary spermidine intake to lower all-cause mortality. These observational associations cannot establish causality, and the current evidence is rated as cohort-supported on this hub — not at the meta-analytic or RCT tier. Marketing claims of "lifespan extension" or "anti-aging" substantially overstate the strength of human evidence.
· source: Spermidine
Are there human RCTs on spermidine and cognition?
A small body of pilot RCTs (notably the SmartAge study cluster from Germany) has evaluated wheat-germ-derived spermidine for cognitive markers in older adults at risk of cognitive decline. Results have been mixed, with some sub-analyses showing modest improvements in specific memory composites and the primary endpoint analyses producing more conservative interpretations. Independent replication and larger trials are needed.
· source: Spermidine
Is spermidine safe?
Spermidine from food sources has a long history of human consumption. Wheat-germ-extract supplements at common clinical-trial doses (1–6 mg/day) have been generally well tolerated in short-term studies. Long-term safety data beyond ~12 months are limited. Individuals with wheat / gluten sensitivities should select gluten-free wheat-germ extracts or alternative sources. Pregnancy and lactation safety data are limited; consult a healthcare provider before use in these contexts.
· source: Spermidine
Where does the current evidence-first content for this page sit?
This is a Lite reference page with a cohort-supported evidence tier. Full content covering the preclinical autophagy mechanism (Eisenberg 2009 Nature Cell Biology baseline reference), the European prospective cohort literature, the SmartAge pilot trial cluster transparency, the dietary-vs-supplemental exposure distinction, and the regulatory status across major markets is part of the future ingredient expansion and not yet published.
· source: Spermidine
Type II collagen is the dominant collagen of articular cartilage. As a dietary supplement, it is studied in two preparation forms: undenatured / native (UC-II, typically 40 mg/day, mechanism proposed via oral immune tolerance pathways) and hydrolyzed (similar to general hydrolyzed collagen peptides — see the collagen-peptides page). These forms have distinct mechanistic frameworks and trial bases.
· source: Type-2 Collagen
How does undenatured type II collagen (UC-II) differ from collagen peptides?
UC-II is administered at a very low daily dose (~40 mg) and is hypothesized to act through oral immune tolerance induction (engagement with gut-associated lymphoid tissue / Peyer's patches) rather than through digestion to free amino acids. Collagen peptides (hydrolyzed collagen) are administered at gram-scale doses (5–15 g/day) and act through amino-acid and bioactive-peptide pathways. The two are not interchangeable products.
· source: Type-2 Collagen
Does type II collagen help osteoarthritis joint pain?
Several RCTs of UC-II 40 mg/day in adults with knee osteoarthritis research populations have reported modest reductions in WOMAC pain and stiffness scores over 90–180 days. A 2017 head-to-head trial (Lugo JP et al., Nutrition Journal) reported UC-II superior to glucosamine + chondroitin in joint-symptom endpoints. Effect sizes are modest, most trials are industry-sponsored, and independent academic replication remains limited. Osteoarthritis (ICD-10 M15–M19) is a clinical diagnosis requiring rheumatologic evaluation.
· source: Type-2 Collagen
Is type II collagen safe?
UC-II at clinical-trial doses (40 mg/day) has been generally well tolerated in published RCTs of up to 180 days. Long-term safety data beyond ~6 months are limited. UC-II is derived from chicken sternum cartilage — individuals with chicken-protein allergy should avoid it. Pregnancy and lactation safety data are limited.
· source: Type-2 Collagen
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the oral immune tolerance mechanism, the UC-II vs glucosamine+chondroitin head-to-head trial cluster, industry-sponsorship transparency, the chicken-cartilage source landscape, and the rheumatoid arthritis adjunctive-research literature is part of the future ingredient expansion and not yet published.
· source: Type-2 Collagen
Urolithin A is a metabolite produced by gut microbiota from dietary ellagitannins and ellagic acid, found in pomegranate, walnuts, and certain berries. Only a subset of individuals (estimated 30–40% in Western populations) host the specific microbial consortia required to convert ellagitannin precursors into urolithin A — these "urolithin-A producers" are a key contextual variable for any dietary ellagitannin discussion. Direct urolithin A supplements (e.g., Mitopure / Amazentis) bypass this microbial conversion variability.
· source: Urolithin A
Does urolithin A improve mitochondrial function in humans?
A 2022 randomized controlled trial in middle-aged overweight adults (Singh A et al., JAMA Network Open) at 500–1000 mg/day for 4 months reported improvements in mitochondrial biomarkers and skeletal muscle endurance markers. A 2019 RCT (Andreux PA et al., Nature Metabolism) in older adults reported skeletal muscle mitochondrial gene expression and plasma biomarker changes. The evidence is encouraging, but cluster-level effect sizes are modest and replication across independent academic groups outside the developer (Amazentis) remains limited.
· source: Urolithin A
Does urolithin A "reverse aging" or extend lifespan?
No human longevity data support this claim. The mitophagy-induction mechanism is well established preclinically (Ryu D et al. 2016, Nature Medicine, in C. elegans and mice), and the human RCTs cited above report biomarker and short-term functional improvements. Lifespan-extension claims in humans cannot be supported by current trial timelines and substantially overstate the evidence.
· source: Urolithin A
Is urolithin A safe?
Direct urolithin A supplements have FDA GRAS notification (GRN 791) for use in food at specified levels. Clinical-trial doses (500–1000 mg/day) have been generally well tolerated over 4 months. Long-term safety data beyond ~4 months in human RCTs are limited. Individuals on prescription medications, with chronic kidney disease, or who are pregnant or lactating should consult a healthcare provider before use.
· source: Urolithin A
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering the producer / non-producer microbiome stratification, dietary-precursor (ellagitannin) vs direct-supplement distinction, the Mitopure RCT cluster with industry-sponsorship transparency, mitophagy mechanism deep-dive, sarcopenia / muscle-quality research framing, and the FDA GRAS regulatory landscape is part of the future ingredient expansion and not yet published.
· source: Urolithin A
Vitamin K2 (menaquinone) is the family of K vitamins distinguished by an isoprenoid side chain of variable length (MK-4, MK-7, MK-9). It is structurally distinct from vitamin K1 (phylloquinone, the form abundant in leafy greens). K2 is required for the post-translational γ-carboxylation of vitamin-K-dependent proteins including osteocalcin (bone) and matrix Gla protein (vascular tissue). Long-chain MK-7 has a substantially longer plasma half-life than short-chain MK-4.
· source: Vitamin K2
Does vitamin K2 improve bone density?
A small body of meta-analytic evidence has reported modest improvements in bone mineral density and reductions in fracture risk with vitamin K2 supplementation (particularly MK-4 4500 µg/day in Japanese postmenopausal populations and MK-7 180 µg/day in European cohorts). Effect sizes are modest, and the evidence is stronger in postmenopausal-osteoporosis-research populations than in healthy adults. Osteoporosis (ICD-10 M81) is a clinical diagnosis requiring physician evaluation.
· source: Vitamin K2
Does vitamin K2 prevent vascular calcification or heart disease?
The Rotterdam Study (Geleijnse JM et al. 2004, J Nutr) reported inverse associations between dietary K2 intake and coronary heart disease incidence in observational follow-up. A subsequent randomized trial (Knapen MH et al. 2015, Thromb Haemost) at 180 µg/day MK-7 for 3 years reported improvements in arterial stiffness markers in postmenopausal women. Pooled meta-analytic evidence for hard cardiovascular endpoints remains preliminary. K2 is not characterized on this hub as a treatment for any cardiovascular disease.
· source: Vitamin K2
Is vitamin K2 safe to take with blood thinners?
Individuals on warfarin (Coumadin) — which acts by inhibiting vitamin K cycling — must consult their treating clinician before any vitamin K supplementation, as it can substantially affect INR control. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, etc.) work via different mechanisms and are not affected the same way. The safety considerations apply specifically to warfarin users.
· source: Vitamin K2
Where does the current evidence-first content for this page sit?
This is a Lite reference page. Full content covering MK-4 vs MK-7 pharmacokinetics, the Japanese MK-4 postmenopausal bone evidence cluster, the European MK-7 arterial stiffness cluster, vitamin D3 co-supplementation rationale (the K2-D3 stack), Rotterdam Study observational evidence, and warfarin interaction transparency is part of the future ingredient expansion and not yet published.
· source: Vitamin K2
About this page
This FAQ aggregator is regenerated at build time by extracting every FAQPage
Q/A pair from the underlying ingredient and evidence pages on asxan.ai. No Q/A is
hand-authored on this page; if you spot an error, the canonical source is the linked
ingredient or evidence page.
